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Abstract
Memory T Cells and the Endothelium in Allograft Rejection

Stephen Lawrence Shiao
2007

Organ transplantation has become increasingly important as a treatment for many
human diseases. Despite the dramatic improvements in immunosuppression in recent
years, acute and chronic rejection remain significant problems.

It has become

increasingly evident that the presence o f T cell memory correlates with both acute and
chronic rejection episodes.

Endothelial cells (EC) have been shown to preferentially

activate memory T cells and, as the lining of every transplanted organ, they are in a
unique position to provide signals to alloreactive memory T cells.

EC activation of

memory T cells depends in part on the costimulatory molecule LFA-3 in addition to other
signals. The nature of these other signals is not well understood. In this dissertation I
further explore the mechanisms by which EC activate memory T cells and investigate the
role that these mechanisms play in a model of memory T cell mediated allograft
rejection.
Several newly described costimulatory pathways, ICOS-ICOSL, 4-1BB-41BBL,
and OX40-OX40L, have recently been recognized as important players in the generation
and function o f memory T cells.

EC can express all three o f the ligands from these

pathways and also increase expression in response to the cytokine tumor necrosis factor
(TNF) and in co-cultures with T cells. Furthermore, blockade o f these pathways using

i
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monoclonal antibodies in co-cultures causes reductions in T cell production o f IFN-y and
IL-2 as well as decreased T cell proliferation.
To examine the contribution of memory T cells to allograft rejection in vivo, I
describe a chimeric model o f human skin grafted onto SCID mice that are adoptively
transferred with various subsets of human T cells.

In this model, rejection o f the human

skin by the transferred T cells is mediated by memory T cells alone. Using this model,
the effect of different costimulatory pathways on allograft rejection is tested.
Interestingly, blockade o f any of the three costimulatory pathways can diminish the T cell
response to the allograft. The role of the B7-CD28 pathway is also examined and found
to partially contribute to the memory T cell response.
Finally, using observations that memory T cells can be further divided into two
functionally distinct subsets known as central and effector memory T cells, the response
of these two subsets to EC is explored.

Central memory T cells respond to EC by

producing IL-2 while effector memory T cells generate IFN-y.

The basis for this

difference may be due to the differential expression and sensitivity o f the two subsets to
costimulation by CD27 and CD28. Further, in the chimeric human-SCID model effector
memory T cells alone can mediate allograft rejection while central memory T cells
cannot.
Our results strongly support the idea that the EC capacity to activate memory T
cells and its subsets depends in part on the CD28-B7 pathway and memory T cell specific
costimulatory molecules. Furthermore, targeting CD28 or these molecules in vivo can
attenuate allograft rejection mediated by memory T cells.
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CHAPTER I - INTRODUCTION
More than 25,000 organ transplants are performed annually with over 93,000
patients waiting to receive a transplant in the United States alone (1) and what was once
an experimental exercise has now become the treatment o f choice for many diseases.
The technical aspects o f organ transplantation were resolved by 1964 when Alexis Carrel
won the Nobel prize in 1964 for the description o f anastomotic technique and
experimental organ transplantation (2).

However, the understanding o f the biological

barriers to transplantation lagged far behind the surgical technique.
Peter Medawar was the first to propose the idea that the immune system could
reject a transplanted organ (3, 4). The basis for this idea came from M edawar’s work
using skin grafts on bums. He discovered that skin grafted from a given donor lasted
about 10 days, but a second graft was rejected immediately. Medawar suggested that the
initial and accelerated rejection were an immunological process whereby the immune
system “remembered” what the graft looked like and promptly rejected it. Medawar’s
experiments coincided with Frances Macfarlane Burnet’s work on a second critical
observation.

Bumet found that chick embryos and fetal animals did not produce

antibodies and that immunocompetence developed slowly over time (5). This finding led
to the concept that during embryonic development there is a period o f “self-recognition”
where tolerance to a given antigen is developed by fetal exposure to “non-self antigens.”
In other words, the immune system had to be clonally selected and taught about self and
non-self (2). Combining Burnet’s observation about self versus non-self and his own
work with skin grafts, Medawar with his postdoctoral fellows Rupert Billingham and
Leslie Brent demonstrated that neonatally acquired transplant tolerance could be achieved
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in mice by inoculating embryos or newborn mice with allogeneic cells (6). These critical
experiments led to the initial understanding that the immune system was responsible for
rejection due to its ability to identify which cells were self and which were not. The
molecular basis o f self recognition came only a few years later with the description o f the
first leukocyte antigen called MAC in 1958 by Jean Dausset, which became known as the
major histocompatability complex (MHC) (7).

These critical experiments formed the

foundation for the biological understanding o f transplant rejection, however, it would
take several decades before the discovery o f a fungal metabolite known as cyclosporin
made transplantation a clinical reality (8, 9).
Despite the introduction o f new protocols and immunosuppressive reagents over
the past twenty years, incidences o f rejection at 1 year remain at 20% for kidneys, 30%
for livers and nearly 40% for hearts (10). Furthermore, current immunosuppressants also
fail to control long-term immune responses to the organ which can lead to more chronic
forms o f rejection such as coronary allograft vasculopathy in heart transplants and
chronic allograft nephropathy in renal transplants. The current drugs also have toxic side
effects that can damage the transplanted organ (such calcineurin inhibitory mediated
nephrotoxicity) as well as contribute to the incidence o f malignancy, infection, diabetes,
hypercholesterolemia and cardiovascular disease (11).

Therefore, finding better and

more specific means o f immunosuppression continues to be a major goal o f
transplantation.
In the search for better immunosuppression, it is important to understand why

current immunosuppressive regimens fail. One hypothesis is that there are portions o f the
immune system that are resistant to immunosuppression and there is increasing

2
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recognition that one reason for the failure o f immunosuppression in both the acute and
chronic settings may be the presence o f immunological memory.

In the setting of

transplantation it has long been recognized that the presence of preformed alloreactive
antibodies may result in hyperacute allograft rejection (12).

Experimental models as

early as the 1970s also recognized the potential for alloreactive memory T cells to elicit
allograft rejection (13, 14).

Since then, the role o f T cell immunologic memory was

largely forgotten because o f the initial successes with immunosuppression.

However,

with advances in our understanding o f the immune system it has now become evident that
memory T cells play a critical role in the immune response to allograft and understanding
their biology has become a major focus o f transplantation research.

1.1 T CELL MEMORY
One o f the defining features o f the immune system is the concept o f immunologic
memory. Immunological memory can be defined as the faster and stronger response of
the immune system in a secondary response to an Ag compared to a primary response to
the same Ag (15, 16). Immunologic memory is also thought to last for the lifetime o f an
organism. The faster and stronger secondary response o f the immune system results from
quantitative as well as qualitative changes in the cell populations that respond to a given
Ag. Among these changes are increases in the frequency o f responding cells, changes in
the activation requirements and alterations o f their migratory patterns. For example, in
humoral responses, there is a greater frequency o f antigen reactive cells specific for an

antigen, as well as antibody products that are clearly different from the initial response
(17).

For T cells, there is a similar increase in frequency o f antigen reactive cells and a

3
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more rapid acquisition o f effector function in a recall response. In order to more closely
examine the properties o f memory T cells it is important to understand the primary
response as a comparison.

The prim ary response
Naive T cells may be defined as T cells that have not encountered antigen and the
primary response describes their response to the first exposure.

Before contacting

antigen, naive T cells circulate between secondary lymphoid organs such as the spleen
and lymph nodes by traveling in the blood or lymph (18, 19). The continuous migration
of naive T cells through the secondary lymphoid tissues is important for T cells to
efficiently encounter antigens. To encounter antigens, naive T cells must make contact
with specialized antigen presenting cells (APCs) such as dendritic cells (DC) that present
antigens in the form o f peptide fragments bound to major histocompatibility complex
(MHC) molecules (20). In animals that have not encountered antigen, the MHC complex
is bound to self peptides which are largely ignored by the naive T cells. Naive T cells
live for extended periods o f time in a metabolically quiescent state, and experiments in
mice have demonstrated that their survival in this state depends on continually receiving
low-levels signals from self-peptide/MHC (21-24) and IL-7 (25, 26).
Without the presence o f foreign antigen, naive T cells circulate through the
secondary lymphoid organs contacting self-peptide/MHC indefinitely.

However, once

naive T cells recognize an APC bearing a foreign peptidc/MHC complex, the naive T
cells undergo a series o f changes in migration and function in response to the foreign
antigen. T cells recognize antigens through highly-specific interactions between their T

4
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cell receptor and peptide/MHC complexes. Upon recognition of a foreign peptide, na'ive
T cells stop circulating and increase contact between the T cell and the APC in part
through the formation o f structures known as synapses (27-30).
A synapse refers to the grouping o f molecules formed at the contact site between
the T cell and the APC and reflects the organization o f the signaling molecules used in T
cell activation (31, 32). The synapse is composed o f a cluster o f TCR molecules and
accumulation

of

signaling

molecules

such

as

LCK,

LAT,

and

PKC0

and

costimulatory/adhesion molecules including CD28, CD2 and LFA-1. The costimulatory
and adhesion molecules are thought to provide key second signals as well as enhance
TCR triggering by stabilizing the synapse or recruiting other intracellular signaling
molecules (33).

Once the T cell has been triggered, the T cells undergo substantial

proliferation and differentiation into effector cells that generally lead to the elimination of
the source o f the foreign antigen.

Once the source o f the antigen is eliminated, the

effector cells are rapidly eliminated and memory T cells are formed (34).
When the organism re-encounters an antigen, the response o f memory T cells
differs from that o f naive T cells in several significant ways. The first major difference is
in the size and speed of the response. The secondary response is generally both larger
and more rapid than the primary response. The second major difference is the conversion
to effector cells. Na'ive T cells when they are activated produce IL-2 initially and require
several rounds o f proliferation before they start to express effector molecules.

In

response to antigen, memory T cells become effector T cells much more quickly.
Identifying the mechanisms that are responsible for these differences in the secondary
response is the basis for studies o f T cell memory.

5
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Surface Markers o f Naive, Effector and Memory T cells
Many o f the differences in activation potential and homing between memory and
na'ive T cells are reflected in the surface molecules used to distinguish them.

These

molecules include those involved in trafficking and adhesion (CD44, C D lla , CD62L);
TCR signaling (CD45) and cytokine and chemokine responses (CD25 (IL-2Ra), CD122
(IL-2/15R|3), CCR7) (see Table 1-1).
In humans, naive T cells are CD45RA positive and CD45RO negative whereas
memory T cells are the converse, CD45RO positive and CD45RA negative (35, 36). The
antibody used to identify CD45RO (UCHL1) identifies an epitope that is present in the
absence of all the other CD45R isoforms (A, B, and C).

In the mouse, there is no

equivalent o f CD45RO that has been studied and so some investigators use CD45RB,
however CD45RB has been shown to change with activation or cytokine treatment (37,
38). Therefore, in the mouse, unlike in humans, memory T cells are most commonly
defined using the adhesion molecule CD44 with na'ive T cells being CD44 low and
memory T cells being CD44 high. The only concern is that this pattern is only true for
the C57BL/6 strain and is less clear for other strains (39). The rat does not upregulate
CD44 on its memory T cells and therefore loss o f CD45RC (OX-22) has been used (37).
In other large mammals such as sheep, adhesion molecules such as CD62L and CD 11 a
have also been used to identify memory T cells (40).

6
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CD11a
CD25
CD44
CD62L
CD69
IL-2/15R
CCR7
CD45RA
CD45RO
CD45RB

Naive

Effector

Lo
Lo
Lo
Hi
Lo
Lo
Hi
Hi
Lo
Hi

Hi
Hi
Hi
Lo
Hi
Hi
Hi
Lo
Hi
Lo

Memory
Effector
Central
Hi
Lo
Hi
Lo
Lo
Hi
Lo
Lo
Hi
Lo

Hi
Lo
Hi
Hi
Lo
Hi
Lo
Lo
Hi
Lo

Table 1-1 Surface markers o f human naive, effector and memory T cells.
Relative expression o f several commonly used markers for distinguishing na'ive from
effector and both central and effector subsets o f memory T cells.

7
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As evidenced by the diversity o f different markers used to identify memory cells,
there are a number o f complications to isolating a true memory T cell population. One
problem with identifying memory T cell populations is that effector cells often share
some o f the same surface molecules as memory T cells most particularly elevated CD44.
However, it is possible to use other markers of activation such as CD25 and CD69 to
distinguish effector cells from bona fide memory T cells (41, 42). Another problem is
that the memory phenotype can be recapitulated in certain situations without having seen
foreign

antigen

including

lymphopenia-induced

proliferation

and

extrathymic

development. In both o f these situations, na'ive T cells acquire the phenotype o f memory
T cells and in some cases even memory T cell functions like rapid IFN-y production (4345). However, all these studies have been carried out in mice and it is unclear what role
these two factors play in determining the memory T cell pool in humans.
In addition to distinguishing between a naive and memory T cell pool, it has
become increasingly clear that memory T cells are heterogeneous and can be further
divided into different subsets based on the expression o f the adhesion molecule CD62L
(L-selectin) and the chemokine receptor CCR7 (46).

These two markers define two

subsets that are distinct in their homing potential and functional capacity.
memory T cells

(T

cm

),

Central

CD62L+CCR7+, are thought to circulate through the secondary

lymphoid organs like naive T cells and have higher proliferative potential but lower
immediate effector function. In contrast, effector memory T cells

(T

em

),

CD62L-CCR7-,

circulate to the periphery and can rapidly secrete cytokines and other effector molecules.
Thus, despite some confusion about which markers to employ in distinguishing
the different subsets especially between species, it is possible to differentiate between
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naive, effector and memory T cells as well as different subsets within memory T cells
using surface markers. Studies carried out on these distinct populations have indicated
that as suggested by their different surface phenotypes, that the three groups possess
significantly different functional capacities.

Functions o f Naive v.s\ Memory T cells
Following clearance o f a given antigen in a primary response, there is a massive
culling o f effector cells.

Despite this massive extinction o f responding T cells, the

precursor frequency o f Ag-specific memory T cells is significantly greater compared to
naive T cells (47, 48). This increased frequency in part explains the increased speed and
size o f secondary responses. This can be seen in studies done in mice, where treatments
that decrease the numbers o f Ag specific memory CD8+ T cells showed diminished
secondary responses to those Ag (49, 50).
In addition to greater numbers, memory T cells also possess different homing
potentials.

As discussed above, memory T cells can be subdivided into two separate

subsets based on expression o f CD62L and CCR7 (46). Tcm have a circulation pattern
that closely resembles naive T cells in terms o f their distribution in the lymphoid tissues.
Expression o f CD62L and CCR7 allows both Tcm and naive T cells to enter lymph nodes
via high endothelial venules (HEV).

Like naive T cells, Tcm appear to require

stimulation in secondary lymphoid organs in order to acquire effector function (46, 51,
52). By contrast, Tem, like effector cells, are CD62L and CCR7 low and consequently
migrate through non-lymphoid tissues. They also display constitutive CTL function and
cytokine synthesis in vivo (34, 51, 53, 54).

The positioning o f TEM allows them to
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provide immediate immunity in a secondary response. This homing potential may in part
account for the faster secondary responses compared to naive T cells.
In addition to quantitative differences in precursor frequency and homing,
memory T cells are also qualitatively different from naive T cells. In general, memory T
cells have a lower activation threshold than naive T cells. They possess the ability to
respond to low affinity/avidity interactions thus allowing them to respond to a much
lower amount o f antigen compared to naive T cells (23, 55-57).

Part of this lower

threshold is related to the fact that memory T cells also have a reduced reliance on APC
provided costimulation (58, 59). In fact, memory T cells have been shown to be less
dependent on the B7/CD28 pathway and independent o f the CD40/CD154 pathway (60).
Memory T cells can also become activated in the absence o f secondary lymphoid organs
(61).

Furthermore,

T

cm

,

despite their similar migratory potential, are clearly less

quiescent than their naive counterparts. For instance, CD8+ Tcm express high levels of
mRNA suggesting that they are in the G1 phase o f cell cycle (62) and show a much
shorter lag time for entering the cell cycle (56, 63-65). Additionally, both Tcm and Tem
also have much faster kinetics for synthesizing cytokines, differentiating into CTL and
migrating to non-lymphoid tissues (56, 62, 63, 65-68).
In sum, memory T cells can detect lower concentrations o f their cognate antigen,
expand far more rapidly, produce a greater amount and broader array of cytokine on a
per-cell basis, and survive longer than either naive or effector cells. It is these unique
properties o f memory T cells that not only serve as the basis for both the beneficial

effects as in the case o f vaccines but also the harmful effects as in autoimmunity and
transplant rejection.

10
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1.2 T CELL COSTIMULATION
In order for T cells to see antigen, there is significant evidence supporting the
concept o f the two-signal hypothesis o f T cells activation (69, 70).

The two-signal

hypothesis results from observations that peptide/MHC complexes alone are in general
insufficient to activate T cells (71).

Therefore, in order for T cells to be activated,

another signal is required to amplify the weak signal coming from the T cell receptor
(TCR). This second signal, known as the co-stimulatory signal, is a critical feature of
competent APCs that provide this signal in addition to the antigen specific signal (signal
one) to initiate an immune response.

Many stromal and epithelial cells lack the

expression o f these co-stimulatory molecules and thus even in the situation where they
express functional peptide/MHC complexes they are unable to activate T cells.
Costimulatory molecules can be divided along structural lines into two families, the Ig
superfamily and the tumor necrosis factor (TNF) family. Included in the Ig superfamily
are the well-known CD28/CTLA-4/B7 family and CD2/LFA-3.

The TNF family

includes CD40/CD40L (CD 154), CD27/CD70, CD 134 (OX40)/OX40L, and CD 137 (4lB B )/4-lB B L (See Table II-1).

The Ig superfamily o f costimulatory molecules
One o f the first costimulatory pathways to be identified in mice and thus perhaps
the best characterized is the CD28/B7 family (72-77).

The B7-l/B7-2:CD28/CTLA-4

pathway consists o f two B7 family members B7-1 (CD80) and B7-2 (CD86) that both
bind the same two receptors, CD28 and CTLA-4 (78).

Both receptors have distinct

kinetics and binding affinities for B7-1 and B7-2 (79). CD28 is constitutively expressed
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on the surface o f T cells while CTLA-4 is upregulated with activation. CTLA-4 also has
a much higher affinity for both B7-1 and B7-2. This difference in kinetics and affinity is
also reflected in the function o f these two receptors in T cell activation. Engagement of
CD28 in conjunction with TCR engagement allows T cells to make IL-2 and survive.
The higher affinity CTLA-4 gets expressed later and both competes with CD28 and
delivers a negative signal to down regulate the T cell response. Professional APCs like
dendritic cells and B cells express low levels o f B7-2 constitutively, but rapidly
upregulate both B7-2 and B7-1 on their surface when they become activated (i.e. through
TLR signals or cytokines). The interaction between B7s and CD28 are critical for the
activation o f naive T cells (80).
There have also been several recently described new members o f the B7 family
including ICOS-ICOSL and PD-1/PD-L1/2 (81). ICOS is upregulated on both CD4+ and
CD8+ T cells following activation and is present on both effector and memory T cells
(82-84). ICOSL is expressed on the surface o f B cells, macrophages, dendritic cells, and
endothelial cells (85, 86). ICOS-ICOSL has been shown to play an important role in T
cell activation, differentiation, and effector responses. The key differences between the
ICOS-ICOSL pathway and the CD28-B7 pathway are that ICOS signaling can only be
delivered after T cells have been activated and that signaling does not upregulate IL-2
production (87).

Therefore, it seems that ICOS plays a role in propagating effector

function, but does not have a role in the primary response.
PD-1 is induced on peripheral CD4+ and CD8+ T cells, B cells and m onocytes
upon activation (88). The ligands for PD-1, PD-L1 and PD-L2, are widely expressed in
both lymphoid and non-lymphoid tissues including B, T, myeloid and DC, but also EC
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and other epithelial cells (89, 90). The PD-1/PD-L1/PD-L2 pathway has a critical role in
regulating T cell activation and tolerance.

PD-1 appears to regulate inflammatory

responses in peripheral tissues and help maintain tolerance particularly in CD8+ T cell
responses (91, 92). In transplantation, PD-1 stimulation by P D -L llg in combination with
other blockade significantly inhibited naive T cell responses in cardiac and islet allografts
(93, 94).
The CD2/LFA-3 (CD58) interaction was the first costimulatory pathway to be
identified in T cell activation and remains an important costimulatory pathway (95-97).
Originally known as LFA-2, CD2 is expressed on the majority o f T cells while LFA-3
can be found on dendritic cells, macrophages, B cells, fibroblasts and ECs (98-101). The
CD2-LFA-3 interaction has been shown to be an important pathway independent o f
CD28 to activate T cells and part o f its costimulatory function may be mediated by its
adhesive properties (102, 103).

No rodent homologue o f LFA-3 has been identified,

however the related molecule CD48 (blast-1, BCM1, 0X 45) has been characterized as a
CD2 ligand in both mice (104) and rats (105). Humans also express CD48, but it has
such a low affinity binding to CD2 that it is not clear that the CD2-CD48 interaction is
physiologically relevant in humans (106).

CD2-CD48 interactions in mice, like their

human counterpart, appear to be important in T cell activation as demonstrated in a
mouse allograft model (107, 108), but as the ligand is not equivalent it is not clear that
murine results can be accurately compared to humans. However, studies have been done
using a chimeric human SCID mouse model and these demonstrated that inhibition o f the
CD2/LFA-3 pathway with blocking antibodies against LFA-3 or an LFA-3Ig fusion
protein can significantly diminish allograft rejection (109).
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The TNFR fam ily o f costimulatory molecules
The TNFR family members can be divided into three groups, death domain (DD)containing receptors, decoy receptors and TNF receptor associated factor (TRAF)
binding receptors (110, 111). TNFR1 and Fas are examples o f DD-containing receptors.
They activate caspase cascades leading to apoptosis.

TRAF binding receptors do not

contain DDs, but possess motifs o f 4-6 amino acids that recruit TRAF proteins (112). All
costimulatory members o f the TNFR family are TRAF binding receptors and in particular
they all bind TRAF2 in conjunction with various other TRAF proteins (112) leading to
NF- k B (113-115) translocation downstream o f all the receptors. CD27 and 4 -IBB have
also been shown to lead to p38 MAPK (116) and JNK activation (117, 118). The result
of this signaling is to enhance survival signaling, cytokine production and cellular
proliferation o f T cells.
The most well-known TNFR receptor pair in T cell responses is CD40/CD40L
(CD154). CD40 is expressed on B cells (119), DC, monocytes, macrophages, EC (120)
and VSMC (121) and is inducible by cytokines such as TNF and interferons (122-124).
Its ligand CD 154 is expressed on activated CD4+ and CD8+ T cells, NK cells,
monocytes, B cells, activated DC, EC and VSMC (119, 121, 124).

CD40-CD154

interactions play a critical role in humoral immunity, activation o f APC costimulatory
function as well as activation o f macrophages and the endothelium (124, 125). The broad
reciprocal expression o f the receptor and ligand pairs suggests that this pair may be used
for bi-directional signaling, for example APC activate T cells through CD40L (126)
while the T cells simultaneously modify the activity o f the APC through CD40 (127).
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Thus, the CD40-CD40L pathway may play a more complex role in the immune response
beyond its pure costimulatory function.
CD27 is expressed on NK cells, B cells, naive and Tcm CD4+ and CD 8 + T cells.
CD27 expression increases transiently with activation and gradually decreases with
successive rounds o f division (128, 129). Its loss is thought to correlate with acquisition
o f effector function (130, 131).

In addition to correlating with effector function,

engagement o f CD27/CD70 costimulatory pathway has been shown to enhance CD 8 +
effector/memory T cell functions (132, 133). Its ligand, CD70, is found on activated T
cells, B cells and DC, but not resting EC (134, 135). In mice, CD70 can be induced on B
cells and DC by anti-CD40 or LPS and on DC with GM-CSF (136) and it is unknown
whether it is similarly inducible in humans.
0X 40 (CD134), originally identified in the rat (137), has its expression restricted
to activated T cells in both mice and humans (138). In a number o f conditions 0X 40 is
preferentially expressed on activated CD4+ T cells rather than CD 8 + T cells suggesting
that there may be a larger role for 0X 40 in CD4 mediated processes (139). Engagement
o f CD28 enhances the kinetics o f 0X 40 expression and expression o f 0X 40 can be
prolonged in a number o f inflammatory conditions (140-143). 0X 40 does not have the
ability to replace CD28 or affect the initial rate o f cell division in naive T cells, but does
allow for recovery of greater numbers o f T cells later in the response likely due to effects
o f 0X 40 signaling on induction o f key survival molecules like Bcl-2 and Bcl-XL (140,
144, 145).

In part through the induction o f these survival m olecules 0 X 4 0 signaling

plays a critical role in the generation and function of memory T cells, particularly CD4+
memory T cells (146, 147). OX40L is expressed on activated B cells (148) and DC (149,
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150), plasmacytoid DC (151), and EC (152, 153). It can be induced by CD40L-activation
on DC (154).
4 -IBB was originally characterized as a molecule expressed on activated T cells
(155), though it has since been found on a number o f other cell types including DC (156),
Mo (157), follicular DC (158), and NK cells (159). Current evidence indicates that both
CD4+ and CD 8 + T cells can express 4 -IBB, but in several circumstances CD 8 + T cells
can upregulate 4-1BB more rapidly and to higher levels than CD4+ T cells (139, 160). 41BB provides signals in a CD28 independent manner that lead to enhanced cell division
and improved survival (161, 162).

Studies in mice and humans have shown that 4 -IBB

engagement prevents activation-induced cell death in T cells and agonistic antibodies to
4 -IBB both in vitro and in vivo show prolonged T cell survival post-activation with
greater effects on CD 8 + T cells (163-167). Signaling through the 4 -IBB pathway is also
critical for the survival and function o f memory CD 8 + T cells (147). The ligand for 41BB, 4-1BBL, is expressed on activated macrophages, DC and B cells (168, 169). 41BBL expression can be upregulated on both B cells and DC via CD40 stimulation (170,
171). There are also reports that 4-1BBL engagement on human monocytes with 4 -IBB
fusion proteins induces reverse signaling implying that like CD40L there may be multiple
bi-directional effects o f receptor-ligand engagement (172, 173).
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Structural Family
Ig Superfamily

TNF Superfamily

Costimlatory
Molecule
CD28
CTLA-4
ICOS
PD-1
CD2
CD154 (CD40L)
0X40 (CD 134)
4-1BB (CD137)
CD27
GITR

Expression of Costimulatory
Molecule
T 4 , 8, N, E , M
T4, 8, E,
T4, 8 , E,

M

T4, 8, E,
T4.8, e ,

M

M» NK
T4i8, B, Mo
T ’
T 4 , 8 , NK, Mo, B, Eo, EC, V, DC

M i B, Mo, NK, DC, Eo
T 4 , 8, N, C M . NK. B
T, Treg

Ligand
B7-1 (CD80), B7-2 (CD 8 6 )
B7-1 (CD80), B7-2 (CD 8 6 )
ICOSL
PD-L1, PD-L2
LFA-3 (CD58)
CD40
OX40L
4-1BBL
CD70
GITRL

Ligand
Expression
B, Mo, DC, T e
B, Mo, DC, T e
B, Mo, DC, T, EC
B, Mo, DC, T, EC
B, Mo, DC, T, EC
B, DC, Mo, EC, V
B, DC, T, EC
B, Mo, DC
B, DC, T e
B, Mo, DC, EC

Table I I - l. Costimulatory molecules and their expression.
The costimulatory molecules discussed in the introduction are listed here along with their
known expression patterns. T = T cell, 4 = CD4+ T cells,

8

= CD 8 + T cells, N = Na'ive T

cells, E = Effector T cells, M = Memory T cells, CM = Central Memory T cells, Treg =
Regulatory T cell, NK = Natural killer cell, B = B cell, Mo = monocyte/macrophage, Eo
= Eosinophil, DC = Dendritic cell, V = Vascular Smooth Muscle Cell
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1.3 ENDOTHELIAL CELLS (EC) AS ANTIGEN PRESENTING CELLS
Endothelial cells (EC), the cells that line the entire vascular tree, are specialized
cells that have an important role in regulating the communication o f oxygen, nutrients,
different proteins and cells between the different organs o f the body. With regards to the
immune system, they play a pivotal role in the recruitment o f immune cells to sites of
inflammation.

As such, they are uniquely positioned to serve as sentinels o f the

peripheral tissue conveying to immune cells the status o f the organs beyond them. It is
this proximity to immune cells such as T cells and the need to for tissues to communicate
to T cells within blood vessels that led to the hypothesis that EC serve as intermediaries
in this process and that an important part o f this role is the ability o f EC to activate T
cells.

EC can express M HC molecules in vivo and in vitro
Antigen presenting cells (APC) are specialized cells that express surface
molecules that synergize with specific antigens and present them to T cells. Among these
specialized molecules are the major histocompatability complex (MHC) molecules whose
only known function is to present peptides to T cells. Professional antigen presenting
cells include dendritic cells, macrophages and B cells and have the capacity to activate
naive T cells.
In humans and other large mammals (not including mice or other rodents), all
endothelial cells strongly express MHC class I.

MHC Class II molecules are also

constitutively expressed, but only on some ECs including postcapillary venules, veins,
some arteries and most o f the microvasculature (174-177).

Expression o f the MHC

molecules in vivo may depend on basal levels o f circulating IFN-y.

This idea is
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supported by the fact that artery segments or skin transplanted into immunodeficient mice
show decreased MHC class I and loss o f expression o f MHC class II both o f which can
be restored by the addition o f exogenous IFN-y (178, 179).

In vitro, a similar

phenomenon is observed, whereby under standard culture conditions, human EC express
MHC class I, but not MHC class II. MHC class I can be augmented by tumor necrosis
factor (TNF) and Type I interferons, while IFN-y can induce class II (180-184).
Consistent with the expression o f MHC, EC can also express key proteins involved in the
assembly o f the MHC and peptide processing such as invariant chain and TAP 1/2 (181,
185). Experiments using cultured human EC to activate peptide-specific T cell clones
further demonstrates that EC can process and present functional peptide-MHC complexes
(186), though recent data has suggested that EC may present a distinct, less immunogenic
repertoire in their peptide-MHC complexes compared with other types o f APCs or
epithelial cells (187).

E C express costimulatory molecules
EC can also provide costimulation via cell-surface signaling molecules, adhesion
molecule and cytokines in addition to the TCR signal they provide via peptide-MHC
complexes. EC have been shown to express several members of both the Ig superfamily
and TNFR family on their cell surface.
In general, human EC do not express B7 molecules (188, 189) which in part
explains their inability to activate naive T cells. However, there is evidence that EC may
induce B7 expression on T cells and provide B7 signaling via a trans costimulatory
mechanism (190). There is also some suggestion that EC from different locations such as
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cardiac microvascular EC and brain EC may be capable o f expressing B7 molecules (191,
192).

ICOSL is constitutively expressed on the surface of HUVEC and has been shown

to be induced by TNF and IL-1 on HUVEC in an NF-kB dependent manner ( 8 6 , 193).
HUVEC expressing ICOSL in vitro can activate memory CD4+ and CD 8 + T cells ( 8 6 ,
193).

In addition to the costimulatory molecules B7 and ICOSL, EC have also been

demonstrated to express the inhibitory B7 molecule PD-L1 (89, 194) and to upregulate
expression o f PD-L1 with treatment from any o f the interferons (89, 195). EC expression
o f PD-L1 has a role in inhibiting CD4+ T cell cytokine synthesis and CD 8 + T cell
cytolytic function (89, 90, 194). EC also constitutively express LFA-3 (100). There is
much evidence that CD2-LFA-3 interactions between EC and T cells is a critical
component o f the costimulatory signals delivered by EC to T cells (188, 196, 197).
EC also have been described to express two o f the TNFR family members
including CD40-CD154 (124) and OX40L (152). EC have been shown to express CD40
constitutively both in vitro and in vivo and upregulate its expression when treated with
TNF, IL-1, IFN-y and IFN-P (120, 122). There have also been reports o f EC expressing
CD154 which is upregulated with IL-1, TNF and IFN-y (121). CD70 is not expressed on
resting endothelium and it is not known if it is inducible on EC (135). EC also express
OX40L constitutively, but there is not much known about its regulation (152).
Expression o f 4-1BBL on EC has not been reported, though 4-1BBL expression has been
reported on cardiac myocytes and aortic tissue (198, 199).
In sum, many EC have been previously reported to express the known
costimulatory molecules ICOSL, PD-L1, CD40/CD154 and OX40L. Therefore, while
most EC do not express the B7 molecules and thus cannot fully activate na'ive T cells,

20

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

they possess sufficient alternative costimulatory molecules which may play a large role in
the activation o f memory T cells.

The CD2/LFA-3 and ICOS/ICOSL interactions in

particular have been demonstrated to be important in EC capacity to activate memory T
cells and will be discussed later. EC also express adhesion molecules such as ICAM-1,
ICAM-2 and hyaluronan (200) and cytokines such as IL-1 a (201), IL-15 (202), IL - 6
(203), IL-11 (204) and IL-18 (205) that may provide additional costimulation to T cells.

EC can costimulate T cells in vitro
Compared to other stromal or epithelial cell types, cultured human EC have a
unique capacity in that they can activate proliferation o f allogeneic T cells freshly
isolated from peripheral blood (206, 207). The kinetics o f this activation is comparable
to that observed with professional APC such as allogeneic blood mononuclear cells, but
the magnitude o f the response in co-cultures between allogeneic T cells and endothelial
cells is generally smaller (180). EC have been shown to activate both CD4+ and CD 8 + T
cells in vitro (196, 208, 209). Both CD 8 + and CD4+ T cells secrete IFN-y in response to
co-culture with EC. Isolated CD 8 + T cells co-cultured with allogeneic EC make some
IL-2 and proliferate, but purified CD4+ T cells make much more IL-2 and proliferate to a
much greater extent (209, 210).

However, the CD4+ response depends upon

pretreatment o f the ECs with IFN-y (or preincubation with natural killer or CD 8 + T cells)
to cause class II MHC molecule expression, whereas constitutive levels of MHC class I
expression are sufficient to activate CD 8 + T cells (209).
Studies using limiting dilution assays to quantify the number o f T cells that
respond to allogeneic EC have indicated that the frequency o f responding T cells is

21

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

significantly lower than the frequency o f T cells responding to professional APC like
adherent monocytes or B cells (211, 212). Part o f this difference in activation capacity
may be attributed to the fact that for both CD4+ and CD 8 + T cells EC preferentially
activate memory T cells whereas professional APC can activate both naive and memory
T cells (213-215).

In vitro experiments suggest that naive T cells ignore and can even

become anergized in response to antigens presented by endothelial cells (216-218). In
contrast, co-cultures o f memory T cells with allogeneic ECs show T cell cytokine
production and proliferation, though even among memory CD4+ or CD 8 + T cells the EC
response is less compared to adherent monocytes (213). One reason for this difference
may be that EC present a different, less immunogenic repertoire than professional APC
(187). Another part o f the difference between EC and APC may lie in the distinct
costimulatory signals provided by EC as compared to professional APCs.
T cell proliferation in response to EC is also dependent on costimulatory
interactions between the T cell and the EC. However, unlike professional APC, most
human EC do not express B7 molecules and consequently cannot activate nai've T cells to
proliferate in allogeneic reactions. Mouse EC which do express B7.2 can activate CD 8 +,
but not CD4+, nai've T cells in vitro and in vivo (216, 219). As discussed previously, the
costimulatory requirements o f T cells change as T cells mature and differentiate.

In

particular, memory T cells require less costimulation than naive T cells (58, 59). Nai've T
cells need the assistance o f professional APC, like dendritic cells, to be activated, while
memory T cells can be activated by less specialized (or “sem i-professional”) APC such
as EC. Early experiments suggested that the costimulatory capacity o f EC appears to be
contact dependent as paraformaldehyde-fixed cells were demonstrated to costimulate T
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cells (98, 197). Interestingly, EC also seems to be capable o f providing costimulation in
trans to cells such as fibroblasts that ordinarily cannot activate T cells (220, 221).
The costimulatory functions o f EC were initially studied using polyclonal
activators such as phytohemagglutinin (PHA) or anti-CD3 antibodies (98, 196, 222, 223).
These studies demonstrated that EC like B lymphoblastoid cells could stimulate the
transcription and secretion o f both IL-2 and IFN-y from T cells whereas fibroblasts or
smooth muscle cells could not.

In examining the alloresponse, blocking interactions

between CD2/LFA-3 partly inhibited proliferation whereas antibodies to ICAM-1/2,
VCAM-1 or B7.1/2 had little effect on EC induced T cell proliferation despite having
significant effects on allogeneic blood adherent cell induced proliferation (209, 213, 224,
225). This suggests a strong role for the CD2/LFA-3 pathway in EC-mediated T cell
activation.

However, since blockade o f the CD2/LFA-3 pathway did not completely

inhibit cytokine production or proliferation (98, 197, 209) this suggests that other
costimulators expressed by EC may play a role in mediating T cell activation.
The consequence of EC interactions with T cells is to generate specific changes in
T cell signaling. ECs can trigger activity from the transcription factors AP-1, NFAT and
NF- kB (226) as well increased the levels o f AP-1 (227) in part due to LFA-3 dependent
aggregation o f lipid rafts (226). In addition to increasing mRNA o f IL-2 and IFN-y in T
cells, ECs can increase production o f IL-4 (223) and CD154 (228, 229) on the surface of
T cells via LFA-3 dependent mRNA stabilization.

CD4+ T cell adhesion, cytokine

production in response to polyclonal activators and IL-2 mRNA stabilization depends
upon signaling via OX40-OX40L (152, 153, 230, 231). The change in signaling leading
to IL-2 synthesis mediated by EC appears to be cyclosporine resistant. This effect is EC-
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specific and cannot be replicated by B lymphoblastoid cells or blood adherent cells
suggesting that EC provide a unique constellation o f costimulation (188, 197).
One caveat to studies done on costimulatory molecules are that T cell clones have
even less costimulatory requirements than resting memory T cells and can often be
stimulated by cells bearing peptide/MHC complexes without the assistance of
costimulatory molecules. Many o f the studies done initially using EC as APCs utilized T
cell clones (186, 232-234) and thus results interpreted from earlier studies may not truly
assess costimulatory function o f EC.

Another important caveat is that there are

significant species differences in the distribution o f costimulatory molecules.

For

example, mice do not possess the gene for LFA-3 (CD58) and in fact do not display a
known CD2 ligand on the surface o f their EC (104, 235, 236). In addition, murine and
porcine EC express B7.2. In humans, some early reports suggested that FIUVEC and
some types o f microvascular EC express B7.2 (191, 237), however, since then several
groups have shown by multiple methods that purified human EC populations largely do
not express B7 molecules (219, 238, 239).

Unique features o f antigen presentation by EC
EC-mediated T cell activation appears to provide signals that are distinct from
other APCs. In comparison to B lymphoblastoid cells from the same donor, EC activate
a smaller number o f both CD4+ and CD 8 + T cells in an MLR or with superantigen (212,
240).

As discussed previously, EC also selectively activate memory but not naive T

lymphocytes (214, 223, 240),

There are several possibilities as to why EC are less
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efficient activators of T cells and cannot activate nai've T cells in comparison to
conventional APC.
One possibility is that EC generate a different contact site compared to
professional APC.

T cells are known to form aggregates o f TCR, adhesion and

costimulatory molecules at the contact site with professional APC known as the
immunological synapse (33). Studies o f T cell-EC contact regions suggest that adhesion
molecules at the T cell-EC synapse may be different from the one T cells form with
professional APC (241, 242). Further evidence to support this comes from studies done
using PHA in which EC can activate naive T cells (223). PHA is known to provide
adhesion molecule-independent bridging between the T cell and the APC and thus with
PHA EC can activate naive T cells whereas in the alloresponse or using other polyclonal
activators like superantigen EC are limited to activating memory T cells (240).

As

mentioned previously, memory T cells also have elevated levels o f |31 and p2 integrins as
well as specialized chemokines receptors that may contribute to their capacity to be
activated by EC (46, 243).
A second possibility is that EC may express molecules that actively inhibit T cell
activation.

Recent work has demonstrated that EC express a large amount o f the

inhibitory molecule PD-L1 and that this molecule is increased by IFN-y and TNF (194).
Blockade o f this interaction can increase T cell cytokine synthesis and proliferation in
vitro (89, 194). EC have also been shown to express an activated form o f TGF-P (244,
245) which is known to have significant inhibitory effects on T cells (246). In addition to
direct inhibitory effects on T cells, EC may also modulate regulatory T cell activity
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through the expression o f GITR-L (247) and IL - 6 (203) both o f which have been
demonstrated to decrease the suppressor function o f regulatory T cells (248-251).
The final possibility is that EC do not express the appropriate costimulatory
molecules and therefore provide less effective activation which would enable only a
fraction o f memory T cells and no naive T cells to reach the activation threshold. This is
consistent with the idea that naive T cells have higher costimulatory requirements than
memory T cells (58). As described above, EC do not express B7 molecules which are
important costimulatory molecules in activating naive T cell (188, 189). However, EC do
express other costimulatory molecules, notably LFA-3 as well as CD40, OX40L and
ICOSL which are costimulators known to be important in T cell activation (124, 140,
145,252, 253).
In addition to activating fewer T cells compared to professional APCs, ECactivated T cells also possess a distinct phenotype from those activated by conventional
APCs.

For instance, CD 8 + T cells activated by EC retain expression o f CD69, CD25

and CD62L at 7 days, but have a lower level o f perforin compared to CD 8 + T cells
activated by B lymphoblastoid cells (BLC) which upregulate then downregulate all three
o f these markers and express high levels o f perforin (214). Additionally, allogeneic ECactivated CTL can kill both EC and BLC targets from the same donor, whereas BLCactivated CTL can only kill BLC, but not EC (215, 254). CD4+ T cells that have been
activated by EC demonstrate a more rapid increase in CD 154 upon activation (228) and
cyclosporine resistance (188).
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In vivo evidence fo r EC antigen presentation
EC occupy a unique niche in that they are in continual contact with T cells in the
periphery. As such, EC have a particular opportunity to influence the T cell response. T
cells may encounter antigen presented on EC and recruit antigen-specific memory T cells
to sites o f infection. This is supported by the observation that intradermal injection of
PPD antigen can elicit a response within hours in sensitized, but not naive test subjects
(255). The rapid kinetics o f this response suggests that EC may be presenting antigen to
PPD-specific T cells and activating them in situ.
Further evidence for EC as APC in vivo comes from transplantation models. CTL
specific for EC can be found in rejecting kidneys and heart transplants (256-258).
Furthermore, depletion of passenger leukocytes using anti-CD45 monoclonal antibodies
from human kidneys, which have MHC class II expressing EC, has no effect on allograft
rejection (259), whereas in rats, whose EC do not express MHC class II, depletion of
passenger leukocytes

can

significantly

delay

or prevent rejection

(260,

261).

Experiments done in mice also suggest the importance o f EC antigen presentation in
mediating transplant rejection.

Kreisel et al showed in a model o f cardiac allograft

rejection that non-hematopoetic cells such as EC can mediate rejection by direct
recognition o f allogeneic MHC class I by naive CD 8 + T cells. In this model, Kreisel et al
used a bone marrow chimera where the donor bone marrow was syngeneic to the
recipient and in this situation the cardiac allograft w as still rejected indicating that

rejection depended on MHC expressed by nonhematopoetic cells (262). In a model of
skin rejection, CD 8 + T cells could recognize the graft only when EC in the graft had been
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replaced by recipient EC demonstrating that EC can cross-present antigen and that EC
alone can sufficiently activate T cells to mediate rejection (263). Another mouse model
utilizing cardiac allografts showed CD4+ T cell allorecognition could also be mediated
by EC. In this model, a TCR transgenic mouse specific for HY antigen presented on
MHC class II molecules was transplanted with an HY positive heart bearing another
MHC class II molecule and rejection only occurred when the donor heart was replaced by
recipient EC (264).

This suggests that like the case for CD 8 + T cells, EC are also

capable o f presenting antigen to CD4+ T cells as well though there is conflicting
evidence.

Unlike the previous experiment, experiments using bone marrow chimeras

where the EC do or do not express MHC class II in a cardiac allograft show that MHC
class II expression on EC, and therefore CD4+ T cell recognition o f EC, does not
influence allograft rejection (216).
The final piece o f evidence for EC presentation in vivo comes from another
mouse model o f diabetes.

In this model, it was observed CD 8 + T cells specific for

insulin could cause diabetes in mice strains that had no preexisting inflammation. It was
found that these T cells could recognize pancreatic endothelium in in vitro islet cultures.
The recognition triggered T cell integrins and EC expression of chemokines, especially
CCL21 or SLC, which mediated firm adhesion o f the specific T cells to the endothelium
(265). This suggests that antigen presentation by EC in addition to chemokine signaling
may be important to in mediating appropriate T cell homing.
Thus, EC express molecules critical for antigen presentation including MHC
molecules and costimulatory molecules.

EC have also been demonstrated to activate

both memory CD4+ and CD 8 + T cells in vitro and in vivo, though this activation appears
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to be qualitatively and quantitatively distinct from activation mediated by other APCs
such as BLC and monocytes. EC antigen presentation may have an important role in the
homing to sites o f inflammation and regulation o f the local immune response.

1.4 MEMORY T CELLS IN TRANSPLANTATION
Identification o f alloreactive memory T cells
Alloreactive memory T cells have been demonstrated to play a role in the
rejection o f heart, kidney and liver transplants.

This has been demonstrated by

correlating the presence o f pre-transplant memory T cells with increased incidence and
severity o f rejection (266-269).

Furthermore, two groups have reported a correlation

between pre-transplant frequency o f alloreactive memory T cells as measured by in vitro
IFN-y production to post-transplant risk o f rejection (270, 271). Reduced numbers of
pre-transplant memory T cells also correlated with improved function o f kidney allografts
12 months following transplantation (270, 272). Late episodes o f rejection in patients 2
to 18 years after transplantation were also associated with an increase in cells with a
memory phenotype (CD45RO+) in the circulation (273). In fact, several studies have
shown that donor-reactive T cells with a memory phenotype can be generated in the
presence o f immunosuppression (271, 274). All these studies suggests that memory T
cells may contribute to both initial and late acute rejection episodes. They also suggest
that despite immunosuppression, existing memory T cells and those generated during
early rejection episodes may contribute to late or chronic graft loss.
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Generation o f alloreactive memory T cells
Memory T cells, by definition, are T cells that have previously encountered
antigen. In the case o f allografts, the major source o f antigen exposure would be via
pregnancy, blood transfusion or prior organ transplant. However, these situations do not
apply to many patients which raises the question o f how memory T cells arise in non
sensitized patients. Two hypotheses for the generation o f this memory population are
heterologous immunity and homeostatic proliferation.
Heterologous immunity refers to the concept that the T cells (or B cells)
responding to one antigen may be cross-reactive with other related or unrelated antigens.
This is applicable to transplantation in that T cells generated from infectious agents may
be capable o f responding to alloantigen. This has been supported by work done in both
mice and humans. Adams et al provided strong evidence that multiple viral infections
were capable o f generating significant numbers o f alloreactive memory T cells that
prevented the induction o f tolerance (275). Memory CD 8 + T cells that can react with
alloantigen have also been found in mice infected with lymphocytic choriomeningitis
virus (LCMV) (275).

Memory CD4+ T cell cross reactivity with alloantigen was

observed in mice infected by Leishmania major (276).

Studies in humans have also

correlated the presence o f alloreactive cytotoxic T cells with seropositivity for Epstein
Barr virus (EBV) and cytomegalovirus (CMV) (277, 278).

Specifically, HLA-B 8

restricted CD 8 + T cells specific for an EBV epitope showed cross reactivity with
alloantigens, in particular HLA-B44 (277). Interestingly, prior to this study B 8 and B44
were identified as an immunological pairing that predicted worse prognosis for allograft
survival compared with pairings between other MHC haplotypes (279). Taken together,
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these studies provide significant evidence in humans to suggest that memory T cells
generated by infection can respond to alloantigen and may contribute to allograft
rejection.
Memory T cells may also be generated by the process known as homeostatic
proliferation.

Homeostatic proliferation refers to the observation that donor T cells

undergo proliferation when transferred into lymphopenic recipients. This phenomenon
has been well-documented in mice (280) and, as mentioned above, this lymphopeniainduced proliferation can generate T cells with a memory phenotype from naive T cells
(44, 281, 282). Memory T cells generated in this fashion possess properties similar to
antigen-experienced memory T cells; for instance, they can mediate rejection without
secondary lymphoid organs (61). Homeostatic proliferation occurs naturally in neonates
during the first wave o f naive T cell release from the thymus into the empty lymphoid
compartment (283).

More relevant for transplantation, homeostatic proliferation can

occur during infection (284), and following chemotherapy in older patients where the
thymus has involuted (285).

Another situation o f lymphopenia relevant for

transplantation is the use o f T-cell depletion strategies such as rabbit anti-human
thymocyte globulin or anti-CD52 (286).

Homeostatic proliferation following any o f

these situations to replenish the T cell pool may generate memory T cells that contribute
to allograft rejection.
While alloreactive memory T cells can be generated from heterologous immunity
and hom eostatic proliferation, it is not clear that these m echanism s generate mem ory T
cells that function like true antigen-specific memory T cells. More specifically, it is not
known if the affinity and frequency o f memory T cells generated by both these
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mechanisms reflect properties o f a true memory T cell response. Some studies suggest
that homeostatically generated T cells are not as efficient at rejecting grafts compared
with alloantigen experienced memory T cells (61).

Studies of heterologous immunity

have also suggested that the frequency o f alloreactive memory T cells generated by
infection is lower than that seen with exposure to alloantigen (275, 276). However, the
same studies also demonstrated that while the frequency o f alloreactive memory T cells
may be lower, rejection o f a skin graft by cross-reactive memory T cells generated from
infection had the same kinetics as second set rejection in mice that had previously been
primed with donor-type alloantigens (276).

Memory T cells and inhibition o f tolerance
In addition to contributing to increased episodes o f allograft rejection and poorer
long-term graft survival, memory T cells may also stymie the development o f transplant
tolerance. The quest to induce tolerance to foreign organ transplants has been the holy
grail o f the transplant field. A number of successful protocols have recently emerged in
rodent models where recipients will tolerate donor organs indefinitely using combinations
o f costimulatory blockade (287-289). However, the same protocols in large animal and
non-human primate models have been largely unsuccessful (290).

One o f the key

differences between rodents and humans/large animals is the significant population of
memory T cells in the circulation o f the latter.
This idea o f m em ory T cells being a barrier to tolerance has been tested in several

rodent models. For instance, mice that have been sensitized to a donor antigen using a
donor-type skin graft could reject a cardiac allograft in the presence o f the anti-CD 154
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which induces tolerance in unsensitized mice (291-293). Memory T cells generated from
infectious sources have also been shown to cause rejection even with a known tolerance
inducing protocol (275).

In those experiments, Adams et al showed that co-infection

with LCMV, vaccinia virus, and vesicular stomatitis virus resulted in the generation o f
alloreactive memory T cells that prevented tolerance with a protocol involving treatment
with CTLA-4Ig, anti-CD 154 mAh, busulfan and donor bone marrow infusion.

That

protocol has been demonstrated by several groups to induced donor-specific tolerance in
nai've animals and Adams et al shows that the presence o f virally-specific CD 8 + memory
T cells prevented the induction o f tolerance in the majority o f mice that had received the
tolerance protocol.
Wu et al have also shown that memory T cells generated from homeostatic
proliferation were similarly resistant to tolerance inducing protocols (281). Blockade o f
either CD28/B7, CD40/CD154 interactions or a combination of both agents which has
been shown to induce tolerance in nai've animals was ineffective at preventing cardiac
allograft rejection when homeostatically generated memory T cells were present. They
further show that the mechanism for this graft rejection relied in part on a reduced
necessity o f memory T cells for CD28 costimulation.
The evidence discussed above highlights the importance of memory T cells in
mediating allograft rejection and in particular how the unique properties o f memory T
cells can not only contribute to enhanced rejection responses, but also to prevention of
tolerance.

Transplant recipients more than likely have had numerous infections,

particularly from EBV and CMV, and thus it is likely that any attempt to manipulate the
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immune response that focuses on T cell activation will need to account for memory T
cells.

Targeting memory T cells
Current

clinical

therapies

for

organ

transplants

that

generate

global

immunosuppression have revolutionized the success o f organ transplantation. However,
it is not clear what effects global immunosuppression has on T cell memory. Studies
correlated pretransplant alloreactive memory T cells with acute rejection episodes that
occurred despite immunosuppression using tacrolimus or sirolimus (270, 271). Memory
T cells may also be resistant to lymphocyte depletion strategies using rabbit anti
thymocyte globulin or anti-human CD52 mAb. A recent study from Pearl et al showed
that memory CD4+ T cells are the dominant remaining subtype following depletion
(286).

The responses o f these memory CD4+ T cells were resistant to steroids,

deoxyspergualin, and sirolimus, but not tacrolimus or cyclosporin A. Other reports have
indicated that memory T cells may be tolerized using a combination o f deoxyspergualin
and costimulation blockade (275) and that cyclosporine instead o f inhibiting memory T
cells actually promotes memory T cell formation and may result in an enhanced recall
response (294, 295).
In addition to global immunosuppression, another strategy to target memory T
cells is the induction o f donor-specific tolerance. One study in mice showed that memory
CD 8 + T cells specific for hemagglutinin A (HA) were tolerized by administration of
soluble HA peptide or via cross-presentation o f antigen from pancreatic islets engineered
to produce HA. Both methods seemed to produce tolerance via induction of peripheral
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apoptosis (296). Memory CD4+ T cells can also be anergized using by low avidity TCR
stimulation (297). Memory T cells may also be subject to regulation from regulatory T
cells. CD4+CD25+ T cells can suppress CD 8 + memory T cells responses to Listeria
monocytogenes and, when adoptively transferred, Tregs can also delay allograft rejection
in a model o f CD 8 + T cell memory (298, 299).
Another strategy, and perhaps the one with the most promise, is to target memory
T cell activation.

Targeting the CD28/B7 and CD40/CD154 pathways has been

demonstrated in numerous rodent models to successfully induce tolerance (288, 289, 300,
301). However, memory T cells have been shown to be less reliant on APC mediated
costimulation (58) and in particular they have a reduced requirement for CD28/B7 and no
requirement for CD40/CD154 signaling (60). Despite being less reliant on CD28/B7 and
CD40/CD154 singaling, it has become increasingly clear that memory T cells may
depend on other costimulatory pathways to become fully activated.

Some newly

described pathways that have been implicated in memory T cell function include
ICOS/ICOSL,

4-1BB/4-1BBL,

OX40/OX40L,

CD30/CD30L

and

CD27/CD70.

ICOS/ICOSL blockade has been shown to prolong allograft survival in rodents,
particularly if administration o f the blocking antibody is delayed suggesting that it
interferes with effects that occur after T cells have been primed (302). Blocking ICOSICOSL interaction has also been shown to prevent chronic rejection and potentiate
tolerance when combined with other immunosuppressive treatments (303).

4-1BB/4-

1BBL has been demonstrated in murine models to be important in CD 8 + T cells
mediated rejection o f allogeneic intestine (304), cardiac (305), and skin (305) allografts.
Blockade o f 4-1BB/4-1BBL pathway prolonged graft survival for all organs by
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decreasing the number o f alloreactive CTL, however blockade did not induced tolerance
to grafts in any o f these models. Despite success in inhibiting nai've T cells responses,
inhibition o f 4 -IBB did not prolong graft survival in a murine model o f memory T cell
mediated skin allograft rejection (306). OX40-OX40L interactions have been shown to
be important in CD4+ memory T cell responses to allografts (307). In this rat model of
transplant rejection, blockade o f OX40-OX40L in combination with B7 blockade
prolonged cardiac allograft survival in recipients receiving primed T cells (307). Vu et al
also showed that OX40-OX40L blockade in conjunction with B7 and CD40/CD154
blockade could induce long term survival o f skin grafts in mice possessing memory T
cells that were generated by either donor-specific priming or homeostatic proliferation
(306).

Finally, targeting CD27-CD70 interactions could lead to indefinite allograft

survival in the presence o f memory CD 8 + T cells (308). All the above evidence suggests
that memory T cells do require costimulation distinct from nai've T cells to achieve full
activation and that targeting these costimulatory pathways can affect the response of
memory T cells to allografts though the specific mechanisms by which they work remain
unclear.

Memory models and the SCID/beige mouse-human skin chimeric transplant model
Murine models o f T cell memory have contributed significantly to our
understanding o f memory and allograft rejection. The existence o f allospecific memory
T cells in vivo was initially suggested using a murine minor Ag (HY) model confirmed
that allosensitized memory T cells mediate an accelerated form o f rejection known as
second set rejection (309). Since that time, murine models have shown that allospecific
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memory T cells can be generated by heterologous immunity or homeostatic proliferation
can mediate transplant rejection (275, 281). These murine models using presensitized
mice or mice with homeostatically generated memory T cells demonstrated that memory
T cell mediated rejection is independent o f secondary lymphoid organs (61) and resistant
to CD28 and CD 154 blockade (281, 291, 292, 306).

However, studying memory in

transplantation remains limited by fact that mice used in these models are either too
young or too antigen inexperienced to have significant populations o f memory T cells.
Almost all o f the current mouse models used to study memory must generate memory T
cells through specific infection or donor-specific priming which may not accurately
recapitulate the numbers and diversity found in large animals and humans. As mentioned
above, this in part may explain why protocols developed in mice for tolerance have not
been successfully translated into large animals or humans.

Therefore, one strategy to

improve our understanding o f memory may be to study the human immune response and
one method to do so in vivo is the human mouse chimera model.
The ability to study a functional human immune system in an in vivo model was
made possible by the development o f immunodeficient mouse hosts. Mice bearing the
severe combined immunodeficiency (SCID) mutation or lacking recombinase activating
gene (RAG) have been successfully used as hosts for human cells. In the absence of
mouse T and B cells, stable long-lived reconstitution o f human T cells can be achieved
with interperitoneal injection o f human peripheral blood leukocytes in the SCID mouse
(310). These mice have been used to study the human immune system in particularly in
HIV and transplantation. Early studies demonstrated that skin could be engrafted onto
SCID mice and that if these mice were reconstituted with human T cells that the
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recruitment o f these T cells are limited to human tissue and that this recruitment depends
on specific cytokines (179, 311).

In addition to mediating allograft rejection, studies

using tetanus toxin demonstrated that human T cells derived from the mouse spleen could
be activated in vitro which indicated that the human T cells retained function in their
murine hosts (312). Furthermore, T cells from human donors immunized with tetanus
toxin, but not naive donors, homed specifically to the human skin graft when tetanus
toxin was injected into the skin graft, but not when it was injected into the adjacent
mouse skin suggesting that recruitment depended on a human microenvironment.
The model used in our laboratory employs SCID/beige mice which have an
additional mutation in a lysosomal transporter that is homologous to the Chediak-Higashi
gene found in humans (313). The effect o f this gene is to effectively eliminate NK cell
function in the mice, which is to ensure human graft acceptance by preventing xenograft
recognition by murine NK cells.

The protocol developed by Murray et al involves

grafting SCID/beige mice with human skin allowing the skin to heal in for several weeks
and then adoptively transferring PBMC allogeneic to the skin into the peritoneal cavity of
the mice (179). CD3+ T cells can be detected in the circulation within one week and no
significant levels o f CD19+ B cells, CD14+ macrophages, or CD16+ NK cells can be
detected in the circulation. Human B and T cells can be found in the lymph nodes in low
numbers and while the mice do produce circulating human immunoglobulin there is no
evidence o f complement deposition or neutrophil invasion (314). Depletion o f B cells
also has no effect on the infiltration or microvascular destruction observed in the
transplanted human skin grafts (315). Graft versus host disease is also negligible in this
model because the human antibodies produced do not appear to be specific for murine

38

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

antigens and the MHC restriction between mice and humans is sufficiently different to
prevent direct recognition. There is also no evidence o f human macrophage or dendritic
cell engraftment (314). Thus, this model describes a largely T cell mediated allograft
response.
The initial studies o f this model characterizing the response demonstrated that this
model recapitulates first set skin rejection observed in humans (179). Human skin grafts
on mice reconstituted with allogeneic PBMC demonstrate progressive leukocyte
infiltration and destruction o f the microvasculature that has equivalent kinetics and
histologic appearance to human allogeneic skin rejection.

Experiments showing

significant graft protection using mouse anti-LFA-3 mAb or human LFA-3-IgGl fusion
protein have demonstrated the utility of using this model to study human allograft
rejection in vivo (109). Expansion o f this model to human arteries has also demonstrated
successful engraftment and further supports the use o f this model to study human
alloresponses (316, 317).

1.5 THESIS OBJECTIVES
The basis for the studies in this thesis derives from three observations.

First,

memory T cells are a significant hindrance to allograft rejection and long-term allograft
survival (318). Second, EC antigen presentation has been shown to play an important
role in transplant rejection (197, 263, 264). Third, EC have been shown to selectively
activate memory T cells (213, 214) through LFA-3 and other as yet unknown
costimulatory molecules expressed on EC (197).

The questions of how EC activate
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memory T cells and what role this activation may play in transplant rejection have not
been explored.
Thus, I hypothesize that EC express molecules that uniquely enable them to activate
memory T cells and that presentation o f antigen by EC using these costimulatory
molecules contributes to memory T cell mediated allograft rejection.

In this thesis, I

address this question with the following four aims. First, I will detail the human memory
T cell response to human EC in vitro and describe an in vivo model to study human
memory T cell mediated allograft rejection (Chapter 3). Second, using this model, I will
investigate the role o f B7 costimulatory molecules on EC-mediated T cell activation in
vitro and in vivo using a novel CD28 blocking reagent (Chapter 4). Third, I will examine
the role o f memory T cell specific costimulators on EC-mediated T cell activation in vitro
and in vivo (Chapter 5). Finally, I will study the response o f different memory T cell
subsets to EC (Chapter 6 ). Completion o f these aims will enhance the understanding of
how EC activate memory T cells and elucidate the role that interactions between EC and
memory T cells play in allograft rejection.
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CHAPTER II - MATERIALS AND METHODS
2.1 MATERIALS
Cytokines
Recombinant human

TNF

(TN Fa)

was purchased

from

R&D

Systems

(Minneapolis, MN) and recombinant human IFN-y from Biosource International
(Camarillo, CA).
Antibodies
Mouse anti-human CD4, CD 8 , CD80, and CD 8 6 conjugated to phycoerythrin
were obtained from BD Biosciences (San Jose, CA). Azide-free IgG l was obtained from
eBioscience (San Diego, CA) and mouse anti-human CD58 (LFA-3) (clone TS2.9) was
purchased from Pierce Biotechnology (Rockford, IL). Mouse anti-CD28 (clone 28.2) and
CD27 (clone M-T271) were purchased from BD Bioscience (San Jose, CA).

Mouse

anti-human 4 -IBB and mouse anti-human OX-40 mAbs were purchased from Ancell
(Bayport, MN). Mouse anti-human ICOS mAb was purchased from eBioscience (San
Diego, CA). Mouse anti-human 4-1BBL mAb was a gift from X.G. Zhang (Suzhou,
China), mouse anti-human ICOSL mAb was a gift from H.W. Mages (Berlin, Germany).
Mouse anti-human OX40L mAb and recombinant human 4-lB B Fc were purchased from
R&D Systems (Minneapolis, MN).

Biotin-conjugated goat and donkey anti-mouse

antibodies were purchased from Jackson ImmunoResearch (West Grove, PA).
FK734 was produced by Fujisawa Pharmaceutical Co., Ltd. (now Astellas Pharma
Inc.).

FK734 is a humanized IgG2ic anti-human CD28 antibody that has the

complementary determining regions (CDRs) o f the mouse anti-human monoclonal
antibody TN228 (319) and the Fc domain o f human IgG2M3, in which 2 amino acid
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mutations (V234A, G237A) have been introduced into the human y2 chain to eliminate
binding o f the antibody to FcyR.

The original TN228 cell line was generated by

immunizing BALB/c mice with human CD28-transfected mouse fibroblast L cells and
fusing immune splenocytes with P3 U1 myeloma cells. The purified molecule consists o f
two heavy chains and two light chains, which are 447 amino acid residues
(C 2 1 7 7 H 3358 N 575 O 6 6 9 S 19 ;

MW

48898.64)

and

218

amino

acid

residues

(C 1043 H 1628 N 279 O 3 4 2 S7 ; M W 23772.21) in length, respectively. FK734 binds to a human
CD28-mouse IgG Fc fusion protein (K d=3.72xl08) and inhibits proliferation o f human T
cells stimulated with anti-CD3 and P815/human CD80+ cells in a concentration
dependent manner with the half inhibitory concentration at 74.6 ng/mL (unpublished
data, K.K.). FK734 does not cross-react with mouse CD28.

2.2 I N VITRO METHODS
Isolation and culture o f human cells
All human cells and tissues were obtained under protocols approved by the Yale
Human Investigations Committee. PBMCs were isolated from by density gradient
centrifugation o f leukapharesis products from healthy adult volunteers by using
Lymphocyte Separation Medium (Gibco BRL, Grand Island, N.Y.). Isolated cells were
stored in 10% DMSO/90% FBS in liquid N 2 (-196°C) and were thawed and washed
before use (320).

CD4+ and CD 8 + T cells were isolated from PBMCs by positive

selection by using Dynabeads (Dynal (now Invitrogen), Lake Success, N.Y.) as described
previously (189).

The selected populations obtained by this procedure were routinely

>97% CD4+ or CD 8 + by FACS analysis (data not shown).

Activated T cells were
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removed by negative selection with an anti-HLA-DR antibody at a concentration o f 5
pg/ml (LB3.1; gift o f J. Strominger, Harvard University, Cambridge, Mass.) for 20 min,
washing twice, and depleting by using magnetic beads conjugated to goat anti-mouse
antibody (Dynal). Naive and memory subsets o f T cells were isolated from the total T cell
population by further negative selection by using anti-CD45RA or anti-CD45RO
antibodies at a concentration o f 2 pg/ml (Biosource, Camarillo, Calif.).

To obtain

memory T cell subsets, CD4+ T cells were isolated from PBMCs by positive selection by
using BD IMag CD4+ magnetic particles (BD Biosciences, San Jose, CA). The selected
population obtained by this procedure was routinely >95% CD4+ by flow cytometry (data
not shown). Cells were then stained with mouse antibodies to mouse anti-human CD62L
(BD Biosciences San Jose, CA), mouse anti-human CD45RO (BD Biosciences, San Jose,
CA) and mouse anti-human CCR7 (R&D Systems, Minneapolis, MN) and subjected to
FACS sorting on a FACSAria (BD Biosciences, San Jose, CA) to isolate T cm
(CD45RO+, CCR7+ and CD62L+) from TEM (CD45RO+, CCR7-, CD62L-).

Monocytes (Mo) were obtained by incubating PBMCs on gelatin-coated tissue
culture plates in RPMI 1640 medium containing 10% FCS, 100 units/ml penicillin, 100
pg/ml streptomycin, and 2 mmol/liter L-glutamine (RPMI/FBS) for 1 hour then washing
away the non-adherent cells. Mo were then harvested by washing the plates with PBS
and incubating the flasks with ice-cold 10 mM EDTA in RPMI 1640 for approximately
5-10 minutes. Detached cells were then collected, centrifuged at 1200 rpm and plated
onto 24-well gelatin-coated plates in RPMI/FBS. The selected population obtained by
this procedure was routinely >80% CD 14+ by FACS analysis and <10% CD3+ (data not
shown).

Alternatively Mo were negatively selected using the Monocyte Negative
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Isolation kit from Dynal (Lake Success, NY). Whole PBMC were incubated with the
blocking and antibody reagents for 15 minutes at 4°C and then washed with PBS/0.5%
BSA/2 mM EDTA. The cells were then incubated with the supplied beads at the ratio
recommended by the manufacturer. The bead/cell mixture was then incubated at 4°C for
15 minutes and then placed on the magnet. The cells left in the supernatant were then
harvested for use.

The population obtained by this procedure was routinely >90%

CD 14+ by FACS analysis and <5% CD3+ (data not shown).

HUVECs, which are uniformly positive for CD31 and negative for CD45 by
FACS analysis, were isolated and cultured as described previously (321).

CD86-

transduced FIUVEC were generated using a retroviral vector containing the full-length
mRNA o f human CD86 using methods described previously (322).

Transduced EC,

control EC (EC transduced with retroviral vector containing LacZ or EGFP), and Mo
expression o f CD80 and CD86 were compared by staining cells with mouse anti-human
CD80 and CD86 and subjected to FACS analysis (Figure 4.3s).

Human dermal

microvascular endothelial cells (HDMEC) were isolated from discarded human skin,
purified using anti-CD31 mini MACS beads (Miltenyi Biotec, Auburn, CA) and cultured
in EGM2-MV growth medium (Clonetics, San Diego, CA) as previously described (323).
When indicated, the cells were treated with 50 ng o f IFN-'f per ml for 3 days prior to
cocultivation. After pretreatment with IFN-7, the ECs were uniformly HLA-DR positive
(data not shown).

Monocyte (Mo) and HUVEC co-cultures with allogeneic T cells
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For the co-cultures, 1.5x10s HUVEC or HDMEC at subculture level 1 or 2 were
plated into gelatin-coated wells o f a 24-well culture plates (Falcon, Becton Dickinson,
Bedford, MA) and grown to visual confluence. EC cultures were treated with 50 ng/mL
o f IFN-y (Biosource, Camarillo, CA) per ml for 3 days prior to the addition o f T cells.
After pretreatment with IFN-y, the ECs were uniformly HLA-DR positive by FACS
analysis (data not shown). 1x10s Mo were collected and plated into gelatin-coated wells
o f a 24-well culture plates and cultured for three days in RPMI/FBS. Purified T cell
pupulations were then added to each well ( ~ lx l0 6 per well) (See Figure 2.1).

All

cultures were maintained in 5% CO 2 at 37°C. The medium for co-culture consisted of
RPMI 1640 supplemented with 10% FBS serum (Gibco BRL, Grand Island, N.Y.), 2 mM
L-glutamine, 100 U/ml penicillin, and 100 pg/ml streptomycin.

For cell surface immunostaining, T cells from co-cultures were collected by
washing wells twice with Hanks-buffered saline solution (HBSS) and centrifugation at
1000 x g for 5 min, washed twice with ice-cold PBS containing 1% bovine serum
albumin and 0.1% sodium azide (PBS/BSA).

T cells were then incubated with the

indicated antibodies or isotype controls at 2 ug/ml in PBS/BSA for 2 h at 4°C and then
analyzed using a FACSort and Cellquest software (BD Biosciences).

To measure

proliferation by carboxy-fluorescein diacetate succinimidyl ester (CFSE) dilution, the T
cells were stained with 250 nM CFSE (Molecular Probes, Eugene, OR) for 15 min prior
to co-culture with ECs. Cells were collected after the indicated times and subjected to
FACS analysis.
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Figure 2.1. E C -T cell co-cultures. For co-cultures with CD4+ T cells, EC are treated with
IFN-y for three days to upregulate MHC class II. T cells are then added to the EC. After 24h
supernatants are collected for analysis o f cytokine production by ELISA. T cells are then either
subject to FACS or radiolabeled thymidine to analyze their proliferation.
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Preparation o f RNA, cDNA, and Procedure fo r Quantitative PCR

RNA was isolated from T cells and EC using RNeasy mini kits (Qiagen, Valencia,
CA) with on-column DNase treatment following the manufacturer's supplied instructions.
RNA was isolated from skin grafts using the RNeasy fibrous tissue mini kit (Qiagen)
again with on-column DNase treatment and following the manufacturer’s supplied
instructions. cDNA was synthesized using Taqman RT reagents (Applied Biosystems),
following the manufacturer's instructions. Quantitative real-time PCR (qRT-PCR) for 41BBL, ICOSL, OX40L, FasL, Granzyme B and Perforin and CD3s was performed as
using primers shown in Table 1-2.

The PCR reaction mixture (final volume 25 pi)

contained 5 pi o f cDNA, 1 pi o f 10 pM forward primer, 1 pi o f 10 pM reverse primer, 2.5
pi o f PCR lOx SYBR Green PCR buffer, 3 pi o f 25mM MgCl2, 2 pi o f dNTP mix (2.5

u im

dATP, 2.5 mM dCTP, 2.5 mM dGTP, and 5 mM dUTP), 0.125 pi o f AmpliTag Gold DNA
polymerase (5 units/pl AmpliTag Gold DNA polymerase), and 10.375 pi o f H20 . The
PCR reaction was performed in triplicate (3 wells o f C96 well plate). The reaction was
amplified with iCycler iQ Multicolor Real Time PCR Detector (Bio-Rad) for 37 cycles
with melting at 94 °C for 30 s, an annealing at 58 °C for 30 s, and extension at 72 °C for 1
min in iCycler iQ PCR 96-well plates (Bio-Rad). Samples were analyzed by generating a
standard curve from plasmids containing the PCR fragment and expressed as copy
number where indicated or by calculating a fold induction. The relative quantification
values for the gene expression was calculated from the accurate C t, which is the PCR
cycle at which an increase in reporter fluorescence from SYBR Green dye can be first
detected obtained above a baseline signal. C t values for GAPDH (or CD3s) cDNA were
subtracted from CT values for the cDNA o f the gene o f interest for each well to calculate
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A -C t. The triplicate

a -C |

values for each sample were averaged. To calculate the fold

induction o f mRNA in experimental cells compared with control cells, the averaged A -C t
values calculated for control cells was subtracted from A-CT values calculated for
experimental cells to calculate AA-Cj. Then, the fold induction for each well was
calculated by using

formula. The fold induction value for triplicate wells was

averaged, and data are presented as the mean ± S.E. o f triplicate wells.

Flow cytometric analysis

For cell surface immunostaining, HDMEC/HUVEC were washed twice with
Hanks-buffered saline solution (HBSS) and incubated with trypsin/EDTA for 1 min.
Detached cells were collected by centrifugation at 1000 x g for 5 min, washed twice with
ice-cold PBS containing 1% bovine serum albumin and 0.1% sodium azide (PBS/BSA).
Either detached cells, monocytes or T cells were then incubated with the antibodies or
isotype controls at 2 pg/ml in PBS/BSA for 2 h at 4°C. After two further washes cells
were incubated with 2 pg/ml biotin-conjugated secondary antibodies in PBS/BSA for 1 h
at 4 °C. Following another two washes, cells were incubated with 1 pg/mL strepavidin-R
phycoerythrin (Molecular Probes, Eugene, OR) in PBS/BSA for 30 minutes at 4°C,
washed a further two times and analyzed on a FACSort using Cellquest software (BD
Biosciences).

ELISA
Supernatants were collected from co-cultures o f T cells with HUVEC or with Mo
after 24h or 48h o f co-culture. The samples were then assessed using an ELISA kit for
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IFN-y (Biosource, Camarillo, CA) or IL-2 (Ebioscience, San Diego, CA). Both ELISAs
were performed as described by the respective manufacturers.

Proliferation Assays
T cell proliferation was measured by [3H]-thymidine incorporation.

In brief,

HDMEC or HUVEC were cultured in 96-well U bottom plates (Falcon) as described
previously (323) and confluent monolayers were then pretreated with 50 ng IFN-y
(Biosource, Camarillo, CA) prior to co-culture with CD4+ T cells. All HUVEC were
then treated with mitomycin C (50 pg/ml in PBS, 30 min; Sigma-Aldrich, St. Louis, MO)
prior to co-culture to prevent their proliferation as described previously (209). 24h prior
to each indicated time point, 1 pCi [3H]-thymidine (Amersham, Arlington Heights, IN)
was added to each well. Plates were frozen, thawed and then harvested on a 96-well
harvester (Tomtec, Hamden, CT) and counted on a Microbeta scintillation counter
(Wallac, Gaithersburg, MD). The mean o f the replicates (n=16) was calculated, and the
mean [JH]-thymidine incorporation into wells containing only EC was subtracted.
To measure proliferation by carboxy-fluorescein diacetate succinimidyl ester
(CFSE) dilution, the cells were stained with 250 nM CFSE (Molecular Probes, Eugene,
Oreg.) for 15 min prior to coculture with ECs. Cells were then collected after co-culture
and subjected to FACS analysis.
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2.3 I N VIVO METHODS
Animals

C.B-17 SCID/beige female mice (Taconic Farms, Germantown, NY) were used at
5-8 wk o f age. All protocols involving animals were approved by the Yale Animal Care
and Use Committee. The animals were housed individually in microisolator cages and
were fed autoclaved food and water. Prior to each experiment, serum mouse IgG levels
were determined by sandwich ELISA using reagents from Cappel (Durham, NC) as
previously described (179). SCID/beige animals were considered "leaky" at IgG levels >1
jig/m land excluded from experimental use.

Skin Grafting

Human skin was obtained from cadaveric donors through the Yale University
Skin Bank under a protocol approved by the Yale Human Investigations Committee.
Human skin was orthotopically transplanted to SCID/beige mice as previously described
(179). In brief, 0.5-mm-thick sheets were divided into 1-cm2 pieces, kept at 4°C in RPMI
1640 medium (GIBCO/BRL) and fixed onto similar sized defects on the dorsum o f C.B17 SCID/beige recipients using staples (3M, St. Paul, MN). The resultant surface area of
healed grafts was kept constant between animals when possible. The skin reproducibly
grafted with a >95% success rate and was allowed to heal for 4 wks before manipulating
the graft. Rare animals that did not successfully engraft were excluded from the
experimental groups before treatments.

PBMC and T cell subset adoptive transfer
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For adoptive transfer o f PBMC, SCID/beige mice were reconstituted with 3 x 108
human PBMC by i.p. inoculation 4-5 weeks after skin engraftment.

Animals

demonstrated no signs o f graft-vs.-host disease. Rare animals that failed to reconstitute
with human T cells were, by prior design, excluded from analysis.

For memory or nai've T cell subsets, CD45RA+ or CD45RO+ T cells were
isolated as described above and cells were >95% pure populations and both populations
contained approximately a 2:3 ratio o f CD8+ to CD4+ cells.

SCID/beige mice were

reconstituted with 3 x 108 human PBMC by i.p. inoculation 4 wk after skin engraftment.
Animals demonstrated no signs o f graft-vs.-host disease. Rare animals that failed to
reconstitute with human T cells were, by prior design, excluded from analysis.
Alternatively, separated nai've or memory T cells were then counted using a Coulter
particle counter (Beckman Coulter, Fullerton, CA) and 1.5 x 108 cells were i.p.
inoculated into SCID/beige mice 4 weeks after skin engraftment.

For memory T cell subsets, CD62L-CCR7-

(T

em

)

or CD62L+CCR7+

(T

cm

)

T

cells were isolated as described above and the resulting cells were >95% pure upon
reanalysis. SCID/beige mice bearing human skin from a donor allograft to the PBMC
were adoptively transferred with 1 x 106 cells from either subset by tail vein injection 4
wk after skin engraftment. None o f the animals demonstrated signs of graft-vs.-host
disease.

Circulating human T cells were evaluated by flow cytometry as previously
described (320). In brief, heparinized retro-orbital venous samples were obtained 14 days
after reconstitution, and the erythrocytes were lysed. The leukocytes were incubated with
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FITC-conjugated mouse anti-human CD3 (Immunotech, Westbrook, ME) and PEconjugated rat anti-mouse CD45 (Sigma-Aldrich, St. Louis, MO) mAbs. Samples were
then analyzed using a FACSort (BD Biosciences, San Jose, CA). (See Figure 2.2)
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Figure 2.2 The hum an-SC ID m ouse chimera. SCID/beige mice are grafted with split thickness human skin. The grafts are
allowed to heal for 4-6 weeks. The mice are then injected with either CD45RA+ or CD45RO+ T cells (A), blocking antibodies
and PBMC (B), or purified central or effector memory T cells (C). The grafts are then harvested and taken for analysis.

Histology and Immunohistochemistry

Human skin grafts, harvested at indicated times, were processed for paraffinembedded or frozen sections as previously described (320).

The degree o f graft

microvascular damage was evaluated from H&E-stained sections by a dermatopathologist
(J.M.M.) blinded to treatment protocols as previously described (109). In brief, the
percentage o f dermal vessels showing injury, defined as EC loss or sloughing, and
thrombosis were assessed from an average o f three high-power (x200) fields using the
following semiquantitative grading scale: grade 0, all vessels patent and uninvolved;
grade 1, <25% o f vessels show injury; grade 2, -'50% of vessels show injury; and grade 3,
>75% o f vessels show injury.

Immunostaining was performed using isotype-matched, nonbinding control Abs
or the following Abs: mouse anti-human CD3 (PS1, IgG l) and mouse anti-human CD31
(HC1/6, IgG l) (Novocastra Ltd., Newcastle Upon Tyne, UK). The number o f human
CD3+ T cell infiltrates and CD31+ vessels were assessed by counting and averaging the
number o f T cells/complete lumens in 10 random, 40x high-power fields (HPF) using the
ImageJ program (NIH).

Preparation o f RNA, cDNA, and Procedure fo r Quantitative PCR

RNA was isolated from skin grafts using the RNeasy fibrous tissue mini kit
(Qiagen, Valencia, CA) again with on-column DNase treatment and following the
manufacturer’s supplied instructions.

Quantitative real-time PCR (qRT-PCR) was

performed exactly as described above, using primers shown in Table 1-3. Samples were
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either analyzed by examining threshold cycles and comparing threshold cycles between
the two groups using a one-tailed t-test with a Bonferroni correction or by calculating the
amount o f mRNA from a standard curve and expressing it as ± S.E.

Statistics

Statistical differences between groups with respect to T cell infiltrates were evaluated
using a two-tailed t-test.

Statistical difference between the pathology scores were

evaluated using a nonparametric analysis Mann-Whitney U test. [ H]-thymidine analysis
was done with a two-tailed t-test.
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Target

Primers (5,_^ 3 ’)

4-1BBL

ACTGCCC AGCT GGT AC ATTC
CACAGGTCCTTTGTCCACCT

ICOSL

AAACCTTGCAGGCAACAATC
C ACTT GGCTT GGAT C AGT C A

OX40L

GT GAAT GGCGGAGAACT GAT
ATGCTGGTGCCTGGTTTTAG

IL-2

AACTCACCAGGCTGCTCACA
GCACTTCCTCCAGAGGTTTG

IL-4

AGCTGATCCGATTCCTGAAAC
ACTCTGGTTGGCTTCCTTCA

IFN-y

GTCCAACGCAAAGCAATACA
TGCTCTTCGACCTTGAAACA

IL-10

TGAGAACCAAGACCCAGACA
CAGGGAAGAAATCGATGACA

CD28

CTGCTCTTGGCTCTCAACTT
TTGT CGT ACGCTACAAGCAT

CD80

CCTGGCTGAAGTGACGTTAT
T CC AG AGGTT GAGC A A ATT A

CD86

TCC ACC AG AT G A ATT CT G A AC
CCGTGTATAGATGAGCAGGTC

CD 152

ATGTACCCACCGCCATACTA
TCCAGAGGAGGAAGTCAGAA

T able 1-2. P C R p rim e rs u sed f o r studies.

Each primer is listed 5' -43'. The forward primer is above and the reverse primer below.
In each case, the identity o f the amplified fragment was confirmed by sequencing.
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CHAPTER III - IN VITRO AND IN VIVO STUDY OF MEMORY
AND NAIVE T CELL RESPONSES TO THE ENDOTHELIUM
3.1 INTRODUCTION
Long-lived memory T cells may play an important role in early events following
transplantation. Alloreactive memory T cell populations are not typically present in the
young rodents commonly used to study transplantation. However, in adult humans, about
one half o f the T cells capable o f responding to allogeneic cells in limiting dilution assays
express CD45RO, a marker o f memory cells (209, 324). However, there is no direct
evidence that human memory T cells, like their murine counterparts, can mediate
rejection.
Memory T cells also have a special relationship to vascular endothelial cells (EC).
Central memory T cells express chemokine receptors (e.g. CCR7) and adhesion
molecules (e.g. CD62L) that preferentially interact with high endothelial venules (46).
Effector memory cells express chemokine receptors like CXCR3 that respond to
inflammatory chemokines and express high levels of adhesion molecules (e.g. LFA-1 or
VLA-4) (325) whose ligands are preferentially expressed by cytokine-activated
peripheral vascular EC (200). This phenotype allows effector memory cells to be directly
recruited to sites o f peripheral inflammatory reactions such as allograft rejection.
Furthermore, resting memory T cells can be activated by alloantigens presented by EC
but not other stromal or parenchymal cells in vitro (206, 213).
It has become increasingly evident that T cell memory may pose a significant
challenge to transplantation. Memory T cells specific for and expanded by microbial Ag,
like nai've T cells, may cross-react with allogeneic MHC-peptide complexes with very
high frequency (275). Recent evidence has suggested that the number o f cross-reactive
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anti-donor memory T cells correlates with increasing rejection rates (271) and may
prevent the ability to achieve tolerance (291).

This phenomenon has largely been

overlooked in the past because alloreactive memory T cell populations are not typically
present in the young rodents commonly used to study transplantation. However, adoptive
transfer o f memory T cells in rodents can rapidly reject a cardiac graft in the absence o f
secondary lymphoid organs whereas transfer o f naive T cells cannot (61).

I have

developed a model in which I can test the capacity o f human memory T cells to mediate
allograft rejection (179, 314). Specifically, I engraft C.B-17 SCID/beige mice with split
thickness human skin, containing the superficial vascular plexus o f the papillary dermis.
The healed graft is perfused through retained human EC-lined microvessels.

At this

point, usually 3-4 weeks post-skin transplantation, I adoptively transfer human allogeneic
PBMC or nai've or memory T cell subpopulations by i.p. inoculation. Within seven days,
human T cells are present in the mouse circulation and by 12-14 days infiltrate the human
graft. Between 14-21 days, human graft EC are progressively destroyed and the graft
frequently ulcerates, indicative o f rejection.

Previous studies have shown that this

response depends upon LFA-3 (109).
The data in this chapter demonstrate memory, but not naive T cells can proliferate
in response to microvascular EC derived from human skin.

I also use the chimeric

human-SCID mouse model described above to show that the graft EC injury is mediated
by human memory but not naive T cells.
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3.2 RESULTS
HDMEC activate memory but not naive T cells
Cultured HUVEC have been shown to preferentially activate allogeneic memory
T cells compared to naive T cells and they do so in an MHC and costimulation dependent
manner (209, 223). Cultured HUVEC are the most widely used model o f human EC, but
the behaviors o f microvascular EC, the targets o f graft injury, are not always reflected
accurately by this cell type. I therefore began my study by examining the capacity o f EC
isolated from human skin microvessels (i.e. HDMEC) to activate memory and naive T
cells in co-culture. Cultured HDMEC, like HUVEC, express HLA-A/B but not HLA-DR
and increase expression o f both type o f molecules in response to IFNy (326). In my
experiments, HDMEC were treated with IFN-y for 3 days (to induce HLA-DR) for
optimal CD4+ T cell stimulation and then co-cultured with allogeneic, CFSE-labeled T
cell subsets. Media were collected at 24h for measurement o f cytokines and T cells were
collected after 7 days for analysis o f proliferation.
optimal in pilot experiments.

These time points were judged

Significant production o f both IFN-y and IL-2 was

observed in co-cultures containing memory but not nai've T cells (Figure 3.1 A).

By

FACS analysis purified memory (CD45RO+) T cells, but not naive (CD45RO-) T cells,
proliferated in co-culture with HDMEC (Figure 3 .IB).

When further separated into

CD4+ and CD8+ memory and naive cells, again memory cells, but not nai've cells
proliferated in response to HDMEC (Figure 3.1C). In control experiments CD4+ T cells
did not respond to HDMEC that were not pretreated with IFN-y (data not shown). Thus,
HDMEC, like HUVEC, selectively activate allogeneic memory T cells and require pre
treatment with IFNy to stimulate CD4+ T cells.
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Figure 3.1. HDM EC activate memory T cells.
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MHC class I/II and subsequently co-cultured
with either nai've (CD45RA+) or memory
(CD45RO+) T cells, (a) Media was taken for
ELISA from HDMEC cultured with either na
ive or memory T cells for 24 hours. Memory
T cells cultured with HDMEC showed signifi
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week o f co-culture, purified and CFSE-labeled
CD4+ or CD8+ nai've and memory T cells
were stained with CD4 or CD8, respectively,
and analyzed using FACS.
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Again, purified
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showed significantly greater proliferation than
their purified nai've counterparts (right panels,
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upper left quadrants, circled population). The
data shown represent one of four experiments
with similar results.
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Memory T cells cause human skin allograft rejection in human PBL-SCID
I have previously described a model o f human T cell responses to allogeneic skin
microvascular EC in vivo involving human skin grafts and adoptive transfer o f human
PBMC in immunodeficient mice (179).

To determine which T cell subsets contribute to

graft EC injury, I adoptively transferred purified T cell subpopulations and compared the
results to those observed following transfer o f PBMC. CD4+ plus CD8+ T cells were
isolated from whole PBMC and then further fractionated into memory and naive subsets
based on negative selection o f CD45 isoform expression (Figure 3.2A).

Memory

(CD45RO+) or nai've (CD45RA+) T cells were then injected i.p. into SCID/beige mice
engrafted with human skin. One week later circulating CD3+ T cells were present in
similar numbers following adoptive transfer o f either CD45RO+ or CD45RA+ T cell
subsets as shown by FACS analysis o f mouse blood (Figure 3.2B). Interestingly, mice
reconstituted with CD45RA+ T cells developed some circulating CD45RO+ T cells
(Figure 3.2B) in addition to circulating CD45RA+ T cells, consistent with observations
that naive T cells acquire some memory markers during homeostatic proliferation (44).
In contrast, mice receiving purified CD45RO+ cells displayed exclusively CD45RO+
cells in their circulation. Similar to effects following adoptive transfer o f whole PBMC,
neither human T cell subset appeared to infiltrate or injure any mouse tissue (data not
shown).
Human skin grafts were harvested from the mice at 15 days after adoptive transfer
o f T cells and analyzed using histology, immunohistochemistry and quantitative real-time
PCR (qRT-PCR). Hematoxylin and eosin (H&E) (Figure 3.3A) and anti-CD3 (Figure
3.3B) staining showed a significantly different pattern o f infiltration and tissue
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Figure 3.2. Injection o f CD45RO+ (memory) T cells or CD45RA+ (naive) T cells results in
circulating human T cells in SCID-beige mice. CD45RA+ T cells (naive), CD45RO+ T cells
(memory) (1.5x 108 cells) or whole PBMC (3* 108) were injected i.p. into SCID mice that had
been grafted with skin allogeneic to the mononuclear cells. After 7 days, peripheral blood lym
phocytes where then stained with anti-human CD3-FITC Ab and either anti-human CD45RAPE (top panel) or anti-human CD45RO-PE and analyzed by flow cytometry. As seen in the top
panel, only mice injected with naive T cells or PBMC have circulating naive cells, whereas
mice receiving only memory cells do not. The bottom panel shows that mice receiving naive T
cells, memory T cells or whole PBMC all have circulating memory T cells. The data shown
represent one o f five experiments with similar results (n=15 per group).
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destruction following transfer o f naive T cells compared to memory T cells. Transferred
CD45RA+ T cells produced only limited perivascular infiltrates whereas CD45RO+ T
cells, like whole PBMC, infiltrated the dermis in a more diffuse pattern. Quantitatively,
naive T cells showed less total infiltration o f CD3+ T cells compared to memory T cells
(Figure 3.3C).

Naive T cells did not produce histological evidence o f EC injury,

whereas memory T cells, like PBMC, did do so (Figure 3.3C), even when mice given
naive cells were followed out to five weeks (data not shown). RNA transcripts encoding
effector molecules (FasL, granzyme B, and perforin) were minimally expressed in the
CD45RA+ inoculated mice compared to expression following either CD45RO+ T cells or
unfractionated PBMC inoculation (Figure 3.3D). These data suggest that memory T cells
largely account for the rejection response observed with whole PBMC since naive T
cells, though they can enter the circulation and focally infiltrate human skin grafts, do not
express effector molecules or cause graft injury. Thus, my model provides a means to
study human memory T cell alloresponses in vivo.
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F ig u re 3.3. Reconstitution o f mice with memory T cells, but not naive T cells, exhibits a re

jection response comparable to whole PBMC. Mice were reconstituted with CD45RA+
(naive) T cells, CD45RO+ (memory) T cells, or PBMC and then grafts were then harvested at
21 days for analysis, (a) H&E staining demonstrates that mice reconstituted with memory cells
exhibit an infiltration pattern (full dermis, ablation o f the dermal papillae architecture) similar
to whole PBMC, while naive cells exhibit a much more focal, perivascular infiltrate that does
not damage the dermal architecture (n=18) (b) CD3 staining o f the infiltrated dermis confirms
that the infiltrate observed in the H&E is human T cells, (c) CD3+ T cell counts showed a de
creased number o f naive T cells infiltrating the skin graft compared to memory T cells and only
the mice reconstituted with memory T cells or whole PBMC show significant endothelial dam
age and vascular thrombosis, (d) qRT-PCR o f RNA isolated from grafts at Day 10 indicate that
memory cells express much higher levels o f FasL, granzyme B and perforin than naive cells,
though less than whole PBMC (n=9). Data are analyzed using standard curves generated from
plasmids and normalized to CD3s transcripts.
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3.3 DISCUSSION
First, I show that human microvascular EC, in this instance HDMEC,
preferentially activate allogeneic CD4+ and CD8+ T memory T cells, defined by
expression o f CD45RO, but not naive T cells.

Second, I demonstrate that following

adoptive transfer in immunodeficient mice, memory but not naive T cells can attack
human microvessels in skin grafts allogeneic to the T cells.
Many previous studies examining the role o f EC in T cell activation have focused
on EC derived from large vessels (namely HUVEC) (208, 209, 327).

However, in

allograft rejection and many other inflammatory situations, it is not the macro vasculature,
but rather the microvasculature, that may be responsible for the recruitment of
inflammatory cells, initiation o f the immune response and eventually the target o f the
alloresponse. Microvascular EC in rejecting grafts express adhesion molecules important
for T cell recruitment, namely ICAM-1, VCAM-1 and E-selectin (191, 328) and may
have prolonged expression compared to HUVEC (323). Furthermore, MHC class II was
shown to be expressed basally on microvasculature in unstimulated, untransplanted hearts
and was up-regulated following rejection episodes (329). The microvasculature has also
been shown to activate CD4+ and CD8+ T cells, however they appear to possess different
requirements for activating T cells compared to macrovascular EC (208, 215, 330). This
difference may be due to a difference in costimulator expression. For example, HUVEC
express the costimulatory molecules LFA-3 and CD40, but lack both B7 molecules,
C D 80 and C D 86 (122); however, unlike IIUVEC, microvascular EC from cardiac tissue

express CD80 after CD40 ligation (191).

I have not detected CD80 or CD86 on the

HDMEC used in my experiments. Finally, microvascular EC are the primary target o f
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rejection in vascularized organ transplants (179).

Due to the important role o f the

microvasculature in the alloimmune response outline above I focused my study on their
behavior. I show in my study that HDMEC, like HUVEC, have the capacity to activate
memory (CD45RO+) T cells, but not naive (CD45RO-) to proliferate and produce
cytokines.
Memory T cells are thought to play an important role in allograft rejection. In
particular, memory T cells may have important roles in rejection resistant to
immunosuppressants because the activation requirements o f memory T cells appear to be
less stringent that those o f nai've T cells (318), and may be more difficult to inhibit and to
tolerize (275, 293). Several previous studies have reported the presence o f memory T
cells (CD45RO+) in heart and kidney allograft biopsies and in the peripheral circulation
correlated with the incidence and intensity o f rejection (267, 331). Heeger et al. also
showed that pretransplant frequency o f donor-specific memory T cells correlates with
risk o f rejection post-transplantation despite high levels o f immunosuppression (271).
All these studies suggest that memory cells could play a large role in determining the
survival o f human allografts; however direct experimental evaluation in humans systems
has not been possible.

I establish here using purified human T cell subsets that the

human PBL-SCID mouse model o f skin allograft injury is an example of memory T celldependent allograft rejection. At three weeks following adoptive transfer o f memory T
cells, the grafts had intense mononuclear infiltrates and significant injury to the
microvasculature, how ever nai've cells transferred to the same m ice demonstrated no

evidence of injury even when followed out to five weeks after the adoptive transfer.
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In sum, I show that in vitro that HDMEC activate resting memory T cells and
demonstrate that memory T cells are the major effector population o f human allograft
rejection following adoptive transfer into immunodeficient mice bearing human skin
grafts.

This chapter presents data introducing a small animal model to study human

memory T cell reactions to allografts.
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CHAPTER IV - TARGETING CD28 IN EC-MEDIATED T CELL
ACTIVATION
4.1 INTRODUCTION
Optimal T cell activation requires the engagement of two signals, the T cell
receptor (TCR) and a costimulatory molecule.
best-characterized costimulatory pathway.

The CD28/CTLA-4/B7 is perhaps the

CD28 is a receptor expressed on resting

CD4+ T cells, some CD8+ T cells, NK cells, neutrophils and eosinophils and binds to
either B7.1 (CD80) or B7.2 (CD86), ligands which are expressed on professional antigen
presenting cells (APC) (80). Binding o f either o f these ligands to CD28 increases IL-2
production, provides a survival signal for T cells, and regulates entry o f T cells into the
cell cycle (332, 333). Both B7.1 and B7.2 also bind to CTLA-4, an alternate receptor,
with higher affinity than they do to CD28. CTLA-4 is primarily expressed by activated
CD4+ and CD8+ T cells and, in contrast to CD28, CTLA-4 is thought to provide negative
costimulation (80, 334), functioning to shut off T cell responses and perhaps contributing
to the induction o f tolerance. Soluble CTLA-4Ig can effectively inhibit T cell activation
by competing with CD28 for B7.1 and B7.2 molecules (335). However, since CTLA-41g
also prevents signaling via CTLA-4, it may prevent the acquisition of tolerance (336).
Therefore, a reagent that selectively targets CD28 could be a more desirable
immunotherapeutic than CTLA-4Ig because it would allow inhibitory CTLA-4 signals to
be received in the absence o f positive CD28 signals.
Human EC are not known to express B7 molecules and several studies
demonstrated that their capacity to activate CD4+ and CD8+ T cells depends on the CD2LFA-3 pathway (98, 209, 239). However, B7 molecule expression can be triggered on
CD4+ T cells co-cultured with EC and these molecules may provide a costimulatory
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signals to other T cells in trans (190). It is not known what role if any these trans B7
signals play in vivo nor for CD8+ T cells. In mice, EC express CD80, but not CD86
which is critical for the murine EC capacity to activate CD8+ T cells, but insufficient for
murine EC to activate CD4+ T cells (216, 219).
One approach to selectively target CD28 is to use an antibody to this receptor.
Using monovalent recombinant antibodies, Vanhove et al. showed that selectively
targeting CD28 could in fact block a human MLR reaction (337).

A rat model o f

transplantation using an antibody that induces CD28 internalization demonstrated that
functional blockade o f the CD28 pathway could induce tolerance (338). While effective
in vitro, monovalent antibodies are unlikely to display sufficient avidity or half-life to be
useful in vivo. Most intact antibodies to human CD28 have been agonistic, replacing and
often exceeding rather than inhibiting CD80 and CD86 signals. Moreover, the properties
o f anti-CD28 mAb have been unpredictable, showing different effects in vitro than in
vivo. In this chapter, I describe the properties o f a humanized IgG2 antibody, designated
FK734 (Astellas Pharma Inc.), that incorporates the variable regions derived from mouse
antibody against human CD28 (clone TN228) and the constant regions from human IgG2
antibody with mutations in the Fc portion o f the heavy chain of human IgG2 to prevent
binding o f the antibody to FcyR. These modifications are designed to make FK734 a
candidate for use as an immunosuppressant in humans. I find that FK734 is a partial
agonist in vitro. More importantly, this reagent reduces the extent of T cell-mediated
damage to a skin graft in a chimeric human-mouse model of human allograft rejection in
vivo.
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4.2 RESULTS
FK734 stimulates T cell cytokine production and proliferation in co-culture with
allogeneic EC or Mo.
I began my analysis o f FK734 (anti-CD28 antibody) by examining its effect on
CD4+ and CD8+ T cells separately co-cultured with allogeneic EC (HUVEC), APCs that
do not express B7 and FcRy molecules. HUVEC were treated with IFN-y for 3 days to
induce HLA-DR expression prior to co-culture with allogeneic, CFSE-labeled CD4+ T
cells. HUVEC for co-culture with CD8+ T cells were untreated. Media was collected at
24 hours for measurement o f cytokines and T cells were collected after 7 days for
analysis o f proliferation. Supernatants collected at 24 hours demonstrated that addition
o f FK734 to the T-EC co-culture increased production o f both IFN-y and IL-2 in
comparison to a control IgG l for both CD4+ (Figure 4.1A) and CD8+ (Figure 4.1C) T
cells. In contrast, T cells co-cultured with EC and an anti-LFA-3 mAb (TS2.9), a reagent
that blocks costimulation o f human T cells via CD2, showed significantly less IFN-y and
IL-2 production (Figure 4.1 A and C). I additionally examined the effects of FK734 in
CD4+ and CD8+ T cell co-cultures with allogeneic Mo, a cell type that basically
expresses low levels o f HLA-DR, CD86 and FcRy (339, 340) . T cells co-cultured with
Mo show the same pattern o f upregulation o f IFN-y and IL-2 secretion by FK734 and
inhibition by TS2.9 compared to IgGl (Figure 4 .IB and D).

Similar results were

obtained at 48 hours for both CD4+ and CD8+ T cells (data not shown).
Proliferation o f the T cells in T-EC or T-Mo co-cultures as assessed by CFSE
dilution mirrored 24-hour cytokine production. Positively isolated CD4+ and CD8+ T
cells were collected from co-cultures at day 7 and stained with anti-CD4 or anti-CD8
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Figure 4.1. T-EC and T-Mo co-culture shows increased IF N -y and IL-2 production in the
presence o f FK734. Positively isolated CD4+ T cells (A, B) or CD8+ T cells (C, D) were cul
tured in the presence o f endothelial cells that were pre-treated with IFN-y (A, C) or adherent
Mo (B, D) and incubated with either IgG l (2 ug/mL), anti-CD28 (FK734) (2 ug/mL), or antiLFA-3 (TS2.9) (2 ug/mL). Supernatants were collected at 24 hours and assessed for IFN-y and
IL-2 by ELISA. T cells, EC and Mo alone all produced less than 5 pg/mL o f IFN-y and IL-2.
Data represents one o f five similar experiments.
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antibodies and analyzed by FACS.

Addition o f FK734 significantly increased the

number o f proliferated cells in both the T-EC and T-Mo co-cultures compared to an IgG
control (Figure 4.2A and B). TS2.9 was mildly inhibitory in the same assays. Thus, in
allogeneic co-cultures, FK734 has agonist activity.

T cells co-cultured in the presence o f B7.2-transduced endothelial cells show inhibition
o f IL-2 but not IFN -y production and reduced proliferation with FK734.
Since addition o f FK734 to standard T-EC or T-Mo co-cultures demonstrated
agonistic effects, I sought to understand if the antibody could be inhibitory in a condition
where strong signals via CD28 would be present at the time o f initial activation. As EC
do not express B7-molecules I transduced endothelial cells with retrovirus encoding B7.2
(CD86) and then examined the effects o f adding FK734. B7.2 transduced EC plus IgGl
or FK734 were either pre-treated with IFN-y for three days then co-cultured with
positively isolated CD4+ T cells or directly co-cultured with positively isolated CD8+ T
cells.

When compared to EGFP-transduced EC, both CD4+ and CD8+ T cells co-

cultured with B7.2-transduced EC produced greater amounts of IFN-y (Figure 4.3A) and
IL-2 (Figure 4.3B). Addition o f FK734 further increased the level o f IFN-y production
(Figure 4.3A) for CD4+ T cells, but inhibited IFN-y secretion by CD8+ T cells (Figure
4.3D).

Both CD4+ and CD8+ T cells showed a marked decrease in IL-2 production

(Figure 4.3B and E). Consistent with the decrease in IL-2 there was also a significant
decrease in proliferation o f CD4+ and, to a lesser extent, CD8+ T cells co-cultured with
B7.2 transduced EC and FK734 as assessed by CFSE dilution (Figure 4.3C and F).
Therefore, it appears that in the absence o f B7 signals (as on control EC) or in
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Figure 4.2. T-EC and T-Mo co-cultures show increased proliferation in the presence o f
FK734. Positively isolated CD4+ T cells (A) or CD8+ T cells (B) stained with CFSE were cul
tured in the presence o f endothelial cells that were pre-treated with IFN-y
incubated with the indicated antibody.

or adherent Mo and

Co-cultures were harvested at Day 7, stained with anti-

CD4 and subjected to FACS analysis. Data from five experiments were pooled and plotted.
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Figure 4.3. T cells co-cultured with B7.2 transduced E C in the presence o f FK734 demon
strate decreased IL-2 production and proliferation. Positively isolated CD4+ (A, B, and C) or
CD8+ (D, E, and F) T cells were co-cultured in the presence o f EC transduced with retrovirus
encoding human B7.2 (CD86) and pre-treated with IFN-y and either with or without FK734 (2
ug/mL). Supernatants were obtained at 24 hours and assessed for IFN-y (A, D) and IL-2 (B, E).
Co-cultures were then harvested at Day 7, stained with anti-CD4 and subjected to FACS analy
sis (C, F). Data represents one o f four similar experiments.
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the presence o f modest B7 signals (as on Mo, Figure 4.3S) FK734 has agonistic effects,
however in the presence o f a strong B7 signal (as on transduced EC), the same reagent
has some antagonistic actions on CD8+ T cell IFN-y production and both CD4+ and
CD8+ T cell IL-2 production as well as proliferation.

FK734 stimulates less cytokine production and proliferation in comparison to another
costimulatory anti-CD28 antibody (28.2).
I next compared FK734 to another anti-CD28 antibody with known costimulatory
activity (clone 28.2).

When either CD4+ or CD8+ T cells were co-cultured with

allogeneic HUVEC, FK734 stimulated IFN-y production at low doses, but did not
stimulate further IFN-y production with increasing concentrations.

In contrast, 28.2

induced more IFN-y production at similar concentration and this effect increased with
higher levels o f mAh (Figure 4.4A and D). FK734 stimulated significantly less IL-2 at
all concentrations tested compared to 28.2 (Figure 4.4B and E).

Consistent with the

stimulation o f less IL-2 production, FK734 also stimulated less proliferation at all
concentrations when compared to 28.2 (Figure 4.4C and F).

FK734 inhibits the rejection response in the hu-SCID chimera.
Finally, I examined the effect o f FK734 on an allogeneic response in vivo. I have
previously described a model o f human T cell responses to allogeneic skin microvascular
EC in vivo involving human skin grafts and adoptive transfer o f human PBMC,
allogeneic to the skin donor in immunodeficient mice (179). I used qRT-PCR to compare
the levels o f expression o f various components o f the CD28 system in these
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Figure 4.4. CD80 and CD86 expression on EC, transduced EC, and Mo.

EC (top), EC-

transduced with a retrovirus encoding B7.2 (middle) and Mo (bottom) were stained with antiCD86 (filled histograms, left side o f panels) and anti-CD80 (filled histograms, right side o f pan
els) and subjected to FACS analysis. The open histograms are IgG l for the indicated cell types.
Data shown is one o f three similar experiments.
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Figure 4.5. FK734 exhibits less costimulatory activity than another anti-CD28 antibody at
similar concentrations. Either FK734 or 28.2 were added to co-cultures o f CD4+ (A, B nd C)
or CD8+ (D, E, and F) T cells and IFN-g pre-treated EC in the concentrations indicated. IFN-g

(A, D) and IL-2 (B, E) production were assessed by ELISA after twenty-four hours o f co
culture. Proliferation was assessed by CFSE dilution at 5 days using FACS analysis. The per
centage of CFSEloCD4+ cells were plotted for each antibody concentration (C, F). Data repre
sents one o f three similar experiments.

77

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

human skin grafts (Table 1-4) in the absence o f PBMC inoculation. Levels o f CD3s,
CD28, CTLA-4 (CD 152) and B7.1 (CD80) were all very low, requiring approximately 30
cycles of amplification to reach the threshold of detection. B7.2 (CD86) was somewhat
higher. The addition o f PBMC led to a significant increase in all o f these molecules
except B7.2. These data suggest that CD28 and its principal ligands are present within
rejecting skin grafts.
Previous experiments using blocking antibodies in this model demonstrated that
some inhibitory antibodies could be given prior to adoptive transfer without effecting
circulating T cell levels.

However, initial pilot experiments with FK734 showed that

administration o f this antibody either immediately before or shortly after adoptive
transfer (within 3 days) inhibited the successful transfer o f human PBMC (Figure 4.5A).
However, if I injected 3 x l0 8 human PBMC i.p. into mice and began administering 100
ug (2.5 mg/kg) o f FK734, anti-LFA-3 (TS2.9) or IgG l s.c. once every three days starting
one week after adoptive transfer, then the inhibitory effect on adoptive transfer was
minimized (Figure 4.5B).
After determining that delayed administration o f FK734 does not significantly
affect adoptive transfer o f human PBMC, I examined the effect o f the antibody on graft
rejection mediated by the transferred PBMC.

Split thickness human skin was grafted

onto SCID-beige mice and allowed to heal for 4-6 weeks.

Human PBMC were then

transferred into mice at day 0, one week later on day 7 100 ug of IgG l, FK734 or TS2.9
were given to the mice. Another dose was given at day 10 and the grafts were harvested
at day 14. Grafts were collected for RNA isolation or fixed in formalin, sectioned and
taken for H&E staining. The resulting slides were scored blindly by a dermatopathlogist
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-PBMC

+PBMC

Fold
Induction

p value

GAPDH

19.5±0.4

18.6±0.5

1.9

0.032

CD3e

31.4±1.0

28.4±0.4

8.1

0.002

CD28

29.5±0.7

27.6±1.3

3.8

0.45

CD80

31.3±1.2

28.8±0.7

5.4

0.013

CD86

27.2±1.1

27.6±0.7

0.7

0.58

CD 152

31.1±1.0

28.8±1.1

4.9

0.013

Table 1-4. Expression o f the CD28 fam ily o f molecules in skin grafts.
RNA was isolated from skin grafts on mice that had either not received any PBMC (PBMC) or received 3X108 PBMC (+PBMC) and were assessed for expression o f the
indicated mRNA by real time qRT-PCR as described in the methods. Values listed are
threshold cycles and are the average from twelve mice (n=12).
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Figure 4.6. Delayed administration o f FK734 in mice does not affect adoptive transfer o f hu
man T cells. Mice were given 250 ug o f either IgG l, FK734 or TS2.9 at either the same time
as the adoptive transfer (A) or one week following adoptive transfer (B). On Day 14, adoptive
transfer was assessed by staining blood obtained via retroorbital bleed for human CD3 and
mouse CD45. The percentage o f CD3+ and mCD45- cells was assessed by FACS and plotted.
Data represents twelve mice (n=12) per group.
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(JMM).

Administration o f FK734 reduced endothelial injury and thrombosis when

compared to the IgG control at one week (Figure 4.6A) and only endothelial injury at two
weeks (Figure 4.6B).

The reduction in injury was comparable to that observed with

TS2.9, whose protective effects have been described previously (109).
Further analysis o f the grafts using immunohistochemistry to quantitate the
number o f CD3+ cells and CD31+ vessels showed an increased presence o f CD31 +
vessels at one week (p<10'5, Figure 4.6D) and two weeks (p<0.002, Figure 4.6D)
compared to IgG l and decreased infiltration o f CD3+ cells at one week (p<10‘4, Figure
4.6C) and two weeks (p<0.008, Figure 4.6C) compared IgG l. I have previously shown
that rejection in this model is largely dependent on memory T cells in that when PMBC
are fractionated into memory (CD45RO+) and naive (CD45RA+) subsets that only
memory T cells can mediate graft rejection (see chapter III). Thus, the data presented
here suggests that CD28 may play a role in this largely memory T cell-dependent
response.
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Figure 4.7. Pathology scoring, vessel counts and cell counts o f day 7 and 14 grafts demon
strates decreased endothelial injury and significant reduction in infiltrating T cells with ad
ministration o f FK734. Grafts from either day 7 (A) or day 14 (B) were scored blindly by a
dermatopathologist on three criteria, infiltration, endothelial injury, and thrombosis using a
semiquantitative scoring scale with 4 indicating 100% graft involvement and 0 indicating 0% of
graft involvement. Data shown is pooled data from four separate experiments.

Grafts har

vested at either day 7 or day 14 were sectioned and stained for CD3 (C) and CD31 (D). Human
CD31 positive vessels and human CD3 positive T cells were scored by counting 10 high pow
e r e d fie ld s

per graft.
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4.3 DISCUSSION
The primary goal o f the studies in this chapter was to characterize a humanized
antibody to human CD28 that may have utility as an immunosuppressive in a model o f
memory T cell mediated allograft rejection. This reagent, designated FK734, has both
agonistic and antagonistic effects in vitro, depending on the strength o f the CD80/CD86
signals provided by the APCs.

Interestingly, the antagonistic effects o f FK734 are most

evident on production o f IL-2 and proliferation in CD4+ T cells whereas the antibody
seems agonistic for IFN-y production even in the presence o f strong B7 signals.
However, under the same conditions, FK734 antagonizes both IFN-y and IL-2 production
in CD8+ T cells. The basis o f these differences is unknown. Since human CD8+ T cells
in peripheral blood are heterogeneous for expression o f CD28, my data suggest that the
CD28 expressing subpopulation o f CD8+ T cells contribute significantly to cytokine
production in allogeneic responses o f this subset. Most importantly, I demonstrate that in
an in vivo model o f human T cell-mediated allograft rejection this antibody can reduce
infiltration and endothelial damage, hallmarks o f graft rejection.
Understanding the role o f CD28/B7 interactions in vivo initially came from
studies performed in the transplant setting.

CTLA-4Ig was one of the first reagents

identified that could selectively target the B7 pathway. Part of the mechanism o f this
reagent depended on the ability o f CTLA-4 to bind with much higher affinity to B7
molecules, effectively blocking CD28 interactions (335). In mice, CTLA-4Ig treatment
was described to prolong graft survival and in some cases could even induce donor
specific tolerance (341). However, CTLA-4Ig and other reagents designed to block the
interactions o f B7 with CD28 may simultaneously prevent negative or regulatory signals
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from being transmitted via CTLA-4.

Signaling through CTLA-4 independent of its

competition with CD28 has been demonstrated to decrease signaling from the CD3
complex in a transgenic rodent model (342). Also, it has been shown that CTLA-4 has a
role in the development o f regulatory T cells in the transplant setting (343).

Thus,

considering the importance o f the signals from CTLA-4, targeting CD28 alone may prove
more effective. While there is extensive murine and non-human primate data studying
the effects o f reagents targeting CD28, human data has been limited to mostly in vitro
studies (336, 337). My chimeric mouse model provides in vivo data with human T cells
using a unique human specific reagent. I find that despite retaining some agonist activity,
a CD28-selective antibody can reduce T cell infiltration and endothelial damage in an
acutely rejecting organ. My in vitro data suggest this may be due to decreased T cell
proliferation secondary to the effects o f FK734 on IL-2 production in CD4+ and CD8+ T
cells receiving a strong B7 signal.
One concern is that the partial agonist activity may boost levels o f IFN-y present
in animals treated with FK734. Previous data from my lab has shown that microvascular
endothelial cells in human skin grafts retain both MHC class I and II expression in situ in
the absence o f exogenously added PBMC (179), perhaps due to low levels o f IFN-y
produced by the small number o f T cells resident in skin (see Table 1-4 for basal CD3s).
Increased IFN-y production provided by PBMC could further enhance expression on
endothelial cells and induce de novo expression on other cell types. Such an effect could
theoretically amplify the allogeneic T cell response to the skin graft.

Despite this

concern, the data show that the overall effect o f FK734 in vivo is inhibitory and

84

Reproduced with permission o f the copyright owner. Further reproduction prohibited without permission.

equivalent to that o f the anti-LFA-3 antibody, TS2.9, which inhibits IFN-y production in
vitro.
An anti-CD28 mAb may function through several different mechanisms. First,
the antibody might block interaction between CD28 and its natural ligands, B7.1 and 2,
either by steric hindrance or by down modulating CD28 expression.

Second, the

antibody could act as an agonist and stimulate CD28. Third, especially in vivo, the
antibody may deplete CD28+ cells. The vast majority o f intact antibodies reactive with
human CD28 described to date have been agonistic with the extent of signaling
downstream o f CD28 related to the degree o f crosslinking o f the receptor (337).
Therefore, it is not surprising that a modified monovalent antibody that selectively targets
human CD28 and does not crosslink was shown to inhibit T cell activation in a mixed
lymphocyte reaction (337).

Further, murine models have shown that CD28 Fab

fragments, which inhibit CD28 signals, ameliorate EAE and uvoretinitis (344, 345). In
fact, selective blockade o f CD28 in the rat was shown to have greater immunosuppressive
effects than CTLA-4Ig in part through the generation o f non-T regulatory cells and the
induction o f indolemine-2,3-dioxygenase (IDO) and iNOS (338). In addition to blockade
o f CD28, there have been reports that suggest the agonistic effects o f a CD28 antibody
may also be paradoxically immunosuppressive through depletion o f activated T cells
(334) or, in the case o f superagonists, selective activation o f regulatory T cells (346). My
mouse model cannot support T cell depletion via ADCC, presumably because of defects
in NK cell-mediated killing due to the beige mutation. FK734 also contains structural
modifications to prevent FcR binding. I cannot rule out inhibition o f tissue injury by
induction o f regulatory T cells and my data indicates the presence o f mRNA for CTLA-4
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in rejecting grafts. This possibility warrants further investigation although I do not yet
know if regulatory T cells are generated or function in my model.
In chapter III, I show that the mouse model o f skin graft rejection I utilized in this
study is mediated principally by memory T cells. Memory T cells have special properties
compared to nai've T cells including lower activation threshold, faster acquisition of
effector function, enhanced proliferation potential and increased survival (16). Many of
the properties o f memory cells reflect changes in the TCR mediated activation o f memory
T cells part o f which includes changes in the costimulation requirements (318).

The

CD28/B7 pathway has been studied in the generation and function of memory T cells and
mouse models have indicated that CD28 signals are not required to mount a CD8+ T cell
response, but may be important in the CD4+ T cell response (347). My data suggest that
CD28 signals do play a role in the ability o f human memory T cells to mount an immune
response in a skin graft rejection model. This finding is interesting in that microvascular
human EC, the primary target o f this alloresponse, do not express detectable levels of
B7.1 or B7.2. Thus the cellular source o f the CD28 signals in this model is unknown,
though my data shows the presence o f B7.2 molecules in the graft at baseline and
induction o f B7.1 with the introduction o f PBMC. It is possible that T cells themselves
provide B7 signals to other T cells (190). Attempts to confirm a role for CD28 by using
CTLA-4Ig in the same model were confounded by an unexpected enhancement o f T cell
engraftment and skin graft infiltration and injury (SS and JSP, data not shown). This
effect is under investigation.
FK734 has been engineered to be a candidate for use in humans as an
immunosuppressant. My in vivo experiments provide evidence that this antibody may
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function as an immunosuppressant despite its partial agonist actions in vitro. Preclinical
studies in a humanized mouse model may be particularly important given recent clinical
trials that demonstrated severe, unanticipated toxicity for another CD28 antibody,
deemed a “superagonist” that was recently tested in a phase I trial in the UK (348). In
that trial, all six patients given an experimental anti-CD28 antibody TGN1412 became
extremely ill even though the antibody had been tested and deemed safe in non-human
primates (349). It would be interesting to examine if TGN1412 induces cytokine release
or exacerbates tissue injury in my model o f human allograft rejection.
In summary, I describe a humanized antibody that targets CD28 and has both
agonist and blocking capability.

Furthermore, I demonstrate that this reagent has the

ability to reduce endothelial cell injury in a model o f human memory T cell mediated
graft rejection. This both suggests the potential o f such a blocking reagent in human
disease and demonstrates a role for CD28 in human memory T cell responses.
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CHAPTER V - MEMORY T CELL SPECIFIC COSTIMULATORS
IN EC-MEDIATED T CELL ACTIVATION
5.1 INTRODUCTION
I have shown in the previous chapter that human dermal EC can preferentially
activate memory T cells and that memory T cells, but not naive can mediate allograft
rejection in a chimeric human-SCID mouse model o f allograft rejection. The capacity for
EC to activate memory, but not naive T cells, may arise from differences in the co
stimulatory signals provided by EC to T cells. This possibility is explored further in this
chapter.
The T cell response to antigen depends both on TCR signals (provided by
peptide-MHC molecule complexes) and antigen-independent costimulatory molecules.
The best described T cell receptors for costimulation are CD28 (which binds B7-1 and -2,
also known as CD80 and CD86, respectively and is discussed in the previous chapter)
and CD2.

CD2 binds CD48 in rodents, but is preferentially activated in humans by

LFA-3 (CD58), a molecule missing from the rodent genome (350). Human EC express
LFA-3 (but generally not B7-1 or -2) and the LFA-3-CD2 pathway seems to be
particularly important in human allogeneic responses to this cell type.

However,

antibody blocking experiments have suggested that LFA-3 does not account for all o f the
costimulation that human EC provide to memory T cells (208, 209).

Several newly

discovered receptors for costimulators in both the B7 family (such as ICOS) and the TNF
fam ily (such as 4 - IB B and 0 X 4 0 ) arc important for the generation o f cffcctor/m cm ory T

cells (140, 160, 351, 352) and ligands for these molecules can be expressed at high levels
on cytokine-activated human umbilical vein EC (HUVEC) (86, 152). It is not know if
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any o f these molecules also contribute to the reactivation o f resting memory T cells by
human microvascular EC.
The above observations suggest that circulating human alloreactive memory T
cells may effectively recognize graft EC in vivo and may do so in a manner dependent
upon costimulators other than LFA-3, CD80 or CD86. I demonstrate here that ICOS
ligand (ICOSL), 0X 40 ligand (OX40L), and 4 -IBB ligand (4-1BBL) are inducible on
cultured human dermal microvascular EC (HDMEC) and that all three molecules
contribute to EC-dependent memory T cell activation in vitro and graft rejection in vivo.
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5.2 RESULTS
HDMEC inducibly express ICOSL, 4-1BBL, and OX40L
LFA-3 is an important costimulator expressed by HUVEC, but blocking the LFA3 interaction with its ligand, CD2, does not fully inhibit proliferation or cytokine
production by allogeneic T cells (98). To characterize additional molecules involved in
costimulation, I initially examined FIDMEC with or without treatment with proinflammatory cytokines (at doses and times shown to be optimal for other HDMEC
responses), for the expression o f three molecules proposed to act preferentially on
activated T cells, namely 4-1BBL, ICOSL, and OX40L (CD134L). Specifically HDMEC
were mock- treated or treated with either TNF (10 ng/mL) or IFN-y (50 ng/mL) for 24,
48, or 72 hours and collected for quantitative real-time (qRT)-PCR and FACS analysis.
Mock-treated HDMEC expressed minimal transcript levels and surface expression for all
three of these memory-selective costimulators. Transcript levels o f all three molecules
were increased many-fold at 24 hours and remain elevated for 4-1BBL and OX40L, but
not ICOSL, over 72 hours (Figure 5.1 A). There were some differences between surface
expression and mRNA expression. 4-1BBL surface expression only increased modestly,
while ICOSL surface expression increased substantially with TNF treatment (Figure
5.2B).

TNF treatment shifted OX40L, which has high basal expression, from a

heterogeneous population o f low and high expressors to a mostly high expressing
population leading to an overall increase in OX40L expression assessed as corrected
mean fluorescence intensity (Figure 5.2B). IFN-y did not affect costimulator mRNA or
protein for any o f the molecules (data not shown).
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H DM EC express inducible memory T cell-selective costimulatory molecules.

HDMEC were cultured with cytokines for the indicated times and mRNA levels were calcu
lated as a percent change from untreated cells, (a) HDMEC cultured with TNF (10 ng/mL)
showed a 50-fold increase in mRNA for 4-1 BBL at 24 hours that remained elevated for 72
hours. 6-fold and 8-fold increases in mRNA were observed for ICOSL and OX40L respec
tively at 24 h that remained elevated for 72h for OX40L, but slowly declined for ICOSL over
the same time period (filled squares). HDMEC cultured with IFN-g (50 ng/mL) showed no in
crease in mRNA for either 4-1 BBL, ICOSL or OX40L over 72 hours (empty squares). The
data shown are pooled from four separate experiments.

(b) By FACS analysis, 4-1 BBL,

ICOSL, and OX40L all show increased surface expression (black line) with 72 hours of TNF
treatment compared to control, untreated EC (dark grey line).

IgG controls which do not

change with cytokine treatment are shown as filled histograms. The data shown represent one
o f four experiments with similar results.
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I next evaluated whether these three costimulators molecules are induced when CD4+ T
cells are co-cultured with IFNy-pretreated allogeneic HDMEC.

Using qRT-PCR

analysis, I found that mRNA for 4-1 BBL, ICOSL and OX40L all increase in HDMEC
after co-culture with allogeneic T cells. The induction o f 4-1 BBL and OX40L was most
pronounced at 48h with almost a hundred-fold induction, while ICOSL showed a more
modest 20-fold induction (Figure 5.2A). Surface expression was then assessed by FACS.
4-1 BBL increased modestly at day 1 and steadily increased through day 7.

ICOSL

showed immediate increase by day 1 and also continued to increase throughout the co
culture. OX40L, in contrast, increased at day 1, but then returned to baseline by day 3
(Figure 5.2B). T cells recovered from the same co-cultures at day 1, 3, 5 and 7 express
increasing levels o f the corresponding receptors (4 -IBB, ICOS, and OX-40) to these EC
ligands on cells that had proliferated, although 0X 40 expression actually declined by day
7. Surprisingly, these molecules were also increased in expression on some T cells that
had not proliferated, as assessed by dilution o f CFSE fluorescence (Figure 5.2C). I do
not know if this is a bystander response to cytokines or a response to suboptimal TCR
stimulation.

Blocking 4-1BBL, ICOSL or OX40L in T cell-EC co-cultures decreases T cell activation
The parallel induction o f the T cell receptors and their EC costimulators suggest
that these interactions could contribute to memory T cell activation by allogeneic
HDMEC. I therefore examined the effect of blocking these pathways using antibodies
and/or fusion proteins in T cell-EC co-cultures.

In my experiments, HDMEC were

treated with IFN-y for 3 days (to induce HLA-DR) for CD4+ T cell stimulation or mock
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Figure 5.2. HDM EC upregulate memory costimulatory molecules in co-culture with T cells
and stimulate T cells to express the corresponding ligands. HDMEC were co-cultured with
allogeneic T cells and cells were harvested at 3, 6, 12, 24, and 48 hours for RNA and at Day 7
for FACS analysis, (a) HDMEC upregulate for mRNA 4-1BBL (filled circle), ICOSL (grey
square), and OX40L (filled diamond) over the course o f 48 hours, (b) 4-1 BBL, ICOSL and
OX40L protein expression on HDMEC after 1, 3, 5, and 7 days o f co-culture with allogeneic T
cells (cMFI = corrected mean fluorescent intensities, i.e. cMFI = Ab MFI - IgG control), (c)
Both proliferating T cells (circled population) and non-proliferating T cells identified by CFSE
dye dilution, show increasing expression of 4 -IBB, ICOS, and OX-40 at day 1, 3, 5, and 7 of
co-culturc (numbers represent percentage o f total T cell population). The data shown represent

one experiment o f four with similar results.
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treated for CD8+ T cell stimulation and then co-cultured with allogeneic T cell subsets.
Pilot titrations were done in T cell-EC co-cultures to determine maximally inhibiting
doses o f each antibody and fusion protein typically between 4-10 pg/mL (data not
shown). Cytokines were assessed by ELISA in the supernatants collected from the co
cultures at 24 hours. By ELISA, I found that blocking either ICOSL or OX40L with
specific antibodies led to a substantial decrease in IFN-y production by CD4+ T cells,
while blockade o f 4-1 BBL with a fusion protein had little effect (Figure 5.3A). IL-2
production by CD4+ T cells showed similar decreases (Figure 5.3A).

In contrast,

blockade o f any o f the three costimulators in CD8+ T cell-EC co-cultures led to at least a
70% decrease in IFN-y production (Figure 5.3A) when compared to control antibody.
Overall, CD8+ T cells produce substantially less IL-2 and exhibited a lesser decrease in
IL-2 production than CD4+ T cells with blockade o f any of the three costimulators
(Figure 5.3A).

T cell proliferation was also reduced by blocking each o f these

costimulators. For CD4+ T cells, blocking 4-1 BBL or OX40L decreased proliferation by
almost 35% and blocking ICOSL led to a decrease of almost 45% at day 5 (Figure 5.4A).
CD8+ T cells also demonstrated decreased proliferation, with 4-1 BBL blockade reducing
proliferation by 40% and ICOSL or OX40L blockade causing lesser, but significant
reductions o f 26% and 20% (Figure 5.4B). My results suggest that these costimulators
can contribute to resting memory T cell activation by allogeneic HDMEC. In several
experiments, combined blockade did not appear more effective than blockade of
individual costimulators (data not shown). The effects of blocking these pathways were
comparable in magnitude to those attained with blockade o f LFA-3 (Figure 5.3 and data
not shown). Overall, my in vitro experiments demonstrate that allogeneic HDMEC, like
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Figure 5.3. CD4+ and CD8+ T cell production o f IFN-g and IL-2 in allogeneic T-EC co
cultures is decreased when memory costimulator molecules are blocked. CD4+ (a) or CD8+
(b) T cells were co-cultured with allogeneic HDMEC pre-treated with IFN-g for 3 days (to
upregulate MHC Class II). Cytokine production was then assessed by ELISA on supernatant
collected at 24 hours, (a) CD4+ T cells exhibit >50% reduction of both IFN-g and IL-2 pro
duction in the presence o f blocking abs to ICOSL or OX40L, but not in the presence o f the
blocking fusion protein 4-lBB-Fc. Combinations o f antibodies do not show additive blocking
effects, (b) CD8+ T cells demonstrate a large decrease in IFN-g production in the presence of
all three blocking reagents, but only modest a decrease in IL-2 production. The data shown
represents one o f four experiments with similar results.
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HUVEC, selectively activate memory T cells and that several newly described
costimulators, which are inducible on HDMEC, contribute to the alloresponse.

Memory T cell-selective costimulators contribute to human allograft injury in vivo
To evaluate the function of the memory T cell-EC costimulatory interaction in
vivo, I again used my model o f human skin allograft rejection in immunodeficient mice.
I first investigated whether skin grafts in my alloimmune response express these ligands.
Although basal expression was low, I found a large increase in the mRNA expression of
4-1 BBL and ICOSL following PBMC transfer; OX40L showed a more modest increase
(Figure 5.5A).

These increases may be explained by the presence o f TNF in the

circulation following adoptive transfer o f human PBMC (353).

Unfortunately, the

reagents available for FACS analysis o f cultured cells are unable to detect these
molecules in tissues so I could not directly assess protein expression in the skin grafts.
To investigate the role o f memory T cell-selective costimulators in the
progression o f immune-mediated damage in human skin grafts, i.p. injections o f blocking
antibodies or IgG control were administered three times a week to groups o f animals with
healed human skin grafts starting on the day before i.p. inoculation with PBMC. The
dosing schedule used was one that gives circulating trough levels o f Ig sufficient to match
in vitro levels. Within each experiment, all skin grafts were obtained from a single donor
and all PBMC came from a second donor allogeneic to the skin graft donor. Data from
five independent experiments were pooled for analysis; in each experiment, additional
control animals bearing skin grafts were injected with blocking antibodies or IgG control
and were not inoculated with PBMC to be certain that injury was not caused by the
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Figure 5.5. Rejecting skin grafts in the human-SCID chimera upregulate mRNA fo r the
memory costimulatory ligands and blocking these pathways decreases rejection pathology.
mRNA was harvested from skin grafts that had been on mice reconstituted for 10 days with
PBMC. Quantitative PCR on the mRNA harvested from these grafts showed an induction of
mRNA for 4-1 BBL, ICOSL and OX40L (n=12) (a). Similar grafts were then harvested from
mice that had been reconstituted for 10 days with PBMC that had also been receiving i.p. injec
tions o f blocking ab (100 ug) every three days, (b) 10 random high-powered fields (HPF) were
taken o f slides cut from the grafts and stained for human CD3e for assessment. Counts o f the
CD3e+ T cells showed similar levels o f T cell infiltration except for LFA-3, which showed a
significantly decreased number o f infiltrating T cells (p<0.001). H&E slides were generated
from these grafts and subsequently evaluated by a dcrm atopathologist blinded to the treatment.

Blocking 4-1BBL, ICOSL or OX40L reduced endothelial injury (p<0.004, 0.05, 0.0003, respec
tively) and thrombosis (p<0.01, 0.1, 0.002), despite having similar levels o f infiltration (c).
LFA-3, as described previously, showed decreases in both endothelial injury (p< 10"6) and
thrombosis (p<0.0004) corresponding with its lower level o f infiltration (n=9 per treatment
group).
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antibodies.

Injury to graft EC was evaluated as microvascular lumenal occlusion or

shedding o f EC, initial steps in human vessel loss (179). Blockade of ICOSL, 4-1BBL or
OX40L all failed to reduce T cell infiltration while blockade o f LFA-3 did do so (Figure
5.5B). ICOSL blockade decreased endothelial injury and thrombosis, but the difference
in thrombosis did not achieve statistical significance. Blockade o f the 4-1BBL or OX40L
pathway reduced both endothelial injury and thrombosis to a significant degree (Figure
5.5C).

However, the decrease in endothelial damage was not as effective as that

observed with blockade o f LFA-3.
In a final series o f experiments, I used qRT-PCR to examine RNA obtained from
grafts on animals treated with blocking antibodies.

Blockade o f 4-1 BBL, ICOSL or

OX40L all significantly decreased FasL and perforin mRNA production in T cells,
though blockade had little effect on granzyme B expression (Table 1-5).

Analysis of

cytokine mRNA expression within skin grafts was less clear cut. Blockade o f 4-1 BBL
caused a decrease in IFN-y, IL-2 and IL-10 mRNA expression compared to control grafts,
but no change in IL-4 mRNA expression (Table 1-5).

In contrast, ICOSL blockade

showed an increase in IFN-y, a decrease in IL-4 mRNA and a modest decrease in IL-2
and IL-10 mRNA levels.

OX40L blockade, when compared to IgG control, showed

dramatic reductions in IFN-y, IL-2 and IL-4 expression, but a comparable level o f IL-10
mRNA. Overall there is a better correlation o f reduction in cytotoxic effector molecule
than on cytokine expression with protection o f grafts from injury, consistent with the
correlation o f effector molecule transcripts with rejection o f human allografts (354, 355).
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Percent inhibition of expression

Treatment

FasL

Granzyme B

Perforin

IFN-y

IL-2

IL-4

IL-10

4-1BBL

85.6±9.8

8.8±8.0

32.3±21.9

42.141.7

59.648.6

(-4.0±5.1)

47.442.4

ICOS-L

98.3±0.7

(-28.3±14.9)

80.5±4.9

(-51.8410.0)

30.4415.0

63.147.7

59.7411.9

OX-40L

81.8±14.5

0.0±8.2

70.8±10.3

59.345.0

92.8±3.5

95.844.2

6.3±14.3

LFA-3

98.7±0.01

82.3±5.9

74.8±8.9

Table 1-5. Effect o f antibody blockade on expression o f effector molecules and
cytokines.
mRNA from human skin grafts harvested from mice that had been reconstituted for 10
days with PBMC and receiving i.p. injections o f blocking mAbs (100 ug) every three
days was obtained for qRT-PCR. Data was analyzed by comparing threshold cycles to a
standard curve generated using plasmid DNA and then expressed as a percentage o f IgG
control.
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5.3 DISCUSSION
In this chapter I present two new observations relevant for human transplantation.
First, I show that three recently described costimulatory molecules, namely ICOSL,
OX40L and 4-1 BBL, are inducible on FIDMEC by TNF or by culture with allogeneic T
cells, and that these ligands contribute to activation o f resting memory T cells by
allogeneic HDMEC. Second, I show that the three costimulators I have determined as
inducible on HDMEC in culture are also inducible in human skin grafts and contribute to
human memory T cell-mediated injury during an alloreaction. Protection correlates with
reduction o f effector molecule transcripts within the infiltrated graft.
I began by looking at the expression o f several newly described molecules 41BBL, ICOSL (also known as B 7R pl, B7h, GL-50 or LICOS) and OX40L (gp34) in
response to cytokines and T cell co-culture.

Previous studies have demonstrated that

activation o f T cells by EC involves the interaction of LFA-3, ICOSL and OX40L (86,
98, 153), however no data exists regarding 4-1BBL on endothelial cells and only ICOSL
has been studied on microvascular EC (86). In addition to EC, 4-1 BBL, OX40L and
ICOSL are expressed on most classical antigen presenting cells (APCs) including
dendritic cells, B cells, activated monocytes (356-358). ICOS is induced following initial
activation of T cells and ligation o f ICOS leads to augmented proliferation (85) and
secretion o f many effector cytokines (including IL-4, IL-10, IFNy) from CD4+ T cells
(359). Like ICOS, in humans, 0X 40 is expressed by T cells after ligation o f the T-cell
receptor and was initially identified as a marker o f T cell activation (360) and appears to
be important for proliferation and cytokine production by CD4+ T cells when stimulated
with HUVEC (231) or allogeneic DC (153). 4 -IBB, like ICOS and 0X 40, augments
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cytokine production and proliferation, however it does so for both CD4+ and CD8+ T
cells (160).
In this chapter, I demonstrate that all three o f these molecules are inducible on
HDMEC in response to TNF, but not IFNy. This is consistent with a previous report of
ICOSL on HDMEC (86); the expression o f OX40L and 4-1 BBL has not been previously
reported on this cell type. Furthermore, previous studies have not examined expression
in co-cultures o f T cells with human endothelial cells. I show that co-culture o f HDMEC
and allogeneic CD4+ T cells induces expression o f both the costimulator on T cells and
their corresponding ligands on HDMEC. The mRNA for the ligands is induced early on
EC for all three ligands, however their surface expression differs markedly with 4-1 BBL
peaking and persisting at Day 7, ICOSL peaking and persisting at Day 3 and OX40L
peaking at Day 1 and then returning to baseline by Day 3 (Figure 5 .IB). This difference
in expression may explain the reduction on 24 hour cytokine production in CD4+ T cells
when ICOSL and OX40L are blocked, but the lack o f effect when 4 -IBB is blocked.
Surface expression o f OX40L did not increase to the degree anticipated by the mRNA.
The reason for this difference is unclear and under current investigation. Blockade o f any
o f the three costimulator molecules seems to have moderate effects on both CD8+ T cell
cytokine production and proliferation.

Preliminary data regarding combinations of

blockade indicate that the effects are less than additive, consistent with overlapping
activity (data not shown).

CD4+ T cells in co-culture with EC showed increasing

expression o f 4 -IBB, ICOS, and 0X 40 in both the proliferated and unproliferated
population as measured by CFSE dilution. The increased expression on the proliferating
cells is consistent with earlier data that showed that these molecules are upregulated on T
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cells upon activation (361, 362), however the increased expression on unproliferated cells
has not been observed previously and may be a response to cytokines produced by the
activated cells or may represent responses o f T cells that are incompletely activated by
TCR signals.
Using the human-SCID model I examined the role o f 4-1 BBL, ICOSL and
OX40L in human allograft injury. Several recent studies using rodent transplant models
have described roles for 4 -IBB, 0X 40, and ICOS in vivo. Genetic ablation or antibody
blockade o f the 4-1BB-4-1BBL pathway prolongs graft survival by reducing T cell
proliferation and cytotoxicity (305, 363, 364). ICOS deficiency or blockade have also
been shown in rodent models to improve transplant survival and, in conjunction with B7
blockade, even induce tolerance (303, 365), although not in all cases (366).

OX40L

blockade, also leads to increased graft survival in presensitized mice in combination with
B7 blockade (307, 366). When any o f these pathways are blocked in my chimeric model
o f human memory I show significantly decreased endothelial damage, vascular
destruction and effector molecule mRNA at 10 days, though none seems to be as
effective as blockade o f LFA-3. One reason for this is that LFA-3 may have some effects
on T cell infiltration into the grafts in addition to any o f its potential costimulatory effects
although the extent o f infiltration was reduced by less than 50%. Thus, my model is the
first to demonstrate a role for 4-1 BBL, ICOSL and OX40L in human allograft rejection
in vivo. To date, previous data suggested a correlation between these costimulators and
graft rejection in human transplantation (367, 368) as well as in other human diseases
(362), but none have explored the effects o f targeting these pathways in humans.
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Though 4-1 BBL, ICOSL, and OX40L appear to have similar potential to reduce
the allograft rejection, the effects on cytokine transcript expression in vivo reveals
differences among the functions o f these costimulators in vivo.

Blockade o f 4-1 BBL

decreased mRNA production o f IFN-y, IL-2, as well as IL-10, but had no effect on IL-4.
This is consistent with observations that 4-1 BBL activates both CD4+ and CD8+ human
T cells to produce IL-2 and IFN-y independently o f B7 interactions (160). In comparison
to 4-1 BBL, blockade o f ICOSL increased IFN-y and only minimally reduced IL-2
production, but showed a much larger decrease in IL-10 and IL-4 production. My in vivo
data correlates with in vitro studies that have indicated a limited role for ICOS in IFN-y
regulation, while playing a large part in the regulation o f IL-10 (369) and IL-4 (370, 371).
OX40L blockade had no effect on the level o f IL-10 mRNA, while reducing all the other
cytokines, suggesting a distinct mechanism o f action different from either 4-1 BBL or
ICOSL blockade and may be related to the role that the 0X 40 interaction plays in the
control o f regulatory T cells (Treg) (372, 373)
In conclusion, I have shown that memory T cell-mediated activation by HDMEC
depends in part on the costimulatory molecules 4-1 BBL, ICOSL and OX40L. Further
that memory T cell-selective costimulation plays a significant role in this model of
memory T cell-dependent allograft rejection. My studies extend the understanding o f the
mechanism by which human memory T cells may be activated by the endothelium and
identify targets for reducing the memory T cell participation in clinical allograft rejection.
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CHAPTER VI - THE IN VITRO AND IN VIVO RESPONSE OF
MEMORY T CELL SUBSETS TO THE ENDOTHELIUM
6.1 INTRODUCTION
A cardinal feature o f the adaptive immune response is memory, i.e. a second
immune response to a given Ag that has been encountered previously is faster and more
vigorous compared to the initial (primary) immune response. In cell-mediated immune
responses, memory arises from changes in the populations o f T lymphocytes that respond
to the specific Ag.

When compared to naive response, a memory response is

characterized by a higher frequency o f Ag-specific T cells and by a series o f changes in
the individual T cells that respond to that Ag (16).

Such changes include an altered

requirement for costimulators and a change in receptors involved in homing. Memory T
cells also have a special relationship to vascular endothelial cells (EC) in that resting
memory T cells can be activated by alloantigens presented by EC, but not by other
stromal or parenchymal cells in vitro (206, 213).
It has recently been discovered that memory T cells exist in at least two subsets
based on their homing characteristics and effector functions (46, 51, 54).
memory T cells

(T c m )

Central

express chemokine receptors (e.g. CCR7) that bind lymph node

derived chemokines like SLC and adhesion molecules (e.g. CD62L) that preferentially
interact with ligands expressed by high endothelial venules o f lymph nodes (46).
Consequently, Tcm migrate preferentially to the T cell areas o f lymphoid organs where
they conduct surveillance for their specific A g displayed by professional A PC s such as

DC (374).

Effector memory T cells

(T em )

have enhanced effector functions, such as

secretion of effector cytokines like IFN-y, and a corresponding preference for migration
to inflamed peripheral tissues (54). This migration pattern is explained by observations
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that

T

em

express chemokine receptors (e.g. CXCR3) that respond to inflammatory

chemokines instead o f CCR7 and express high levels o f adhesion molecules (e.g. LFA-1
or VLA-4) (325) whose ligands (ICAM-1 and VCAM-1, respectively) are preferentially
expressed by cytokine-activated peripheral vascular EC (200). These homing properties
are shared with activated effector T cells and may allow circulating effector memory cells
to be directly recruited to sites o f peripheral inflammatory reactions without first
requiring Ag recognition and activation in secondary lymphoid organs.
As discussed previously, the T cell response to antigen depends both on TCR
signals (provided by peptide-MHC molecule complexes) and antigen-independent
costimulatory molecules.

The majority o f costimulatory molecules fall into two

structural families, those that are part o f the Ig superfamily and those that are part o f the
tumor necrosis factor (TNF) superfamily.

The best described T cell receptors for

costimulation are those from the Ig superfamily, particularly CD28 (which binds B7-1
and -2, also known as CD80 and CD86, respectively) and CD2 (which binds CD58 in
humans and CD48 in rodents) (350). Fluman EC express LFA-3 (but generally not B7-1
or -2) and the LFA-3-CD2 pathway seems to be particularly important in human
allogeneic responses to this cell type.

However, antibody blocking experiments have

suggested that LFA-3 does not account for all o f the costimulation that human EC
provide to memory T cells (208, 209).

Several newly discovered receptors for

costimulators in both the B7 family (such as ICOS) and the TNF receptor family (such as
CD27, 4 IBB and 0X 40) are important for the generation of effector/memory T cells
(140, 160, 352, 375). Ligands for these molecules are expressed on cytokine-activated
human EC cultured from umbilical vein (86, 152) and dermal microvessels (See chapter
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V). Results from Chapter V demonstrate that ICOS, 4 IBB and 0X 40 can contribute to
EC mediated activation o f memory T cells, but the specific costimulatory requirements of
the different memory T cell subsets has not been fully explored.
In addition to addressing whether naive or memory T cells can mediate allograft
rejection, the subset o f memory T cells responsible for this phenomenon is not clear.
W ork by Adams et al has shown that CD8+ central memory T cells are principally
responsible for memory cell-mediated rejection (275) while others have described a role
for CD4+ T effector cells (376). Little is known about differences between alloreactive
human

T

cm

and

T

em

-

In this chapter I demonstrate that both Tcm and Tem subsets from human
peripheral blood respond can proliferate in response to allogeneic HUVEC in vitro, but
that these two subsets respond differently to EC vs. professional APC. Further, I also
demonstrate in the human-SCID chimeric model o f allograft rejection that adoptively
transferred

T Em

are capable o f mediating rejection whereas human

T

cm

cannot. These

observations may be important for the design o f new therapies to address the problem of
immunological memory in transplant rejection.
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6.2 RESULTS
Tcm

to

proliferate more and produce greater amounts o f IL-2 in response to EC compared
while

Tem ,

Tem

proliferate less and produce more IFN-y.

Memory T cells in humans have been defined by expression o f CD45RO (377).
These memory T cells can be further divided into separate subsets based on CD62L and
CCR7 expression (46). I took positively isolated CD4+ T cells from human peripheral
blood and sorted then for the CD45RO+CCR7+CD62L+ population (“central” memory T
cells,
6.1).

T

cm

)

and the CD45RO+CCR7-CD62L- (“effector” memory T cells,

T cell subsets were sorted with >95% purity.

T

em

)

(Figure

Previous work from Chapter III

demonstrated that CD4+ memory T cells but not naive T cells respond to class II MHCexpressing HDMEC in vitro. To assess the responses o f T c m

vs

T Em ,

I used the FACS-

sorted memory CD4+ T cells subsets described above and co-cultured them with EC pre
treated with IFN-y for 72 h to induce class II MHC molecules, assaying the supernatants
for IFN-y and IL-2 after 24 h. I found that

T

em

cultured with allogeneic EC produce

significantly more o f IFN-y but less IL-2 than do Tcm (Figure 6.2A and B).

The

increased production o f IL-2 by Tcm correlates with increased proliferation o f Tcm in
response to allogeneic EC compared to Tem assessed by 3H-thymidine incorporation at
days 5, 6, and 7 (Figure 6.2C).

In contrast I did not observe a difference in IFN-y

production when these same subsets are co-cultured with allogeneic Mo. However, both
IL-2 production and T cell proliferation are greater for
cultures with allogeneic Mo (Figure 6.2A, B, and D).

T

cm

compared to

T

em

in co

In other words, EC appear to

provide a signal that selectively augments IFN-y production by TEM or, conversely, lack a
signal needed for optimal IFN-y production by Tcm-
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CD45RO

CCR7

CD45RO

CCR7

Figure 6.1. FACSort o f human T cells demonstrates good purity o f subsets. CD4+ T cells
were isolated using magnetic beads prior to being stained with antibodies to CD45RO, CD62L
and CCR7. Cells were then sorted into Tcm and T em by collecting only the gated regions.
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Figure 6.2. Effector memory T cells exhibit
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Tcm

express different levels o f costimulatory and adhesion molecules compared with

Tem -

In order to explore the differences that underlie the varying responses o f Tcm and
T

em

, I

examined the expression level o f several known costimulatory and adhesion

molecules on the surface o f the two subsets. I found that for the costimulatory molecules
that Tcm express significantly more CD27 and slightly more CD28, CD 152 (CTLA-4),
ICOS and 4-1BB compared to

T Em

(Figure 6.3A). Expression o f CD27 on

T Em

was,

however, heterogeneous with two populations o f cells, a small population with an
intermediate level o f CD27 expression and much larger population o f TEm expressing low
levels o f CD27. Unexpectedly, I found slightly higher levels of expression o f LFA-1 on
T Cm

than on TEM (Figure 6.3A). HUVEC lack ligands that may engage CD28, but do

express both ICOSL and 4-1BBL (189). They also express ICAM-1 and 2, the ligands
for LFA-1 (200). Expression o f CD70, the ligand for CD27, has not been previously
described. As shown in Figure 3B, EC do not express CD70 or B7 molecules at rest nor
do they increase CD70 or B7 molecules with IFN-y treatment or co-culture with T cells.
Adherent Mo, however, express low levels o f CD70 and B7 molecules at baseline.

Effects o f costimulation blockade on Tcm and Tem response.
Due to the differential expression o f CD70 on Mo compared to EC and CD27 on
Tcm compared to TEm, I examined the effect of adding a blocking antibody to this T cell
receptor in my allogeneic co-culture experiments. Blocking CD27 decreased production
o f IL-2 by T cm but not by TEm in co-cultures with EC or Mo (Figure 6.4C and D, p <
0.05).

Surprisingly, blocking CD27 inhibited IFN-y production in co-cultures of
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CD28

Figure 6.3. Effector memory T cells express
lower levels o f CD27, CD152 (CTLA-4), 41BB and ICOS compared to central memory
4-1BB

ICOS

T cells and E C do not express CD70 or B7,
but M o express both. CD4+CD45RO+ T cells
were isolated from PBMCs using magnetic
beads and subsequently stained with CCR7 and

LFA-1

0X40

CD62L.

The TCM CCR7+CD62L+ (gray

filled) population was gated on and compared
with the Tem CCR7-CD62L- (black line) popu
lation (A). HUVEC or negatively isolated Mo
were either treated with IFN-g for 3 d, co
cultured with CD4+ T cells or both and as

B

sessed for CD70 expression or binding to

EC

CTLA-4Ig by FACS analysis (B). Data repre

l
j

sents one o f three experiments.
•r~

s

I

EC + IFN-g

EC + CD4+ T

EC + IFN-g +
CD4+T

Mo

CD70

CTLA-4lg
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EC with T cm or TEm, but has no effect on co-cultures o f either subset with Mo (Figure
6.4A and B).
I also examined the effects o f signaling through CD28 since human Mo but not
EC express B7 (189). I found that if B7 signaling is blocked using CTLA-4Ig that there
is no effect on IFN-y production in either subset with EC (Figure 6.4A), but that there is a
significant reduction in both subsets when they are cultured with Mo (Figure 6.4B, p <
0.01).

For IL-2 production I find that CTLA-4Ig inhibits Tcm, but not TEm IL-2

production in co-cultures with EC (Figure 6.4C, p < 0.04), but inhibits IL-2 production
from both subsets in co-cultures with Mo (Figure 6.4D, p < 0.005). To further test if B7mediated costimulation accounts for the decreased IFN-y production in TCm cultured with
EC I generated EC that express B7.2 using retrovirus (Figure 6.5A). When co-cultured
with these EC, Tcm produce greater amounts o f both IFN-y (p < 0.002) and IL-2 (p <
lxlO"4).

Interestingly, TEm do not produce any additional IFN-y, but do produce

significantly more IL-2 (p < 0.001), similar to the response when TEm are cultured with
AMo (Figure 6.5B and C). These data suggest that the absence o f B7-ligands on EC may
contribute to the reduced capacity o f EC to activate TCm- The ability o f CTLA-4Ig to
reduce IL-2 synthesis by Tcm cultured with EC is consistent with a previous study in
which T cells proved to be the source o f B7 ligands (190).

Tem alone can mediate graft rejection in a hu-SCID model o f allograft rejection.
I have recently shown that human skin injury observed in a human mouse chimera
can be mediated by isolated memory T cells but not naive T cells (189). Knowing that
both

central

and

effector

memory

T

cells

can

respond

to

EC
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Figure 6.4. CD27 and CD28 have different roles fo r E C and Mo in stimulating memory T
cell subset cytokine production. Tcm and TEMwere then co-cultured with EC (A, C) or Mo (B,
D) and blocking antibody to CD27, CTLA-4Ig or IgG l.
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Figure 6.5.
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only effector memory T cells can produce high amounts o f IFN-y, I wanted to see which
memory T cell subset was responsible for the rejection response. I adoptively transferred
either central or effector memory T cells into SCID/beige mice that had been grafted with
human skin. After three weeks, the grafts were harvested and analyzed. I found in three
separate experiments that effector memory T cells (Figure 6.6C and D), but not central
memory T cells (Figure 6.6A and B) could infiltrate and destroy graft microvessels.
When scored by a blinded dermatopathologist, mice receiving adoptively transferred
effector memory T cells showed significantly more infiltration and endothelial damage (p
> 0.0001) compared to mice receiving central memory T cells (Figure 6.6E).
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Figure 6.6. E ffecto r m em ory T cells alone can m ediate g ra ft rejection. Grafts from mice that
received either TCm (2 0 x -A , 4 0 x -B ) or TEM (20x-C, 40x-D) for 14 days were harvested and
stained with H&E. Grafts were then scored blindly by a dermatopathologist (E). The data rep
resent n=12 mice per group.

117

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

6.3 DISCUSSION
In this chapter, I present two new observations about memory T cell subsets and
their relationship to EC. First, I demonstrate that human T cm and T em subsets, defined by
the expression o f CCR7 and CD62L, produce different levels o f cytokine in response to
allogeneic endothelial cells.

Specifically, TCm produce less IFN-y and more IL-2

compared to Tem when co-cultured with EC but not with allogeneic peripheral blood Mo.
Second, I show that both T cell CD27 and CD28 may be involved in the different
response o f memory T cell subsets to allogeneic EC vs. Mo. Third, I demonstrate that
following adoptive transfer, Tem but not Tcm can mediate graft injury in a hu-SCID
chimera model o f skin allograft rejection.
The current conception o f T cell memory proposes that the memory T cell pool
may be divided into central memory (TCm) and effector memory (TEm) (46). This model
proposes that T cm cells which are CCR7+ preferentially migrate into secondary lymphoid
organs and lack immediate effector functions such as IFN-y production or cytolytic
activity. However, TEm, which lack expression o f CCR7, more rapidly acquire effector
function and have a migratory pattern that favors extralymphoid sites. Studies in mice
have demonstrated that a large number o f CD4+ memory T cells can be found in
extralymphoid sites and that there is a functional difference between memory T cells
residing in the lymphoid tissue compared to those o f the extralymphoid tissues (51, 54).
However, several human and mouse studies have not been able to confirm the
relationship between immediate effector function and the potential to migrate to
extralymphoid sites (as defined by the expression of CCR7).

In fact, these studies

suggest that the majority o f cytokine producing memory T cells express CCR7 and that
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immediate effector function did not correlate with CCR7 or CD62L expression (378380).

My data shows that human memory T cell subsets do show such differences but

only when responding to allogeneic EC. One consideration, however, is the definition of
T

cm

and

T

em

,

some groups use CCR7 alone and others have used CCR7 in combination

with CD62L. As seen in figure 6.1 there is a significant population that is CCR7- but
CD62L+; the contributions o f this subset are unclear.
It is now become evident that the existence o f memory T cells presents a
significant challenge to long-term graft survival.

The presence o f alloreactive CD4+

memory T cells correlates with increased episodes o f acute rejection and diminished graft
function (270, 271). However, the role o f memory T cells in allograft rejection has not
been well-studied due to the lack of appropriate in vivo models. Mouse models have
been described that use donor-specific alloreactive memory T cells (376) or those that
have been generated from viral infection (275), but these still lack the diversity o f the
human memory T cell pool. My study using human memory T cells fractionated into
their different subsets shows a role for Tem in allograft rejection, but not Tcm- One key
difference between my human-mouse chimera and the current mouse models is that,
though SCID/bg mice possess lymph nodes, human T cells cannot effectively circulate to
the mouse secondary lymphoid organs thus providing an isolated model o f peripheral
rejection only. I did not find any human T cells in any lymph nodes examines and this
lack o f ability to circulate in the secondary lymphoid organs may explain why, in contrast
to experiments with mice,

T Cm

in my model appear unable to mediate graft rejection.

This is supported by my in vitro data suggesting that Tem can produce more IFN-y in
response to the endothelium compared to Tcm which produce significantly more IL-2.
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This difference in vitro is abolished with sufficient B7-signals (i.e. from monocytes or
transduced EC) which further supports the idea that TCm may need to circulate through
the secondary lymphoid organs and encounter B7 bearing APC to attain full functional
capacity.
Recent data have suggested that memory T cells may have different costimulatory
requirements for activation when compared to their naive counterparts. Early work in
mice (60) and humans (381) demonstrated that memory T cells can be activated
independently o f CD28 and more recently it has been appreciated that there may be a role
for memory specific costimulators in memory T cell activation (361, 362). In accordance
with other studies that have shown decreased CD27 and CD28 in the effector memory T
cell population (131, 382), I have also found decreases in CD27 and CD28 in the effector
memory populations used in my experiments.

To explore whether the differential

expression o f these costimulatory molecules on the two different subsets is responsible
for the difference in their response to EC I used a blocking antibody to CD27 and
CTLA4-Ig to block the B7-interaction. My results were surprising in that blockade of
CD27 showed decreased IFN-y production from the effector memory T cell subset as
well as decreased IL-2 production from the central memory T cell subset. One possible
explanation is that the majority o f the IFN-y may be produced by the sub-population in
the effector memory T cells that are expressing CD27 at an intermediate level and thus
blockade o f CD27 decreases their IFN-y production. The other possible explanation is
that blockade o f CD27 o f this intermediate population may be affecting the production of
IFN-y production from the CD27- population.

The other surprising result from my

blocking experiments was the effect that CTLA-4Ig had on IL-2 production in the central
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memory T cell population co-cultured with EC. As EC do not express B7 molecules it is
unclear where the source o f CD28 stimulation for the central memory T cells is
originating. One source o f CD80 and CD86 may be the T cells themselves. Previous
work has demonstrated that interaction o f CD4+ T cells with EC can induce expression of
CD 80 and CD 86 on the T cells in vitro (190). The increased IL-2 production in central
memory T cells may depend on this source o f B7 stimulation and my experiments with
B7-transduced endothelial cells supports this hypothesis in that central memory T cells
seem to be more responsive to B7 signals than their effector memory counterparts.
There has also been evidence showing that the memory T cell subsets are not
fixed, but rather retain some flexibility in terms o f their differentiation and that
differentiation into the different subsets may be dependent on the microenvironment
(383, 384).

Endothelial cells may play a central role in the determination o f this

microenvironment.

My data supports this hypothesis in that interaction between the

different memory T cell subsets and EC produces different responses.

Further

examination o f memory T cell expression o f costimulatory and adhesive molecules
whose ligands are known to be expressed on surface o f EC suggests that these molecules
may play an integral role in the differential stimulation o f T

c m

and

T

e m

-

In conclusion, I demonstrate here that when the different memory T cell subsets
are co-cultured with EC, Tcm favor IL-2 production and Tem produce more IFN-y. The
difference in IFN-y production is abolished in the presence o f AMo or B7-transduced EC,
but the difference in IL-2 production is retained. I also show that in a chimeric hu-SCID
model of allograft rejection that T em alone can mediate rejection whereas T cm cannot.
This study introduces the idea that EC may activate different memory T cell subsets
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differently and that this differential in activation may have a functional consequence
allograft rejection.
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CHAPTER VII - CONCLUSIONS AND FUTURE DIRECTIONS
This thesis describes several new observations. First, I demonstrate that human
dermal microvascular endothelial cells (HDMEC) like other human EC preferentially
activate allogeneic memory T cells. Second, I also show that allograft rejection in my
chimeric human skin-SCID mouse model is mediated by memory T cells.

Third, I

demonstrate that the CD28-B7 pathway may have a role in memory T cell mediated
rejection by using a novel reagent that blocks CD28. Fourth, I show that E1DMEC can
express memory T cell specific costimulatory molecules 4-1BBL, OX40L and ICOSL
and that these molecules have a role in human memory T cell mediated allograft
rejection.

Finally, I describe the different responses o f central memory and effector

memory T cells to the endothelium and provide evidence that T em alone can mediate
allograft rejection.

T cell activation by EC
The question o f whether EC can activate CD4+ and CD8+ T cells in vitro has
been controversial.

The first reason is species differences between humans and other

animals such as mice. My lab has previously demonstrated that HUVEC activate resting
allogeneic CD8+ T cells to proliferate, produce IL-2 and acquire cytolytic potential (209,
215). In the human system, FIUVEC preferentially activate memory CD8+ T cells (214).
Studies done in the mouse have yielded conflicting results. It was initially reported that
murine cardiac EC are capable of directly activating naive CD8+ T cells (385), however a
subsequent study using a model o f indirect presentation suggested that IFN-y activated
lung microvascular EC fail to induce proliferation or activation o f naive CD8+ T cells
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(386). Further studies using murine aortic EC have shown that both resting and IFN-y
activated EC are capable o f activating naive CD8+ T cells (219).

Since EC in those

studies derived from different organs, the conflicting findings among the murine studies
may be due to the fact that EC from different locations have been shown to display
significant heterogeneity in function which may include their capacity to activate T cells
(387).

Differences between the human and mouse capacity to activate naive allogeneic

CD8+ T cells may be attributable to the different types o f costimulatory molecules
provided by mouse EC, which express B7, and human EC which do not (388). Despite
these differences, both murine and human data support the idea that EC possess the
capacity to directly activate allogeneic CD8+ T cells. The results from Chapter 3 agree
with these findings in that FIDMEC, like the large vessel-derived HUVEC, are capable of
activating allogeneic memory CD8+ T cells preferentially over naive CD8+ T cells.
This situation for CD4+ T cells is similar to that o f the CD8+ T cells. My lab and
others have previously demonstrated that HUVEC can activate CD4+ T cells (208, 389)
and that HUVEC also preferentially activate memory CD4+ T cells (223). McDouall et
al further showed that EC derived from large vessels and microvessels o f the heart can
activate CD4+ T cells (390). Vora et al verified the capacity o f HDMEC to present
specific Ag in experiments using CD4+ T cells clones (233).

Other groups have

questioned the ability o f human EC to activate CD4+ T cells (217, 327) and one reason
may be the insufficient sensitivity of their assays to detect the initial primary activation.
Marelli-Berg at al demonstrate that culture o f EC with CD4+ memory T cells does enable
them to be subsequently activated by EC in the presence o f B7 costimulation suggesting
that the T cells in their assays did receive some signal from the EC (327). I confirm in
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this thesis that HDMEC possess the capacity to activate CD4+ T cells and provide
evidence that HDMEC specifically activate resting memory CD4+ T cells and not naive
CD4+ T cells (Chapter 3).

Similar to the human data, several groups have provided

convincing evidence that murine EC do not possess the capacity to activate naive CD4+
T cells (216, 385), but may possess the capacity to activate CD4+ memory T cells (391).
In sum, I show that HDMEC can activate both memory CD4+ and CD8+ T cells, but not
naive T cells o f either subset. This observation is consistent with previous data derived
from large-vessel human EC, but distinct from murine data in that EC from mice can
activate naive CD8+ T cells.

Memory T cell models in transplant rejection
Much o f the progress in my understanding o f memory has come from studies that
make use o f murine models.

Most o f the mice used in these studies do not possess

significant numbers o f memory T cells due in part to the relatively pathogen-free
environments in which mice are housed and the young age o f the mice. Thus, in using
mice to study memory T cells, the two most common approaches are to generate memory
T cells prior to a given study (priming) or to adoptively transfer memory T cells that have
been generated in another source.
As discussed in the introduction, one o f the major limitations o f the murine
models o f memory used to study transplantation is the lack o f the diversity and numbers
o f memory T cells found in mice compared to those in found in large animals. It is this

significant population o f memory T cells that is thought to underlie the failure to translate
strategies to inhibit rejection from mice to other animals.

In this thesis, I provide

evidence that the rejection response seen in my previously described model o f adoptively
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transferring human PBMC in to human skin-SCID mouse chimeras actually (179)
represents a model o f memory T cell mediated destruction (Chapter 3). Thus, my system
provides a small animal model to test strategies that target human memory T cells. This
chimera provides a useful bridge between pure murine models and large animal models
to test hypotheses developed in mice before embarking on the more costly large animal
models as shown in Chapter 4 where I test a novel reagent against CD28.
Before discussing how the model can be used, there are several technical
considerations that may be relevant to the understanding of this model.

The first

consideration is the repertoire o f the memory T cells used in this system. Murine models
o f memory because o f their requirement for generating memory T cells and the use o f T
cell receptor transgenics have very precise control o f the specificity o f the memory T
cells generated. Thus, it is possible to study the rejection in models o f memory with T
cells that are limited to cross-reactivity from specific infectious agents (275) or are
specific for minor antigens (392). My model has much less control o f the specificity in
that my HLA mismatches are random and likely involve multiple major MHC
mismatches between the skin and the adoptively transferred leukocytes. The implication
o f this is that my model may have an alloresponse that is more difficult to inhibit because
o f the multiple mismatches and that this model may be more vigorous than a typical
clinical transplant where the MHC alleles between donor and host, particularly in kidney
and bone marrow transplants (but not liver or hearts), would be HLA matched (393).
Therefore, any effects seen in my model may be diminished in comparison to a model
where the specificity is more limited. This may explain why costimulatory blockade in
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my system, while partially ameliorating graft rejection, does not fully recapitulate the
results seen using murine models o f allograft rejection (305, 306, 365).
A second consideration to note is the role that homeostatic proliferation plays in
my model. Homeostatic proliferation occurs as a result o f low-affinity recognition of
MHC-peptide ligands and cytokine in a setting where the T cell compartment has been
depleted, i.e. lymphopenia (24, 48, 280).

These dividing cells appear to transiently

acquire memory markers and have memory-like function during the period during which
they are undergoing homeostatic proliferation (43, 44, 394, 395). In T cells undergoing
homeostatic proliferation there is decreased CD62L, increased CD44 and further these
cells, like bone fide memory cells, show a decreased reliance on CD28 signaling (396).
The lymphocytes in my model exhibit this type o f change and this is most pronounced in
the CD45RA group that when adoptively transferred appears to transiently acquire
CD45RO positivity (See Figure 3.2) suggesting that the T cells in my model are
undergoing homeostatic proliferation in the mouse. However, in contrast to evidence that
this conversion o f a naive to memory phenotype during homeostatic proliferation leads to
enhanced rejection (281) it appears that in my model this is not the case. The adoptively
transferred naive T cells despite acquisition o f a memory marker do not seem capable of
mediating a rejection response. This may be because naive T cells require activation in
secondary lymphoid organs whereas memory T cell do not (61). In my model there are
no human dendritic cells in addition to the fact that human T cells may not possess the
appropriate cross-reacting chemokines and/or adhesion molecules to enter the secondary
lymphoid organs o f mice. Thus, while there is significant homeostatic proliferation going

127

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

on in my model, it is not clear that it contributes to the observed allograft response, which
appears to depend solely on memory T cells.
My model provides the unique opportunity to study the role o f human memory T
cells in allograft rejection. I chose to focus on the effects o f costimulation blockade, but
certainly there are a number of studies that could be carried out in my model to study the
regulation o f memory T cells. In particular, the role o f regulatory T cells or peripheral
tolerance in memory T cell mediated rejection would be interesting topics to pursue in
future studies.

CD28 costimulation in memory T cell mediated rejection
Costimulation o f T cells through CD28 by EC has been a contentious issue
largely because o f differences in results between experiments with human cells compared
with other animals. In humans, HUVEC initially activate T cells independently o f CD28
(98, 188, 197) and in fact do not express any B7 molecules (188, 397).

In contrast,

mouse and porcine EC express CD80 and CD86 respectively (239, 388) and can utilize
these molecules to activate naive T cells (219). Despite these differences, it is clear that
agents targeting the CD28-B7 pathway have no effect on the initial stimulation that
human EC provide to T cells.

However, the question o f whether CD28 mediated

signaling plays any role in the ensuing reaction remains unclear.

Denton et al have

shown that while HUVEC themselves do not express B7 molecules, HUVEC can
stimulate CD4+ T cells to express CD86 and CD80 in culture (190). Thus, in Chapter 4 I
used a novel reagent that blocks CD28 to try and identify the effects o f this reagent on
possible B7 interactions in co-cultures o f T cells and EC. In characterizing this reagent, I
discovered that the reagent, a monoclonal antibody, is actually partially costimulatory
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except in the presence o f high levels o f B7 expression.

However, the level of

costimulation is less than the typical antibodies used for costimulation (Chapter 4). The
partial costimulatory activity made it difficult to assess the effects o f CD28 blockade in
vitro other than the interesting point that in the presence o f excess B7.2 that the antibody
did not inhibit CD4+ T cell IFN-y production, while it did inhibit IL-2 production.

This

may be due to the fact that CD4+ IFN-y production may be much more sensitive to the
level of B7 stimulation and the small amount o f blockade that is not inhibited by the
antibody may augment IFN-y production.
Initial studies done in mice with CTLA-4Ig, which binds B7 molecules with high
affinity and blocks their interaction with CD28, demonstrated much promise for
inhibiting T cell reactions (288).

In combination with anti-CD 154 blockade this

combination proved to be very effective in preventing allograft rejection (289).

As

discussed in Chapter 4, one of the problems with CTLA-4Ig is that it has become
increasingly evident that signals delivered from CTLA-4 binding B7 molecules is
important for the function o f regulatory T cells (398). Therefore, this antibody with the
ability to specifically target CD28 provides an opportunity to deliver inhibitory CTLA-4
signals while simultaneously preventing activating CD28 signals. Unfortunately, the two
reagents could not be compared in vivo because CTLA-4Ig augmented the adoptive
transfer leading to dramatic increases in the level o f circulating human cells in my model
(data not shown). With regards to FK734, despite the partial agonist activity in vitro I
found that blocking CD28 in vivo is able to ameliorate memory T cell mediated allograft
rejection. However, the effect o f blockade is modest at best and this is consistent with
my understanding of the resistance o f memory T cells to CD28-B7 blockade (291).
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There is ample evidence in mice suggesting that memory T cells are less reliant on
CD28-B7 signals than naive T cells (58, 60).

While these studies suggest that other

pathways may compensate for the loss o f CD28-B7 costimulation making memory T
cells resistant to CD28-B7 blockade, it is important to note that in the normal memory T
cell response the CD28-B7 pathway retains an large role because blockade o f these
alternative pathways alone do not delay allograft rejection (306). My findings further
support this idea and suggest a role for CD28 mediated signals in memory T cell
activation.
Thus, while memory T cells may be resistant to CD28 blockade, it may be that
blockade o f this pathway is needed for the other pathways to become prominent. To test
this idea, again, combinations o f blockade would be useful to identify the precise
hierarchy o f signals mediating the allograft rejection seen in my model. Based on the
murine data, the most useful combination should be CD28 and 0X 40 blockade (306),
though my data suggests that blockade o f all three costimulatory pathways in addition to
B7 and/or LFA-3 blockade would likely have the greatest effect.

Memory specific costimulators in memory T cell- mediated rejection
In contrast to CD28, which is expressed constitutively on naive T cells, the
memory specific costimulators, ICOS, 4 -IBB and 0X 40, are expressed only upon T cell
activation. This suggests that their function is likely related to the effector/memory phase
o f T cell activation rather than the initial phase of T cell activation. As discussed above,
EC also have a unique ability to activate memory T cells in partly LFA-3 dependent
manner. In Chapter 5, I examined whether the EC capacity to activate memory T cells
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depended on their expression o f these memory T cell-specific costimulators and if
targeting these interactions could ameliorate graft rejection.
EC have been shown to express functional ICOS-L which is important for EC
reactivation o f effector/memory T cells (86). In that study, Khayyamian et al examined
HUVEC and demonstrated that HUVEC express ICOSL and that blockade o f EC ICOSL
partially inhibits the EC capacity to activate CD4+ T cells.

My data with HDMEC

corroborates the evidence from this study showing that HDMEC express ICOSL
constitutively, upregulate it with TNF and that blocking ICOSL inhibits CD4+ and CD8+
cytokine production and proliferation (Chapter 5).

The reduction in T cell cytokine

production and proliferation was approximately 50% suggesting that ICOSL plays a
significant, but partial role in EC mediated T cell activation.
ICOS-ICOSL interactions have been shown to play a significant role in transplant
rejection.

Studies in mice using an anti-ICOS mAb, an ICOS-Ig fusion protein, or

transfer into an ICOS deficient recipient show prolonged survival o f a mismatched
cardiac allograft, though to a lesser extent than administration o f CTLA-4Ig or an antiCD40L mAb (303). Treatment with both CTLA-4Ig or anti-CD40L mAb and ICOS-Ig
resulted in the long-term survival o f a cardiac allograft (302, 399) suggesting there may
be a synergistic effect between the ICOS-ICOSL pathway and the CD40-CD154 or
CD28-B7 pathways. The timing o f the administration o f blockade o f the ICOS-ICOSL
pathway can also appears to influence transplant rejection. Harada et al demonstrated in
a major mismatch cardiac allograft model that delayed ICOS blockade was more
effective that early ICOS blockade in prolonging allograft survival because early
blockade targeted only CD4+ T cells while delayed blockade inhibited both CD4+ and
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CD8+ T ell expansion (365). All these studies focused on rejection mediated by mostly
naive T cells and recent work using memory T cells generated by homeostatically
proliferated memory T cells or by donor Ag priming suprisingly showed no effect of
blocking the ICOS-ICOSL pathway alone or in combination with CD28/CD154 blockade
on skin allograft rejection (306).

My studies using the hu-SCID chimera showed an

increase in intragraft ICOSL mRNA during rejection and that blocking the ICOS-ICOSL
pathway could inhibit T cell mediated endothelial injury and intragraft expression o f IL2, 4, and 10 mRNA (Chapter 5). This contradicts the mouse data with memory T cells,
but is consistent with studies done in mice using naive T cell recipients. One explanation
for this difference is access o f the memory T cells to the secondary lymphoid organs.
While memory T cells apparently do not need secondary lymphoid organs to mediate
rejection, those derived from homeostatic proliferation in the absence of the secondary
lymphoid organs have been shown to be inferior to antigen experienced memory T cells
(61). My model does not allow memory T cells access to functional secondary lymphoid
organs and as such this may explain the greater effect o f ICOS blockade in my system
where T cells may rely more on ICOSL provided in the graft for activation without
access to the secondary lymphoid organs.
4-1BBL expression on EC has not been described previously. I demonstrate in
this thesis that 4-1BBL can be induced at a low level on the surface o f HDMEC both in
response to TNF and co-culture with allogeneic T cells (Chapter 5). It has been shown to
be induced by CD40 and IL-1 signaling on DC, but these stimuli have not been tested in
EC (169). Blockade o f this pathway inhibits CD8+ T cell, but not CD4+ T cell, IFN-y
and IL-2 production (Chapter 5).

However, blockade does decrease both CD4+ and
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CD8+ T cell proliferation in response to EC. These data are in agreement with data
showing that 4 -IBB signaling affects both CD4+ and CD8+ T cells, but has a stronger
effect on the activation o f CD8+ T cells (160, 400).

One consideration to the data

regarding 4 -IBB signaling is that 4-1BBL is also known to induce reverse signaling. In
human monocytes, stimulating 4-1BBL enhances their activation and survival (172, 173).
The effects o f 4-1BBL signaling in EC have not been examined and will be important to
explore further.
With regard to transplantation, using 4-lB B Ig (401), blocking mAbs, or genetic
ablation (305) to eliminated 4-1BB signals demonstrated prolonged graft survival in
murine cardiac allograft models showing decreased T cell infiltration and vascular
damage. In skin allografts, however, deletion o f 4-1BBL had no effect unless it was
combined with ablation o f CD28 (364) or CD 154 and CD45RB blockade (402). Thus,
for naive T cells targeting 4 -IBB can prolong graft survival in both skin and cardiac
allografts possibly affecting CD8+ T cell effector function.

In one study looking at

memory T cells derived from homeostatic proliferation or donor specific priming there
was no effect o f an anti-4-1BBL mAh (306). My data again contradicts the results in the
murine model o f memory and instead supports the data for naive T cells. In Chapter 5,
administration o f a blocking 4-1BBL mAb ameliorated memory T cell mediated allograft
rejection and showed decreased intragraft IFN-y and IL-2 (Chapter 5). There was no
change in T cell infiltration or perforin/granzyme B mRNA so it is not clear if decreased
cytolytic function o f CD8+ T cells is the mechanism o f protection.

The discrepancy

between my model and the murine model may again lie in the lack o f access to functional
secondary lymphoid organs in my model compared to the murine model. Blockade o f the
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4-1BB-4-1BBL pathway in EC-T cell co-cultures showed effects on CD4+ and CD8+ T
cells and without access to other signals in the secondary lymphoid organs this pathway
may be more important in my model than in the murine model.
The final pathway I examined in Chapter 5 was the OX40-OX40L pathway.
OX40L expression on HUVEC has been described previously and been shown to mediate
both adhesion to EC as well as costimulation with a polyclonal activator (152, 153). I
demonstrate in Chapter 5 that HDMEC constitutively express significant levels of
OX40L and that stimulation with TNF or co-culture with T cells increased those levels
slightly. Blockade o f OX40L in co-cultures led to decreased IFN-y and IL-2 production
from both CD4+ and CD8+ T cells. This supports observations from other groups that
have shown that in mice agonistic anti-OX40 antibodies enhance the expansion o f both
CD4+ and CD8+ T cells in vivo (403, 404).
In allograft responses, 0X 40 has emerged as a key player in the activation o f
memory T cells.

Initial work in mice with OX40L showed that in alloresponses DC

deficient in OX40L induced less effector cytokine production and weaker CTL
generation (150, 405).

Work from GVHD murine models have suggested that 0X 40

deficiency has a much greater impact on CD4+ T cells compared to CD8+ T cells (406,
407). The Sayegh group further demonstrated a critical role for OX40-OX40L signaling
in both CD28/CD154 independent rejection and memory T cell mediated rejection in
conjunction with CD28/CD154 blockade (306, 366). This data supports the observation
that blockade o f OX40L has significant impact on memory T cell mediated allograft
rejection. OX40L blockade produced the greatest reduction in intragraft IFN-y, IL-2, IL4, FasL and perforin mRNA expression in comparison to the other memory costimulators
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suggesting that blockade o f OX40L in my model likely has strong effects on both CD4+
and CD8+ T cells.
In sum, I found that blockade o f any o f these three memory T cell specific
costimulators can reduce allograft injury significantly, but not completely. Interestingly,
all three o f these costimulatory molecules can be found on the surface o f HDMEC and
blockade o f any o f them can partially inhibit EC-mediated memory T cell activation for
both CD4+ and CD8+ T cells. From my studies, it is not clear if the effects that I have
observed here are redundant and testing blockade in different combinations will be
important to understand if they have overlapping function. It may also be useful to know
if they have additive function with LFA-3, which is the original costimulatory molecule
described on EC. More detailed data about the numbers and phenotype of CD4+ and
CD8+ T cells infiltrating the graft might also shed some light as to whether these
costimulatory molecules work by similar or distinct mechanisms.
Another interesting issue to pursue is one raised in the discussion o f 4-1BBL, the
idea that reverse signaling o f the costimulatory molecule to their respective ligand may
be occurring in EC.

While it is not clear if ICOSL has signaling function, there is

evidence to suggest that ligation and signaling through B7-molecules may have important
regulatory function in DC (408, 409) and B cells (410). Evidence for reverse signaling in
the TNFR family is much stronger with evidence supporting bi-directional signaling for
CD40/CD154 (411) and 4-1BB/4-1BBL (172, 173).

Recent evidence using EC have

shown that OX40L ligation can induce the production CXCR5 (412) and RANTES (413)
suggesting that OX40L may also have signaling capabilities.

As all my antibodies

involve blockade o f these ligands, it is possible that the effects that I have observed may

135

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

be mediated by positive signaling in EC or other cells expressing the appropriate ligand
in addition to blockade o f the signal delivered to T cells. This issue requires further study
to identify whether reverse signaling is occurring in EC and, if it is, what are the
functional consequences of such signaling on the EC capacity to activate memory T cells.

The response o f memory T cell subsets to EC and their role in allograft rejection
As described in the Introduction and Chapter 6, human and mouse memory T cell
can be broadly divided into two groups based on effector function and homing capacity
(46, 51, 54). Tcm home to lymph nodes and have limited effector function, but have a
large proliferative capacity and become effector cells upon restimulation. TEm on the
other hand can home to peripheral tissues, rapidly produce IFN-y upon antigenic
stimulation, but have limited proliferative potential.

These distinctions were first

described by Sallusto et al using polyclonal activators and little is known about the
response o f these different subsets to the endothelium.

In considering how the two

subsets would respond, there are two likely possibilities to consider. The first is given
that Tem would typically see EC in the periphery I expected Tem to respond as they would
to polyclonal stimulation and since Tcm likely depend upon DC mediated activation in
the lymph nodes that, like naive T cells, they would not respond to allogeneic EC. The
second possibility is that both subsets would respond similarly as they do to polyclonal
activators with Tem favoring effector cytokines and Tcm favoring IL-2. It is the second
hypothesis that proved to be true, that in response to EC

T em

produced more IFN-y and

less IL-2, whereas TCm produced more IL-2 and less IFN-y.

Their corresponding

proliferative capacity is also consistent with the original observations that like the
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response to polyclonal activators in response to EC,
capacity than
with
IL-2.

T Cm

T Em -

T Cm

possess greater proliferative

Co-culture o f the different subsets with Mo showed a different pattern

producing equivalent amounts o f IFN-y as

T Em

though

T Em

still produce less

One explanation for this difference may be differences in the costimulatory

capacity o f EC compared to Mo.
In examining the two subsets for a variety o f costimulatory and adhesion
molecules, I found that TEm express less CD27, CD28, CD152 (CTLA-4), 4-1BB, ICOS,
LFA-1 and PD-1 when compared to Tcm- I decided to examine the role that CD27 and
CD28 played in this difference in activation because o f the corresponding difference in
expression o f the ligand on EC versus Mo.

For IFN-y, about 50% o f T cm and T Em

production depended on signals from CD27 in co-cultures with EC, whereas co-cultures
with Mo did not depend on CD27 signaling at all. For IL-2, about 50% o f Tcm IL-2
production depended on CD27 costimulation for both EC and Mo, but TEm IL-2
production seems to be independent o f CD27 signals. Studies from the Lipsky group
showed that CCR7-CD27+ T cells produce more IFN-y compared to the CCR7+CD27+
or CCR7-CD27- and my TEM population does have a small percentage o f CD27+ cells
(Figure 6.3A) and this may explain why both Tcm and TEM IFN-y production may depend
on CD27 signaling (131). The fact that IFN-y production was not affected in co-cultures
with Mo could be because CD28 signals in Mo may mask any effect o f CD27 signals on
IFN-y production. IL-2 production is consistent with observations from the Lipsky group
that T cm, which express CD27 highly, produce a greater amount of IL-2 than T em, and it
appears that CD27 signaling may mediate part o f the difference in IL-2 production
between T cm and TEm in response to EC or Mo.
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Due to the differences in B7 expression on the surface o f EC compared Mo and
the relative importance o f B7 signaling for T cell activation, a likely explanation for the
different responses o f the T cell subsets may lie in the ability of the two different APC to
deliver CD28 mediated signals. The slight reduction in CD28 expression on Tem also
suggests that Tem may not be as sensitive to B7 mediated signals. The observations in
Chapter 6 are consistent with work in Rhesus macaques where Pitcher et al found that
T Cm

express CD28, whereas TEM do not (414) and experiments from Fontenot et al who

studied beryllium specific T cells in humans and found a gradual decrease in CD28
expression and dependence when memory T cells convert from

T

cm

to

T Em

(415). Given

my observations and the data from these other groups I was surprised to find that CTLA4Ig blockade o f B7-signaling affected both

T

cm

and

T Em

cytokine production co-cultures

with Mo, however consistent with data from other groups I found that the percent
reduction in Tcm cytokine production was several fold higher than that o f Tem suggesting
that

T

cm

have a greater reliance on CD28 signaling. It was also interesting to find that

CTLA-4Ig also had significant effects on IL-2 production from both subsets in cultures
with EC though again there was a much greater effect on

T

cm

compared to

T Em -

It is not

clear where the B7 signals are coming from in co-cultures with EC and the reduction in
IL-2 may be related to the trans-costimulation effect observed in co-cultures with EC
from Denton et al (190).

When the different subsets were co-cultured with EC

expressing B7.2, the difference in IFN-y production was abolished while the difference in
IL-2 production was retained.
enhanced the

T

cm

Thus, addition o f B7.2 signals on the surface o f EC

production o f IFN-y suggesting that

T Cm

are more sensitive to B7-
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signals.

Therefore CD28 signaling may underlie the difference between EC and Mo

activation o f the Tcm subset.
In conclusion, I find that Tem produce more IFN-y versus Tcm in response to
allogeneic EC but not with Mo. I believe that this difference in activation may be due to
the ability of Mo to deliver B7 signals to the Tcm whereas EC cannot. It appears that Mo
activate both subsets to produce IFN-y via CD28 without needing CD27 signals and the
increased sensitivity o f Tcm to CD28 signaling allows them to produce equivalent or
more IFN-y compared to Tem in response to Mo. Since EC do not express B7 molecules,
it appears that EC rely on CD27 to enhance Tem IFN-y production in combination with
some other unknown signals.

It seems that CD27 works in conjunction with other

signals to augment cytokine production for IL-2 as well. From my data it appears that
both EC and Mo stimulate

T Cm

and

T Em

to produce IL-2 at a certain level likely through

CD28 and that additional IL-2 production by Tcm relies on CD27 signals.
Using my model o f allograft rejection I next sought to identify which o f the
memory T cell subsets could mediate allograft rejection. Interestingly, only Tem and not
Tcm could mediate allograft rejection in my model. This does not agree with Adams et al
who studied heterologous memory in mice and showed that CD8+ Tcm were significantly
more effective at mediating allogeneic skin graft rejection than CD8+

T Em

(275). One

reason for the differences in my results is again that my model lacks functional secondary
lymphoid organs as the adoptively transferred human T cells do not effectively circulate
through the murine lymph nodes or spleen. While it has been shown that both CD4+ and
CD8+ memory T cells of both subsets can survive and function without secondary
lymphoid organs (416), one hypothesis is that once Tcm in my model are deprived o f key
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signals like B7 that they would ordinarily receive in secondary lymphoid organs they
cannot attain full effector function. Another related possibility is that the Tcm may be
able to mediate rejection, but can not appropriately home to a peripheral organ without
first encountering secondary lymphoid organs. Studies from my lab have shown that TEm
can migrate in response to inflammatory chemokines presented on EC whereas Tcm
cannot. This may indicate that even though Tcm can produce IL-2 and some IFN-y in
response to EC, they might never get the chance to mediate rejection in my model
because o f their failure to transmigrate across the endothelium (417). Thus, in my model
Tem, but not T cm, can mediate allograft rejection and I speculate that this may be due to

deficiencies in costimulation and/or homing.

Final Conclusions
In this thesis I have provided evidence that expands my current understanding of
both the mechanisms and details o f EC-mediated activation of memory T cells. I find
that EC derived from human skin (HDMEC) can activate memory T cells and that EC use
newly described memory T cell specific costimulators to do so. I also describe a model
to study memory T cell mediated allograft rejection in vivo using human T cells. Using
this model I find that memory T cell specific allograft rejection can be mediated in part
by both B7 mediated costimulation and the memory T cell specific costimulators. I also
characterize the response o f difference memory T cell subsets to the endothelium and
find that TCm respond differently than TEM to EC compared to Mo. I provide evidence to
suggest that this difference may be due to differences in CD28 and CD27 signaling
provided by EC versus Mo. Finally I show that in my model of peripheral rejection that
Tem but not Tcm can mediate an allograft response.

140

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Recognizing that EC mediated activation o f memory T cells plays a critical role in
allograft rejection, I propose that EC use the newly described memory specific
costimulatory molecules, ICOSL, 4-1BBL, and OX40L to activate memory T cells.
These pathways in addition to the classic B7 pathway are important in memory T cell
mediated rejection. The mechanism by which the costimulatory molecules interact with
each other is unclear. In particular, the effects o f reverse signaling on the endothelium or
the signaling pathways they stimulate in T cells and EC remain poorly understood. These
are concepts that will need to be explored further.
In addition to the unique costimulatory properties o f EC, I also propose that the
subset of memory T cells known as effector memory T cells through their capacity to
express effector molecules in response to EC can directly mediate peripheral rejection
whereas central memory T cells in response to EC do not fully differentiate and therefore
lack the ability to mediate peripheral rejection.

It is not clear whether it is lack of

costimulation, difficulties in homing or some other mechanism like differences in T cell
repertoire that prevents the Tcm from mediating rejection in vivo and these will be an
important questions to address in future studies.
The identification o f important costimulatory pathways and the introduction of a
new model o f allogeneic memory T cell responses may have important implications for
studying and ameliorating allograft rejection.

141

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

REFERENCES
1.

2005. The Organ Procurement and Transplantation Network (www.optn.ors).

2.

Nobelstiftelsen. 1964. Physiology or medicine. Elsevier Publishing Company on
behalf o f the Nobel Foundation, Amsterdam, NY.

3.

Billingham, R. E., and P. B. Medawar. 1951. Technique o f free skin grafting in
mammals. J E x p Biol:385.

4.

Billingham, R. E., L. Brent, and P. B. Medawar. 1956. Quantitative studies on
tissue transplantation immunity. III. Actively acquired tolerance. Philos Trans R
Soc Lond (Biol) 239:357.

5.

Burnet, F. M., J. D. Stone, and M. Edney. 1950. The failure o f antibody
production in the chick embryo. A u stJ E x p Biol M ed Sci 28:291.

6.

Billingham, R. E., L. Brent, and P. B. Medawar. 1953. Actively acquired
tolerance o f foreign cells. Nature 172:603.

7.

Dausset, J. 1984. The birth o f MAC. Vox Sang 46:235.

8.

Caine, R. Y., D. J. White, S. Thiru, D. B. Evans, P. McMaster, D. C. Dunn, G. N.
Craddock, B. D. Pentlow, and K. Rolles. 1978. Cyclosporin A in patients
receiving renal allografts from cadaver donors. Lancet 2:1323.

9.

Merion, R. M., D. J. White, S. Thiru, D. B. Evans, and R. Y. Caine. 1984.
Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J
M ed 310:148.

10.

Kaufman, D. B., R. Shapiro, M. R. Lucey, W. S. Cherikh, T. B. R, and D. B.
Dyke. 2004. Immunosuppression: practice and trends. Am J Transplant 4 Suppl
9:38.

11.

Waldmann, H. 2001. Therapeutic approaches for transplantation. Curr Opin
Immunol 13:606.

12.

Patel, R., and P. I. Terasaki. 1969. Significance o f the positive crossmatch test in
kidney transplantation. N E ngl J M ed 280:735.

13.

Cemy, A., H. Ramseier, H. Bazin, and R. M. Zinkemagel. 1988. Unimpaired
first-set and second-set skin graft rejection in agammaglobulinemic mice.
Transplantation 45:1111.

142

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

14.

Hall, B. M., S. Dorsch, and B. Roser. 1978. The cellular basis o f allograft
rejection in vivo. II. The nature o f memory cells mediating second set heart graft
rejection. J Exp M ed 148:890.

15.

Burkett, P. R., R. Koka, M. Chien, D. L. Boone, and A. Ma. 2004. Generation,
maintenance, and function o f memory T cells. Adv Immunol 83:191.

16.

Sprent, J., and C. D. Surh. 2002. T cell memory. Annu Rev Immunol 20:551.

17.

Janeway, C., P. Travers, M. Walport, and J. Capra. 1999. Immunobiology.
Elsevier Sciecne Ltd/Garland Publishing, New York, NY.

18.

Picker, L. J., and E. C. Butcher. 1992. Physiological and molecular mechanisms
o f lymphocyte homing. Annu Rev Immunol 10:561.

19.

Gowans, J. L., and E. J. Knight. 1964. The Route o f Re-Circulation of
Lymphocytes in the Rat. Proc R Soc Lond B Biol Sci 159:257.

20.

Steinman, R. M. 1991. The dendritic cell system and its role in immunogenicity.
Annu Rev Immunol 9:271.

21.

Takeda, S., H. R. Rodewald, H. Arakawa, H. Bluethmann, and T. Shimizu. 1996.
MHC class II molecules are not required for survival o f newly generated CD4+ T
cells, but affect their long-term life span. Immunity 5:217.

22.

Rooke, R., C. Waltzinger, C. Benoist, and D. Mathis. 1997. Targeted
complementation o f MHC class II deficiency by intrathymic delivery of
recombinant adenoviruses. Immunity 7:123.

23.

Tanchot, C., F. A. Lemonnier, B. Peramau, A. A. Freitas, and B. Rocha. 1997.
Differential requirements for survival and proliferation o f CD8 naive or memory
T cells. Science 276:2057.

24.

Ernst, B., D. S. Lee, J. M. Chang, J. Sprent, and C. D. Surh. 1999. The peptide
ligands mediating positive selection in the thymus control T cell survival and
homeostatic proliferation in the periphery. Immunity 11:173.

25.

Tan, J. T., E. Dudl, E. LeRoy, R. Murray, J. Sprent, K. I. Weinberg, and C. D.
Surh. 2001. IL-7 is critical for homeostatic proliferation and survival of naive T
cells. Proc Natl Acad Sci U S A 98:8732.

26.

Schluns, K. S., W. C. Kieper, S. C. Jameson, and L. Lefrancois. 2000. Interleukin7 mediates the homeostasis o f naive and memory CD8 T cells in vivo. Nat
Immunol 1:426.

143

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

27.

Shakhar, G., R. L. Lindquist, D. Skokos, D. Dudziak, J. H. Huang, M. C.
Nussenzweig, and M. L. Dustin. 2005. Stable T cell-dendritic cell interactions
precede the development o f both tolerance and immunity in vivo. Nat Immunol
6:707.

28.

Stoll, S., J. Delon, T. M. Brotz, and R. N. Germain. 2002. Dynamic imaging o f T
cell-dendritic cell interactions in lymph nodes. Science 296:1873.

29.

Miller, M. J., O. Safrina, I. Parker, and M. D. Cahalan. 2004. Imaging the single
cell dynamics o f CD4+ T cell activation by dendritic cells in lymph nodes. J Exp
M ed 200:847.

30.

Mempel, T. R., S. E. Henrickson, and U. H. Von Andrian. 2004. T-cell priming
by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427:154.

31.

Monks, C. R., B. A. Freiberg, H. Kupfer, N. Sciaky, and A. Kupfer. 1998. Threedimensional segregation o f supramolecular activation clusters in T cells. Nature
395:82.

32.

Grakoui, A., S. K. Bromley, C. Sumen, M. M. Davis, A. S. Shaw, P. M. Allen,
and M. L. Dustin. 1999. The immunological synapse: a molecular machine
controlling T cell activation. Science 285:221.

33.

Bromley, S. K., W. R. Burack, K. G. Johnson, K. Somersalo, T. N. Sims, C.
Sumen, M. M. Davis, A. S. Shaw, P. M. Allen, and M. L. Dustin. 2001. The
immunological synapse. Annu Rev Immunol 19:375.

34.

Lanzavecchia, A., and F. Sallusto. 2000. Dynamics o f T lymphocyte responses:
intermediates, effectors, and memory cells. Science 290:92.

35.

Akbar, A. N., L. Terry, A. Timms, P. C. Beverley, and G. Janossy. 1988. Loss o f
CD45R and gain o f UCHL1 reactivity is a feature o f primed T cells. J Immunol
140:2171.

36.

Byrne, J. A., J. L. Butler, and M. D. Cooper. 1988. Differential activation
requirements for virgin and memory T cells. J Immunol 141:3249.

37.

Bunce, C., and E. B. Bell. 1997. CD45RC isoforms define two types o f CD4
memory T cells, one o f which depends on persisting antigen. J Exp M ed 185:767.

38.

Birkeland, M. L., P. Johnson, I. S. Trowbridge, and E. Pure. 1989. Changes in
CD45 isoform expression accompany antigen-induced murine T-cell activation.
Proc Natl Acad Sci U S A 86:6734.

39.

Budd, R. C., J. C. Cerottini, C. Horvath, C. Bron, T. Pedrazzini, R. C. Howe, and
H. R. MacDonald. 1987. Distinction o f virgin and memory T lymphocytes. Stable

144

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

acquisition o f the Pgp-1 glycoprotein concomitant with antigenic stimulation. J
Immunol 138:3120.
40.

Mackay, C. R., D. P. Andrew, M. Briskin, D. J. Ringler, and E. C. Butcher. 1996.
Phenotype, and migration properties o f three major subsets o f tissue homing T
cells in sheep. Eur J Immunol 26:2433.

41.

Dutton, R. W., L. M. Bradley, and S. L. Swain. 1998. T cell memory. Annu Rev
Immunol 16:201.

42.

Hamann, D., P. A. Baars, M. H. Rep, B. Hooibrink, S. R. Kerkhof-Garde, M. R.
Klein, and R. A. van Lier. 1997. Phenotypic and functional separation o f memory
and effector human CD8+ T cells. J Exp M ed 186:1407.

43.

Cho, B. K., V. P. Rao, Q. Ge, H. N. Eisen, and J. Chen. 2000. Homeostasisstimulated proliferation drives naive T cells to differentiate directly into memory
T cells. J E x p M ed 192:549.

44.

Goldrath, A. W., L. Y. Bogatzki, and M. J. Bevan. 2000. Naive T cells transiently
acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp
Med 192:557.

45.

Yamada, H., G. Matsuzaki, Q. Chen, Y. Iwamoto, and K. Nomoto. 2001.
Reevaluation of the origin o f CD44(high) "memory phenotype" CD8 T cells:
comparison between memory CD8 T cells and thymus-independent CD8 T cells.
Eur J Immunol 31:1917.

46.

Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two
subsets o f memory T lymphocytes with distinct homing potentials and effector
functions. Nature 401:708.

47.

Bradley, L. M., D. D. Duncan, S. Tonkonogy, and S. L. Swain. 1991.
Characterization o f antigen-specific CD4+ effector T cells in vivo: immunization
results in a transient population o f M EL-14-, CD45RB- helper cells that secretes
interleukin 2 (IL-2), IL-3, IL-4, and interferon gamma. J Exp M ed 174:547.

48.

Murali-Krishna, K., L. L. Lau, S. Sambhara, F. Lemonnier, J. Altman, and R.
Ahmed. 1999. Persistence o f memory CD8 T cells in MHC class I-deficient mice.
Science 286:1377.

49.

Borrow, P., D. F. Tough, D. Eto, A. Tishon, I. S. Grewal, J. Sprent, R. A. Flavell,
and M. B. Oldstone. 1998. CD40 ligand-mediated interactions are involved in the
generation o f memory CD8(+) cytotoxic T lymphocytes (CTL) but are not
required for the maintenance o f CTL memory following virus infection. J Virol
72:7440.

145

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

50.

Khan, I. A., M. Moretto, X. Q. Wei, M. Williams, J. D. Schwartzman, and F. Y.
Liew. 2002. Treatment with soluble interleukin-15 Ralpha exacerbates
intracellular parasitic infection by blocking the development o f memory CD8+ T
cell response. J Exp M ed 195:1463.

51.

Reinhardt, R. L., A. Khoruts, R. Merica, T. Zell, and M. K. Jenkins. 2001.
Visualizing the generation o f memory CD4 T cells in the whole body. Nature
410:101.

52.

Hengel, R. L., V. Thaker, M. V. Pavlick, J. A. Metcalf, G. Dennis, Jr., J. Yang, R.
A. Lempicki, I. Sereti, and H. C. Lane. 2003. Cutting edge: L-selectin (CD62L)
expression distinguishes small resting memory CD4+ T cells that preferentially
respond to recall antigen. J Immunol 170:28.

53.

Hogan, R. J., W. Zhong, E. J. Usherwood, T. Cookenham, A. D. Roberts, and D.
L. Woodland. 2001. Protection from respiratory virus infections can be mediated
by antigen-specific CD4(+) T cells that persist in the lungs. J Exp M ed 193:981.

54.

Masopust, D., V. Vezys, A. L. Marzo, and L. Lefrancois. 2001. Preferential
localization o f effector memory cells in nonlymphoid tissue. Science 291:2413.

55.

Pihlgren, M., P. M. Dubois, M. Tomkowiak, T. Sjogren, and J. Marvel. 1996.
Resting memory CD8+ T cells are hyperreactive to antigenic challenge in vitro. J
Exp M ed 184:2141.

56.

Rogers, P. R., C. Dubey, and S. L. Swain. 2000. Qualitative changes accompany
memory T cell generation: faster, more effective responses at lower doses of
antigen. J Immunol 164:2338.

57.

Cho, B. K., C. Wang, S. Sugawa, H. N. Eisen, and J. Chen. 1999. Functional
differences between memory and naive CD8 T cells. Proc Natl Acad Sci U S A
96:2976.

58.

Croft, M., L. M. Bradley, and S. L. Swain. 1994. Naive versus memory CD4 T
cell response to antigen. Memory cells are less dependent on accessory cell
costimulation and can respond to many antigen-presenting cell types including
resting B cells. J Immunol 152:2675.

59.

de Jong, R., M. Brouwer, F. Miedema, and R. A. van Lier. 1991. Human CD8+ T
lymphocytes can be divided into CD45RA+ and CD45RO+ cells with different
requirements for activation and differentiation. J Immunol 146:2088.

60.

London, C. A., M. P. Lodge, and A. K. Abbas. 2000. Functional responses and
costimulator dependence o f memory CD4+ T cells. J Immunol 164:265.

146

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

61.

Chalasani, G., Z. Dai, B. T. Konieczny, F. K. Baddoura, and F. G. Lakkis. 2002.
Recall and propagation o f allospecific memory T cells independent o f secondary
lymphoid organs. Proc Natl Acad Sci U S A 99:6175.

62.

Veiga-Femandes, H., U. Walter, C. Bourgeois, A. McLean, and B. Rocha. 2000.
Response o f naive and memory CD8+ T cells to antigen stimulation in vivo. Nat
Immunol 1:47.

63.

Iezzi, G., D. Scheidegger, and A. Lanzavecchia. 2001. Migration and function o f
antigen-primed nonpolarized T lymphocytes in vivo. J Exp M ed 193:987.

64.

Zimmermann, C., A. Prevost-Blondel, C. Blaser, and H. Pircher. 1999. Kinetics
o f the response o f naive and memory CD8 T cells to antigen: similarities and
differences. Eur J Immunol 29:284.

65.

Garcia, S., J. DiSanto, and B. Stockinger. 1999. Following the development o f a
CD4 T cell response in vivo: from activation to memory formation. Immunity
11:163.

66.

Bachmann, M. F., M. Bamer, A. Viola, and M. Kopf. 1999. Distinct kinetics of
cytokine production and cytolysis in effector and memory T cells after viral
infection. Eur J Immunol 29:291.

67.

Roberts, A. D., and D. L. Woodland. 2004. Cutting edge: effector memory CD8+
T cells play a prominent role in recall responses to secondary viral infection in the
lung. J Immunol 172:6533.

68.

Ely, K. H., A. D. Roberts, and D. L. Woodland. 2003. Cutting edge: effector
memory CD8+ T cells in the lung airways retain the potential to mediate recall
responses. J Immunol 171:3338.

69.

Chambers, C. A. 2001. The expanding world o f co-stimulation: the two-signal
model revisited. Trends Immunol 22:217.

70.

Janeway, C. A., Jr., and K. Bottomly. 1994. Signals and signs for lymphocyte
responses. Cell 76:275.

71.

Jenkins, M. K., D. M. Pardoll, J. Mizuguchi, H. Quill, and R. H. Schwartz. 1987.
T-cell unresponsiveness in vivo and in vitro: fine specificity o f induction and
molecular characterization o f the unresponsive state. Immunol Rev 95:113.

72.

Azuma, M., D. Ito, H. Yagita, K. Okumura, J. H. Phillips, L. L. Lanier, and C.
Somoza. 1993. B70 antigen is a second ligand for CTLA-4 and CD28. Nature
366:76.

147

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

73.

Gmunder, H., and W. Lesslauer. 1984. A 45-kDa human T-cell membrane
glycoprotein functions in the regulation o f cell proliferative responses. Eur J
Biochem 142:153.

74.

Hara, T., S. M. Fu, and J. A. Hansen. 1985. Human T cell activation. II. A new
activation pathway used by a major T cell population via a disulfide-bonded
dimer o f a 44 kilodalton polypeptide (9.3 antigen). J Exp M ed 161:1513.

75.

Freeman, G. J., G. S. Gray, C. D. Gimmi, D. B. Lombard, L. J. Zhou, M. White, J.
D. Fingeroth, J. G. Gribben, and L. M. Nadler. 1991. Structure, expression, and T
cell costimulatory activity o f the murine homologue o f the human B lymphocyte
activation antigen B7. J Exp M ed 174:625.

76.

Freeman, G. J., A. S. Freedman, J. M. Segil, G. Lee, J. F. Whitman, and L. M.
Nadler. 1989. B7, a new member o f the Ig superfamily with unique expression on
activated and neoplastic B cells. J Immunol 143:2714.

77.

Freeman, G. J., J. G. Gribben, V. A. Boussiotis, J. W. Ng, V. A. Restivo, Jr., L. A.
Lombard, G. S. Gray, and L. M. Nadler. 1993. Cloning o f B7-2: a CTLA-4
counter-receptor that costimulates human T cell proliferation. Science 262:909.

78.

Sharpe, A. H., and G. J. Freeman. 2002. The B7-CD28 superfamily. Nat Rev
Immunol 2:116.

79.

van der Merwe, P. A., and S. J. Davis. 2003. Molecular interactions mediating T
cell antigen recognition. Annu Rev Immunol 21:659.

80.

Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system o f T
cell costimulation. Annu Rev Immunol 14:233.

81.

Ishida, Y., Y. Agata, K. Shibahara, and T. Honjo. 1992. Induced expression of
PD-1, a novel member o f the immunoglobulin gene superfamily, upon
programmed cell death. Embo J 11:3887.

82.

Yoshinaga, S. K., J. S. Whoriskey, S. D. Khare, U. Sarmiento, J. Guo, T. Horan,
G. Shih, M. Zhang, M. A. Coccia, T. Kohno, A. Tafuri-Bladt, D. Brankow, P.
Campbell, D. Chang, L. Chiu, T. Dai, G. Duncan, G. S. Elliott, A. Hui, S. M.
McCabe, S. Scully, A. Shahinian, C. L. Shaklee, G. Van, T. W. Mak, and G.
Senaldi. 1999. T-cell co-stimulation through B7RP-1 and ICOS. Nature 402:827.

83.

Coyle, A. J., S. Lehar, C. Lloyd, J. Tian, T. Delaney, S. Manning, T. Nguyen, T.
Burwell, H. Schneider, J. A. Gonzalo, M. Gosselin, L. R. Owen, C. E. Rudd, and
J. C. Gutierrez-Ramos. 2000. The CD28-related molecule ICOS is required for
effective T cell-dependent immune responses. Immunity 13:95.

148

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

84.

Wassink, L., P. L. Vieira, H. H. Smits, G. A. Kingsbury, A. J. Coyle, M. L.
Kapsenberg, and E. A. Wierenga. 2004. ICOS expression by activated human Th
cells is enhanced by IL-12 and IL-23: increased ICOS expression enhances the
effector function o f both T hl and Th2 cells. J Immunol 173:1779.

85.

Aicher, A., M. Hayden-Ledbetter, W. A. Brady, A. Pezzutto, G. Richter, D.
Magaletti, S. Buckwalter, J. A. Ledbetter, and E. A. Clark. 2000. Characterization
of human inducible costimulator ligand expression and function. J Immunol
164:4689.

86.

Khayyamian, S., A. Hutloff, K. Buchner, M. Grafe, V. Henn, R. A. Kroczek, and
H. W. Mages. 2002. ICOS-ligand, expressed on human endothelial cells,
costimulates T hl and Th2 cytokine secretion by memory CD4+ T cells. Proc Natl
Acad Sci U S A 99:6198.

87.

Sperling, A. I., and J. A. Bluestone. 2001. ICOS costimulation: It's not just for
TH2 cells anymore. Nat Immunol 2:573.

88.

Agata, Y., A. Kawasaki, H. Nishimura, Y. Ishida, T. Tsubata, H. Yagita, and T.
Honjo. 1996. Expression o f the PD-1 antigen on the surface o f stimulated mouse
T and B lymphocytes. Int Immunol 8:765.

89.

LaGier, A. J., and J. S. Pober. 2006. Immune accessory functions o f human
endothelial cells are modulated by overexpression of B7-H1 (PDL1). Hum
Immunol 67:568.

90.

Rodig, N., T. Ryan, J. A. Allen, H. Pang, N. Grabie, T. Chernova, E. A.
Greenfield, S. C. Liang, A. H. Sharpe, A. H. Lichtman, and G. J. Freeman. 2003.
Endothelial expression o f PD-L1 and PD-L2 down-regulates CD8+ T cell
activation and cytolysis. Eur J Immunol 33:3117.

91.

Okazaki, T., and T. Honjo. 2006. The PD-1-PD-L pathway in immunological
tolerance. Trends Immunol 27:195.

92.

Keir, M. E., S. C. Liang, I. Guleria, Y. E. Latchman, A. Qipo, L. A. Albacker, M.
Koulmanda, G. J. Freeman, M. H. Sayegh, and A. H. Sharpe. 2006. Tissue
expression o f PD-L1 mediates peripheral T cell tolerance. J Exp M ed 203:883.

93.

Ozkaynak, E., L. Wang, A. Goodearl, K. McDonald, S. Qin, T. O'Keefe, T.
Duong, T. Smith, J. C. Gutierrez-Ramos, J. B. Rottman, A. J. Coyle, and W. W.
Hancock. 2002. Programmed death-1 targeting can promote allograft survival. J
Immunol 169:6546.

94.

Gao, W ., G. Demirci, T. B. Strom, and X. C. Li. 2003. Stimulating PD-1-negative
signals concurrent with blocking CD 154 co-stimulation induces long-term islet
allograft survival. Transplantation 76:994.

149

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

95.

Sanchez-Madrid, F., A. M. Krensky, C. F. Ware, E. Robbins, J. L. Strominger, S.
J. Burakoff, and T. A. Springer. 1982. Three distinct antigens associated with
human T-lymphocyte-mediated cytolysis: LFA-1, LFA-2, and LFA-3. Proc Natl
Acad Sci U S A 79:7489.

96.

Bierer, B. E., A. Peterson, J. C. Gorga, S. H. Herrmann, and S. J. Burakoff. 1988.
Synergistic T cell activation via the physiological ligands for CD2 and the T cell
receptor. J Exp M ed 168:1145.

97.

Bierer, B. E., J. Barbosa, S. Herrmann, and S. J. Burakoff. 1988. Interaction of
CD2 with its ligand, LFA-3, in human T cell proliferation. J Immunol 140:3358.

98.

Hughes, C. C., C. O. Savage, and J. S. Pober. 1990. Endothelial cells augment T
cell interleukin 2 production by a contact-dependent mechanism involving
CD2/LFA-3 interaction. J Exp M ed 171:1453.

99.

Krensky, A. M., E. Robbins, T. A. Springer, and S. J. Burakoff. 1984. LFA-1,
LFA-2, and LFA-3 antigens are involved in CTL-target conjugation. J Immunol
132:2180.

100.

Smith, M. E., and J. A. Thomas. 1990. Cellular expression o f lymphocyte
function associated antigens and the intercellular adhesion molecule-1 in normal
tissue. J Clin Pathol 43:893.

101.

Grundy, J. E., and K. L. Downes. 1993. Up-regulation of LFA-3 and ICAM-1 on
the surface o f fibroblasts infected with cytomegalovirus. Immunology 78:405.

102.

Parra, E., A. G. Wingren, G. Hedlund, M. Bjorklund, H. O. Sjogren, T. Kalland,
D. Sansom, and M. Dohlsten. 1994. Costimulation o f human CD4+ T
lymphocytes with B7 and lymphocyte function-associated antigen-3 results in
distinct cell activation profdes. J Immunol 153:2479.

103.

Damle, N. K., K. Klussman, P. S. Linsley, and A. Aruffo. 1992. Differential
costimulatory effects o f adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1
on resting and antigen-primed CD4+ T lymphocytes. J Immunol 148:1985.

104.

Kato, K., M. Koyanagi, H. Okada, T. Takanashi, Y. W. Wong, A. F. Williams, K.
Okumura, and H. Yagita. 1992. CD48 is a counter-receptor for mouse CD2 and is
involved in T cell activation. J Exp M ed 176:1241.

105.

van der Merwe, P. A., D. C. McPherson, M. H. Brown, A. N. Barclay, J. G.
Cyster, A. F. Williams, and S. J. Davis. 1993. The NH2-terminal domain o f rat
CD2 binds rat CD48 with a low affinity and binding does not require
glycosylation o f CD2. Eur J Immunol 23:1373.

150

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

106.

Arulanandam, A. R., P. Moingeon, M. F. Concino, M. A. Recny, K. Kato, H.
Yagita, S. Koyasu, and E. L. Reinherz. 1993. A soluble multimeric recombinant
CD2 protein identifies CD48 as a low affinity ligand for human CD2: divergence
of CD2 ligands during the evolution o f humans and mice. J Exp M ed 177:1439.

107.

Chavin, K. D., L. Qin, J. Lin, J. Woodward, P. Baliga, K. Kato, H. Yagita, and J.
S. Bromberg. 1994. Anti-CD48 (murine CD2 ligand) mAbs suppress cell
mediated immunity in vivo. Int Immunol 6:701.

108.

Bai, Y., S. Fu, S. Honig, Y. Wang, L. Qin, D. Chen, and J. S. Bromberg. 2002.
CD2 is a dominant target for allogeneic responses. Am J Transplant 2:618.

109.

Sultan, P., J. S. Schechner, J. M. McNiff, P. S. Hochman, C. C. Hughes, M. I.
Lorber, P. W. Askenase, and J. S. Pober. 1997. Blockade o f CD2-LFA-3
interactions protects human skin allografts in immunodeficient mouse/human
chimeras. Nat Biotechnol 15:759.

110.

Locksley, R. M., N. Killeen, and M. J. Lenardo. 2001. The TNF and TNF receptor
superfamilies: integrating mammalian biology. Cell 104:487.

111.

Aggarwal, B. B. 2003. Signalling pathways o f the TNF superfamily: a doubleedged sword. Nat Rev Immunol 3:745.

112.

Arch, R. H., R. W. Gedrich, and C. B. Thompson. 1998. Tumor necrosis factor
receptor-associated factors (TRAFs)—a family o f adapter proteins that regulates
life and death. Genes Dev 12:2821.

113.

Akiba, H., H. Nakano, S. Nishinaka, M. Shindo, T. Kobata, M. Atsuta, C.
Morimoto, C. F. Ware, N. L. Malinin, D. Wallach, H. Yagita, and K. Okumura.
1998. CD27, a member of the tumor necrosis factor receptor superfamily,
activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase
via TRAF2, TRAF5, and NF-kappaB-inducing kinase. J Biol Chem 273:13353.

114.

Kawamata, S., T. Hori, A. Imura, A. Takaori-Kondo, and T. Uchiyama. 1998.
Activation o f 0X 40 signal transduction pathways leads to tumor necrosis factor
receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB
activation. J Biol Chem 273:5808.

115.

Arch, R. H., and C. B. Thompson. 1998. 4-1BB and 0x40 are members o f a
tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind
TNF receptor-associated factors and activate nuclear factor kappaB. M ol Cell Biol
18:558.

116.

Cannons, J. L., Y. Choi, and T. H. Watts. 2000. Role of TNF receptor-associated
factor 2 and p38 mitogen-activated protein kinase activation during 4-1BBdependent immune response. J Immunol 165:6193.

151

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

117.

Cannons, J. L., K. P. Hoeflich, J. R. Woodgett, and T. H. Watts. 1999. Role o f the
stress kinase pathway in signaling via the T cell costimulatory receptor 4 -IBB. J
Immunol 163:2990.

118.

Gravestein, L. A., D. Amsen, M. Boes, C. R. Calvo, A. M. Kruisbeek, and J.
Borst. 1998. The TNF receptor family member CD27 signals to Jun N-terminal
kinase via Traf-2. Eur J Immunol 28:2208.

119.

Clark, L. B., T. M. Foy, and R. J. Noelle. 1996. CD40 and its ligand. Adv
Immunol 63:43.

120.

Hollenbaugh, D., N. Mischel-Petty, C. P. Edwards, J. C. Simon, R. W. Denfeld, P.
A. Kiener, and A. Aruffo. 1995. Expression o f functional CD40 by vascular
endothelial cells. J Exp M ed 182:33.

121.

Mach, F., U. Schonbeck, G. K. Sukhova, T. Bourcier, J. Y. Bonnefoy, J. S. Pober,
and P. Libby. 1997. Functional CD40 ligand is expressed on human vascular
endothelial cells, smooth muscle cells, and macrophages: implications for CD40CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A 94:1931.

122.

Karmann, K., C. C. Flughes, J. Schechner, W. C. Fanslow, and J. S. Pober. 1995.
CD40 on human endothelial cells: inducibility by cytokines and functional
regulation o f adhesion molecule expression. Proc Natl Acad Sci U S A 92:4342.

123.

Vyth-Dreese, F. A., T. A. Dellemijn, D. Majoor, and D. de Jong. 1995.
Localization in situ o f the co-stimulatory molecules B7.1, B7.2, CD40 and their
ligands in normal human lymphoid tissue. Eur J Immunol 25:3023.

124.

Grewal, I. S., and R. A. Flavell. 1998. CD40 and CD154 in cell-mediated
immunity. Annu Rev Immunol 16:111.

125.

Monaco, C., E. Andreakos, S. Young, M. Feldmann, and E. Paleolog. 2002. T
cell-mediated signaling to vascular endothelium: induction o f cytokines,
chemokines, and tissue factor. JL eu ko c Biol 71:659.

126.

van Essen, D., H. Kikutani, and D. Gray. 1995. CD40 ligand-transduced co
stimulation o f T cells in the development o f helper function. Nature 378:620.

127.

Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, C. Van Kootcn, I. Durand,
and J. Banchereau. 1994. Activation o f human dendritic cells through CD40
cross-linking. J Exp M ed 180:1263.

128.

Borst, J., C. Sluyser, E. De Vries, FI. Klein, C. J. Melief, and R. A. Van Lier.
1989. Alternative molecular form o f human T cell-specific antigen CD27
expressed upon T cell activation. Eur J Immunol 19:357.

152

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

129.

de Jong, R., W. A. Loenen, M. Brouwer, L. van Emmerik, E. F. de Vries, J. Borst,
and R. A. van Lier. 1991. Regulation o f expression of CD27, a T cell-specific
member o f a novel family o f membrane receptors. J Immunol 146:2488.

130.

Hamann, D., S. Kostense, K. C. Wolthers, S. A. Otto, P. A. Baars, F. Miedema,
and R. A. van Lier. 1999. Evidence that human CD8+CD45RA+CD27- cells are
induced by antigen and evolve through extensive rounds o f division. Int Immunol
11:1027.

131.

Fritsch, R. D., X. Shen, G. P. Sims, K. S. Hathcock, R. J. Hodes, and P. E.
Lipsky. 2005. Stepwise differentiation o f CD4 memory T cells defined by
expression o f CCR7 and CD27. J Immunol 175:6489.

132.

Arens, R., K. Schepers, M. A. Nolte, M. F. van Oosterwijk, R. A. van Lier, T. N.
Schumacher, and M. H. van Oers. 2004. Tumor rejection induced by CD70mediated quantitative and qualitative effects on effector CD8+ T cell formation. J
Exp M ed 199:1595.

133.

Ochsenbein, A. F., S. R. Riddell, M. Brown, L. Corey, G. M. Baerlocher, P. M.
Lansdorp, and P. D. Greenberg. 2004. CD27 expression promotes long-term
survival o f functional effector-memory CD8+ cytotoxic T lymphocytes in HIVinfected patients. J Exp M ed 200:1407.

134.

Bowman, M. R., M. A. Crimmins, J. Yetz-Aldape, R. Kriz, K. Kelleher, and S.
Herrmann. 1994. The cloning o f CD70 and its identification as the ligand for
C m i . J Immunol 152:1756.

135.

Hintzen, R. Q., S. M. Lens, M. P. Beckmann, R. G. Goodwin, D. Lynch, and R.
A. van Lier. 1994. Characterization o f the human CD27 ligand, a novel member
o f the TNF gene family. J Immunol 152:1762.

136.

Tesselaar, K., Y. Xiao, R. Arens, G. M. van Schijndel, D. H. Schuurhuis, R. E.
Mebius, J. Borst, and R. A. van Lier. 2003. Expression of the murine CD27 ligand
CD70 in vitro and in vivo. J Immunol 170:33.

137.

Paterson, D. J., W. A. Jefferies, J. R. Green, M. R. Brandon, P. Corthesy, M.
Puklavec, and A. F. Williams. 1987. Antigens o f activated rat T lymphocytes
including a molecule o f 50,000 Mr detected only on CD4 positive T blasts. Mol
Immunol 24:1281.

138.

Sugamura, K., N. Ishii, and A. D. Weinberg. 2004. Therapeutic targeting o f the
effector T-cell co-stimulatory molecule 0X 40. Nat Rev Immunol 4:420.

139.

Taraban, V. Y., T. F. Rowley, L. O'Brien, H. T. Chan, L. E. Haswell, M. H.
Green, A. L. Tutt, M. J. Glennie, and A. Al-Shamkhani. 2002. Expression and
costimulatory effects o f the TNF receptor superfamily members CD 134 (0X 40)

153

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

and CD 137 (4-IBB), and their role in the generation of anti-tumor immune
responses. Eur J Immunol 32:3617.
140.

Rogers, P. R., J. Song, I. Gramaglia, N. Killeen, and M. Croft. 2001. 0X 40
promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of
CD4 T cells. Immunity 15:445.

141.

Gramaglia, I., A. D. Weinberg, M. Lemon, and M. Croft. 1998. Ox-40 ligand: a
potent costimulatory molecule for sustaining primary CD4 T cell responses. J
Immunol 161:6510.

142.

Stuber, E., A. Buschenfeld, J. Luttges, A. Von Freier, T. Arendt, and U. R.
Folsch. 2000. The expression o f 0X 40 in immunologically mediated diseases of
the gastrointestinal tract (celiac disease, Crohn's disease, ulcerative colitis). Eur J
Clin Invest 30:594.

143.

Giacomelli, R., A. Passacantando, R. Perricone, I. Parzanese, M. Rascente, G.
Minisola, and G. Tonietti. 2001. T lymphocytes in the synovial fluid o f patients
with active rheumatoid arthritis display CD 134-0X40 surface antigen. Clin Exp
Rheumatol 19:317.

144.

Song, J., S. Salek-Ardakani, P. R. Rogers, M. Cheng, L. Van Parijs, and M. Croft.
2004. The costimulation-regulated duration o f PKB activation controls T cell
longevity. Nat Immunol 5:150.

145.

Gramaglia, I., A. Jember, S. D. Pippig, A. D. Weinberg, N. Killeen, and M. Croft.
2000. The 0X 40 costimulatory receptor determines the development o f CD4
memory by regulating primary clonal expansion. J Immunol 165:3043.

146.

Prell, R. A., D. E. Evans, C. Thalhofer, T. Shi, C. Funatake, and A. D. Weinberg.
2003. OX40-mediated memory T cell generation is TNF receptor-associated
factor 2 dependent. J Immunol 171:5997.

\\1 .

Dawicki, W., E. M. Bertram, A. H. Sharpe, and T. FI. Watts. 2004. 4 -IBB and
0X 40 act independently to facilitate robust CD8 and CD4 recall responses. J
Immunol 173:5944.

148.

Akiba, H., H. Oshima, K. Takeda, M. Atsuta, H. Nakano, A. Nakajima, C.
Nohara, H. Yagita, and K. Okumura. 1999. CD28-independent costimulation o f T
cells by 0X 40 ligand and CD70 on activated B cells. J Immunol 162:7058.

149.

Ohshima, Y., L. P. Yang, T. Uchiyama, Y. Tanaka, P. Baum, M. Sergerie, P.
Hermann, and G. Delespesse. 1998. 0X 40 costimulation enhances interleukin-4
(IL-4) expression at priming and promotes the differentiation o f naive human
CD4(+) T cells into high IL-4-producing effectors. Blood 92:3338.

154

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

150.

Chen, A. I., A. J. McAdam, J. E. Buhlmann, S. Scott, M. L. Lupher, Jr., E. A.
Greenfield, P. R. Baum, W. C. Fanslow, D. M. Calderhead, G. J. Freeman, and A.
H. Sharpe. 1999. Ox40-ligand has a critical costimulatory role in dendritic cell:T
cell interactions. Immunity 11:689.

151.

Ito, T., R. Amakawa, M. Inaba, T. Hori, M. Ota, K. Nakamura, M. Takebayashi,
M. Miyaji, T. Yoshimura, K. Inaba, and S. Fukuhara. 2004. Plasmacytoid
dendritic cells regulate Th cell responses through 0X 40 ligand and type I IFNs. J
Immunol 172:4253.

152.

Imura, A., T. Flori, K. Imada, T. Ishikawa, Y. Tanaka, M. Maeda, S. Imamura,
and T. Uchiyama. 1996. The human OX40/gp34 system directly mediates
adhesion o f activated T cells to vascular endothelial cells. J Exp M ed 183:2185.

153.

Kunitomi, A., T. Hori, A. Imura, and T. Uchiyama. 2000. Vascular endothelial
cells provide T cells with costimulatory signals via the OX40/gp34 system. J
Leukoc Biol 68:111.

154.

Fillatreau, S., and D. Gray. 2003. T cell accumulation in B cell follicles is
regulated by dendritic cells and is independent o f B cell activation. J Exp M ed
197:195.

155.

Kwon, B. S., and S. M. Weissman. 1989. cDNA sequences o f two inducible Tcell genes. Proc Natl Acad Sci U S A 86:1963.

156.

Wilcox, R. A., A. I. Chapoval, K. S. Gorski, M. Otsuji, T. Shin, D. B. Flies, K.
Tamada, R. S. Mittler, H. Tsuchiya, D. M. Pardoll, and L. Chen. 2002. Cutting
edge: Expression o f functional CD 137 receptor by dendritic cells. J Immunol
168:4262.

157.

Kienzle, G., and J. von Kempis. 2000. CD137 (ILA/4-1BB), expressed by
primary human monocytes, induces monocyte activation and apoptosis o f B
lymphocytes. Int Immunol 12:73.

158.

Pauly, S., K. Broil, M. Wittmann, G. Giegerich, and H. Schwarz. 2002. CD137 is
expressed by follicular dendritic cells and costimulates B lymphocyte activation
in germinal centers. J Leukoc Biol 72:35.

159.

Wilcox, R. A., K. Tamada, S. E. Strome, and L. Chen. 2002. Signaling through
NK cell-associated CD 137 promotes both helper function for CD8+ cytolytic T
cells and responsiveness to IL-2 but not cytolytic activity. J Immunol 169:4230.

160.

Wen, T., J. Bukczynski, and T. H. Watts. 2002. 4 -IBB ligand-mediated
costimulation o f human T cells induces CD4 and CD8 T cell expansion, cytokine
production, and the development o f cytolytic effector function. J Immunol
168:4897.

155

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

161.

Bukczynski, J., T. Wen, and T. H. Watts. 2003. Costimulation o f human CD28- T
cells by 4-1BB ligand. Eur J Immunol 33:446.

162.

Bertram, E. M., W. Dawicki, B. Sedgmen, J. L. Bramson, D. H. Lynch, and T. H.
Watts. 2004. A switch in costimulation from CD28 to 4 -IBB during primary
versus secondary CD8 T cell response to influenza in vivo. J Immunol 172:981.

163.

Hurtado, J. C., Y. J. Kim, and B. S. Kwon. 1997. Signals through 4-1BB are
costimulatory to previously activated splenic T cells and inhibit activationinduced cell death. J Immunol 158:2600.

164.

Shuford, W. W., K. Klussman, D. D. Tritchler, D. T. Loo, J. Chalupny, A. W.
Siadak, T. J. Brown, J. Emswiler, H. Raecho, C. P. Larsen, T. C. Pearson, J. A.
Ledbetter, A. Aruffo, and R. S. Mittler. 1997. 4-1BB costimulatory signals
preferentially induce CD8+ T cell proliferation and lead to the amplification in
vivo o f cytotoxic T cell responses. J Exp M ed 186:47.

165.

Takahashi, C., R. S. Mittler, and A. T. Vella. 1999. Cutting edge: 4-1BB is a bona
fide CD8 T cell survival signal. J Immunol 162:5037.

166.

Kim, Y. J., R. R. Brutkiewicz, and H. E. Broxmeyer. 2002. Role o f 4-1BB
(CD 137) in the functional activation o f cord blood CD28(-)CD8(+) T cells. Blood
100:3253.

167.

Bansal-Pakala, P., and M. Croft. 2002. Defective T cell priming associated with
aging can be rescued by signaling through 4-1BB (CD137). J Immunol 169:5005.

168.

Goodwin, R. G., W. S. Din, T. Davis-Smith, D. M. Anderson, S. D. Gimpel, T. A.
Sato, C. R. Maliszewski, C. I. Brannan, N. G. Copeland, N. A. Jenkins, and et al.
1993. Molecular cloning o f a ligand for the inducible T cell gene 4 -IBB: a
member o f an emerging family o f cytokines with homology to tumor necrosis
factor. Eur J Immunol 23:2631.

169.

Laderach, D., A. Wesa, and A. Galy. 2003. 4-lBB-ligand is regulated on human
dendritic cells and induces the production o f IL-12. Cell Immunol 226:37.

170.

DeBenedette, M. A., A. Shahinian, T. W. Mak, and T. H. Watts. 1997.
Costimulation of CD28- T lymphocytes by 4 -IBB ligand. J Immunol 158:551.

171.

Diehl, L., G. J. van Mierlo, A. T. den Boer, E. van der Voort, M. Fransen, L. van
Bostelen, P. Krimpenfort, C. J. Melief, R. Mittler, R. E. Toes, and R. Offringa.
2002. In vivo triggering through 4 -IBB enables Th-independent priming o f CTL
in the presence o f an intact CD28 costimulatory pathway. J Immunol 168:3755.

156

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

172.

Langstein, J., J. Michel, J. Fritsche, M. Kreutz, R. Andreesen, and H. Schwarz.
1998. CD137 (ILA/4-1BB), a member o f the TNF receptor family, induces
monocyte activation via bidirectional signaling. J Immunol 160:2488.

173.

Langstein, J., and H. Schwarz. 1999. Identification o f CD137 as a potent
monocyte survival factor. J Leukoc Biol 65:829.

174.

Page, C., M. Rose, M. Yacoub, and R. Pigott. 1992. Antigenic heterogeneity of
vascular endothelium. Am J Pathol 141:673.

175.

Baldwin, W. M., 3rd, F. H. Claas, L. A. van Es, and J. J. van Rood. 1981.
Distribution o f endothelial-monocyte and FILA antigens on renal vascular
endothelium. Transplant Proc 13:103.

176.

Flayry, P., E. von Willebrand, and L. C. Andersson. 1980. Expression o f HLAABC and -DR locus antigens on human kidney, endothelial, tubular and
glomerular cells. Scand J Immunol 11:303.

111.

Natali, P. G., C. De Martino, V. Quaranta, M. R. Nicotra, F. Frezza, M. A.
Pellegrino, and S. Ferrone. 1981. Expression o f Ia-like antigens in normal human
nonlymphoid tissues. Transplantation 31:75.

178.

Tereb, D. A., N. C. Kirkiles-Smith, R. W. Kim, Y. Wang, R. D. Rudic, J. S.
Schechner, M. I. Lorber, A. L. Bothwell, J. S. Pober, and G. Tellides. 2001.
Human T cells infiltrate and injure pig coronary artery grafts with activated but
not quiescent endothelium in immunodeficient mouse hosts. Transplantation
71:1622.

179.

Murray, A. G., P. Petzelbauer, C. C. Hughes, J. Costa, P. Askenase, and J. S.
Pober. 1994. Human T-cell-mediated destruction o f allogeneic dermal
microvessels in a severe combined immunodeficient mouse. Proc Natl Acad Sci U
S A 91:9146.

180.

Pober, J. S., M. A. Gimbrone, Jr., R. S. Cotran, C. S. Reiss, S. J. Burakoff, W.
Fiers, and K. A. Ault. 1983. Ia expression by vascular endothelium is inducible by
activated T cells and by human gamma interferon. J Exp M ed 157:1339.

181.

Collins, T., A. J. Korman, C. T. Wake, J. M. Boss, D. J. Kappes, W. Fiers, K. A.
Ault, M. A. Gimbrone, Jr., J. L. Strominger, and J. S. Pober. 1984. Immune
interferon activates multiple class II major histocompatibility complex genes and
the associated invariant chain gene in human endothelial cells and dermal
fibroblasts. Proc Natl Acad Sci U S A 81:4917.

182.

McDouall, R. M., P. Batten, A. McCormack, M. H. Yacoub, and M. L. Rose.
1997. MHC class II expression on human heart micro vascular endothelial cells:

157

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

exquisite sensitivity to interferon-gamma and natural killer cells. Transplantation
64:1175.
183.

Lapierre, L. A., W. Fiers,
and J. S. Pober. 1988. Three distinct classes o f
regulatory cytokines control endothelial cell MFIC antigen expression.
Interactions with immune gamma interferon differentiate the effects o f tumor
necrosis factor and lymphotoxin from those o f leukocyte alpha and fibroblast beta
interferons. J Exp M ed 167:794.

184.

Collins, T., L. A. Lapierre, W. Fiers, J. L. Strominger, and J. S. Pober. 1986.
Recombinant human tumor necrosis factor increases mRNA levels and surface
expression o f F1LA-A,B antigens in vascular endothelial cells and dermal
fibroblasts in vitro. Proc Natl Acad Sci U S A 83:446.

185.

Min, W., J. S. Pober, and D. R. Johnson. 1996. Kinetically coordinated induction
of TAPI and HLA class I by IFN-gamma: the rapid induction o f TAPI by IFNgamma is mediated by Statl alpha. J Immunol 156:3174.

186.

Savage, C. O., C. J. Brooks, G. C. Harcourt, J. K. Picard, W. King, D. M.
Sansom, and N. Willcox. 1995. Fluman vascular endothelial cells process and
present autoantigen to human T cell lines. Int Immunol 7:471.

187.

Kummer, M., A. Lev, Y. Reiter, and B. C. Biedermann. 2005. Vascular
endothelial cells have impaired capacity to present immunodominant, antigenic
peptides: a mechanism o f cell type-specific immune escape. J Immunol 174:1947.

188.

Karmann, K., J. S. Pober, and C. C. Hughes. 1994. Endothelial cell-induced
resistance to cyclosporin A in human peripheral blood T cells requires contactdependent interactions involving CD2 but not CD28. J Immunol 153:3929.

189.

Shiao, S. L., J. M. McNiff, and J. S. Pober. 2005. Memory T cells and their
costimulators in human allograft injury. J Immunol 175:4886.

190.

Denton, M. D., C. S. Geehan, S. I. Alexander, M. H. Sayegh, and D. M. Briscoe.
1999. Endothelial cells modify the costimulatory capacity of transmigrating
leukocytes and promote CD28-mediated CD4(+) T cell alloactivation. J Exp M ed
190:555.

191.

Jollow, K. C., J. C. Zimring, J. B. Sundstrom, and A. A. Ansari. 1999. CD40
ligation induced phenotypic and functional expression of CD80 by human cardiac
microvascular endothelial cells. Transplantation 68:430.

192.

Prat, A., K. Biemacki, B. Becher, and J. P. Antel. 2000. B7 expression and
antigen presentation by human brain endothelial cells: requirement for
proinflammatory cytokines. J Neuropathol Exp Neurol 59:129.

158

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

193.

Klingenberg, R., F. Autschbach, C. Gleissner, T. Giese, N. Wambsganss, N.
Sommer, G. Richter, H. A. Katus, and T. J. Dengler. 2005. Endothelial inducible
costimulator ligand expression is increased during human cardiac allograft
rejection and regulates endothelial cell-dependent allo-activation o f CD8+ T cells
in vitro. Eur J Immunol 35:1712.

194.

Mazanet, M. M., and C. C. Hughes. 2002. B7-H1 is expressed by human
endothelial cells and suppresses T cell cytokine synthesis. J Immunol 169:3581.

195.

Eppihimer, M. J., J. Gunn, G. J. Freeman, E. A. Greenfield, T. Chernova, J.
Erickson, and J. P. Leonard. 2002. Expression and regulation o f the PD-L1
immunoinhibitory molecule on microvascular endothelial cells. Microcirculation
9:133.

196.

Westphal, J. R., H. W. Willems, W. J. Tax, R. A. Koene, D. J. Ruiter, and R. M.
de Waal. 1993. The proliferative response o f human T cells to allogeneic IFNgamma-treated endothelial cells is mediated via both CD2/LFA-3 and LFA1/ICAM-l and -2 adhesion pathways. TransplImmunol 1:183.

197.

Savage, C. O., C. C. Hughes, R. B. Pepinsky, B. P. Wallner, A. S. Freedman, and
J. S. Pober. 1991. Endothelial cell lymphocyte function-associated antigen-3 and
an unidentified ligand act in concert to provide costimulation to human peripheral
blood CD4+ T cells. Cell Immunol 137:150.

198.

Seko, Y., K. Sugishita, O. Sato, A. Takagi, Y. Tada, H. Matsuo, H. Yagita, K.
Okumura, and R. Nagai. 2004. Expression o f costimulatory molecules (4-1BBL
and Fas) and major histocompatibility class I chain-related A (MICA) in aortic
tissue with Takayasu's arteritis. J Vase Res 41:84.

199.

Seko, Y., N. Takahashi, H. Oshima, O. Shimozato, H. Akiba, K. Takeda, T.
Kobata, H. Yagita, K. Okumura, M. Azuma, and R. Nagai. 2001. Expression of
tumour necrosis factor (TNF) ligand superfamily co-stimulatory molecules
CD30L, CD27L, OX40L, and 4-1BBL in murine hearts with acute myocarditis
caused by Coxsackievirus B3. J Pathol 195:593.

200.

Choi, J., D. R. Enis, K. P. Koh, S. L. Shiao, and J. S. Pober. 2004. T lymphocyteendothelial cell interactions. Annu Rev Immunol 22:683.

201.

Kurt-Jones, E. A., W. Fiers, and J. S. Pober. 1987. Membrane interleukin 1
induction on human endothelial cells and dermal fibroblasts. J Immunol
139:2317.

202.

Waldmann, T. A., and Y. Tagaya. 1999. The multifaceted regulation of
interleukin-15 expression and the role o f this cytokine in NK cell differentiation
and host response to intracellular pathogens. Annu Rev Immunol 17:19.

159

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

203.

Loppnow, H., and P. Libby. 1989. Adult human vascular endothelial cells express
the IL6 gene differentially in response to LPS or IL1. Cell Immunol 122:493.

204.

Suen, Y., M. Chang, S. M. Lee, J. S. Buzby, and M. S. Cairo. 1994. Regulation of
interleukin-11 protein and mRNA expression in neonatal and adult fibroblasts and
endothelial cells. Blood 84:4125.

205.

Gerdes, N., G. K. Sukhova, P. Libby, R. S. Reynolds, J. L. Young, and U.
Schonbeck. 2002. Expression o f interleukin (IL)-l 8 and functional IL-18 receptor
on human vascular endothelial cells, smooth muscle cells, and macrophages:
implications for atherogenesis. J Exp M ed 195:245.

206.

Pober, J. S., T. Collins, M. A. Gimbrone, Jr., R. S. Cotran, J. D. Gitlin, W. Fiers,
C. Clayberger, A. M. Krensky, S. J. Burakoff, and C. S. Reiss. 1983.
Lymphocytes recognize human vascular endothelial and dermal fibroblast la
antigens induced by recombinant immune interferon. Nature 305:726.

207.

Briscoe, D. M., L. E. DesRoches, J. M. Kiely, J. A. Lederer, and A. H. Lichtman.
1995. Antigen-dependent activation o f T helper cell subsets by endothelium.
Transplantation 59:1638.

208.

Savage, C. O., C. C. Hughes, B. W. McIntyre, J. K. Picard, and J. S. Pober. 1993.
Human CD4+ T cells proliferate to HLA-DR+ allogeneic vascular endothelium.
Identification o f accessory interactions. Transplantation 56:128.

209.

Epperson, D. E., and J. S. Pober. 1994. Antigen-presenting function o f human
endothelial cells. Direct activation o f resting CD8 T cells. J Immunol 153:5402.

210.

Brooks, C. J., A. Stackpoole, and C. O. Savage. 1993. Synergistic interactions of
CD4+ and CD8+ T cell subsets with human vascular endothelial cells in primary
proliferative allogeneic responses. Int Immunol 5:1041.

211.

Adams, P. W., H. S. Lee, R. M. Ferguson, and C. G. Orosz. 1994.
Alloantigenicity of human endothelial cells. II. Analysis o f interleukin 2
production and proliferation by T cells after contact with allogeneic endothelia.
Transplantation 57:115.

212.

Dengler, T. J., D. R. Johnson, and J. S. Pober. 2001. Human vascular endothelial
cells stimulate a lower frequency o f alloreactive CD8+ pre-CTL and induce less
clonal expansion than matching B lymphoblastoid cells: development o f a novel
limiting dilution analysis method based on CFSE labeling o f lymphocytes. J
Immunol 166:3846.

213.

Murray, A. G., P. Libby, and J. S. Pober. 1995. Human vascular smooth muscle
cells poorly co-stimulate and actively inhibit allogeneic CD4+ T cell proliferation
in vitro. J Immunol 154:151.

160

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

214.

Dengler, T. J., and J. S. Pober. 2000. Human vascular endothelial cells stimulate
memory but not naive CD8+ T cells to differentiate into CTL retaining an early
activation phenotype. J Immunol 164:5146.

215.

Biedermann, B. C., and J. S. Pober. 1998. Human endothelial cells induce and
regulate cytolytic T cell differentiation. J Immunol 161:4679.

216.

Kreisel, D., A. M. Krasinskas, A. S. Krupnick, A. E. Gelman, K. R. Balsara, S. H.
Popma, M. Riha, A. M. Rosengard, L. A. Turka, and B. R. Rosengard. 2004.
Vascular endothelium does not activate CD4+ direct allorecognition in graft
rejection . J Immunol 173:3027.

217.

Marelli-Berg, F. M., L. Frasca, N. Imami, G. Lombardi, and R. I. Lechler. 1999.
Lack o f T cell proliferation without induction o f nonresponsiveness after antigen
presentation by endothelial cells. Transplantation 68:280.

218.

Berg, L. P., M. J. James, M. Alvarez-Iglesias, S. Glennie, R. I. Lechler, and F. M.
Marelli-Berg. 2002. Functional consequences o f noncognate interactions between
CD4+ memory T lymphocytes and the endothelium. J Immunol 168:3227.

219.

Kreisel, D., A. S. Krupnick, K. R. Balsara, M. Riha, A. E. Gelman, S. H. Popma,
W. Y. Szeto, L. A. Turka, and B. R. Rosengard. 2002. Mouse vascular
endothelium activates CD8+ T lymphocytes in a B7-dependent fashion. J
Immunol 169:6154.

220.

Geppert, T. D., and P. E. Lipsky. 1985. Antigen presentation by interferongamma-treated endothelial cells and fibroblasts: differential ability to function as
antigen-presenting cells despite comparable la expression. J Immunol 135:3750.

221.

Geppert, T. D., and P. E. Lipsky. 1987. Dissection o f defective antigen
presentation by interferon-gamma-treated fibroblasts. J Immunol 138:385.

222.

Guinan, E. C., B. R. Smith, J. T. Doukas, R. A. Miller, and J. S. Pober. 1989.
Vascular endothelial cells enhance T cell responses by markedly augmenting IL-2
concentrations. Cell Immunol 118:166.

223.

Ma, W., and J. S. Pober. 1998. Human endothelial cells effectively costimulate
cytokine production by, but not differentiation of, naive CD4+ T cells. J Immunol
161:2158.

224.

Doukas, J., and J. S. Pober. 1990. Lymphocyte-mediated activation o f cultured
endothelial cells (EC). CD4+ T cells inhibit EC class II MHC expression despite
secreting IFN-gamma and increasing EC class I MHC and intercellular adhesion
molecule-1 expression. J Immunol 145:1088.

161

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

225.

Wagner, C. R., R. M. Vetto, and D. R. Burger. 1984. The mechanism o f antigen
presentation by endothelial cells. Immunobiology 168:453.

226.

Mestas, J., and C. C. Hughes. 2001. Endothelial cell costimulation o f T cell
activation through CD58-CD2 interactions involves lipid raft aggregation. J
Immunol 167:4378.

227.

Hughes, C. C., and J. S. Pober. 1996. Transcriptional regulation o f the interleukin2 gene in normal human peripheral blood T cells. Convergence o f costimulatory
signals and differences from transformed T cells. J Biol Chem 271:5369.

228.

Murakami, K., W. Ma, R. Fuleihan, and J. S. Pober. 1999. Human endothelial
cells augment early CD40 ligand expression in activated CD4+ T cells through
LFA-3-mediated stabilization o f mRNA. J Immunol 163:2667.

229.

Karmann, K., C. C. Hughes, W. C. Fanslow, and J. S. Pober. 1996. Endothelial
cells augment the expression o f CD40 ligand on newly activated human CD4+ T
cells through a CD2/LFA-3 signaling pathway. Eur J Immunol 26:610.

230.

Mestas, J., S. P. Crampton, T. Hori, and C. C. Hughes. 2005. Endothelial cell co
stimulation through 0X 40 augments and prolongs T cell cytokine synthesis by
stabilization o f cytokine mRNA. Int Immunol 17:737.

231.

Ukyo, N., T. Hori, S. Yanagita, T. Ishikawa, and T. Uchiyama. 2003.
Costimulation through 0X 40 is crucial for induction o f an alloreactive human Tcell response. Immunology 109:226.

232.

Fling, S. P., B. Arp, and D. Pious. 1994. HLA-DMA and -DMB genes are both
required for MHC class II/peptide complex formation in antigen-presenting cells.
Nature 368:554.

233.

Vora, M., H. Yssel, J. E. de Vries, and M. A. Karasek. 1994. Antigen presentation
by human dermal microvascular endothelial cells. Immunoregulatory effect o f
IFN-gamma and IL-10. J Immunol 152:5734.

234.

Umetsu, D. T., J. S. Pober, H. H. Jabara, W. Fiers, E. J. Yunis, S. J. Burakoff, C.
S. Reiss, and R. S. Geha. 1985. Human dermal fibroblasts present tetanus toxoid
antigen to antigen-specific T cell clones. J Clin Invest 76:254.

235.

Wong, Y. W., A. F. Williams, S. F. Kingsmore, and M. F. Seldin. 1990. Structure,
expression, and genetic linkage o f the mouse BCM1 (0X 45 or Blast-1) antigen.
Evidence for genetic duplication giving rise to the BCM1 region on mouse
chromosome 1 and the CD2/LFA3 region on mouse chromosome 3. J Exp M ed
171:2115.

162

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

236.

Yokoyama, S., D. Staunton, R. Fisher, M. Amiot, J. J. Fortin, and D. A. ThorleyLawson. 1991. Expression o f the Blast-1 activation/adhesion molecule and its
identification as CD48. J Immunol 146:2192.

237.

Seino, K., M. Azuma, H. Bashuda, K. Fukao, H. Yagita, and K. Okumura. 1995.
CD86 (B70/B7-2) on endothelial cells co-stimulates allogeneic CD4+ T cells. Int
Immunol 7:1331.

238.

Murray, A. G., M. M. Khodadoust, J. S. Pober, and A. L. Bothwell. 1994. Porcine
aortic endothelial cells activate human T cells: direct presentation o f MHC
antigens and costimulation by ligands for human CD2 and CD28. Immunity 1:57.

239.

Davis, T. A., N. Craighead, A. J. Williams, A. Scadron, C. H. June, and K. P. Lee.
1996. Primary porcine endothelial cells express membrane-bound B7-2 (CD86)
and a soluble factor that co-stimulate cyclosporin A-resistant and CD28dependent human T cell proliferation. Int Immunol 8:1099.

240.

Murphy, L. L., M. M. Mazanet, A. C. Taylor, J. Mestas, and C. C. Hughes. 1999.
Single-cell analysis o f costimulation by B cells, endothelial cells, and fibroblasts
demonstrates heterogeneity in responses o f CD4(+) memory T cells. Cell
Immunol 194:150.

241.

Pober, J. S. 1999. Immunobiology o f human vascular endothelium. Immunol Res
19:225.

242.

Barreiro, O., M. Yanez-Mo, J. M. Serrador, M. C. Montoya, M. VicenteManzanares, R. Tejedor, H. Furthmayr, and F. Sanchez-Madrid. 2002. Dynamic
interaction o f VC A M -1 and ICAM-1 with moesin and ezrin in a novel endothelial
docking structure for adherent leukocytes. J Cell Biol 157:1233.

243.

Baron, J. L., J. A. Madri, N. H. Ruddle, G. Hashim, and C. A. Janeway, Jr. 1993.
Surface expression o f alpha 4 integrin by CD4 T cells is required for their entry
into brain parenchyma. J Exp M ed 177:57.

244.

Sato, Y., and D. B. Rifkin. 1989. Inhibition o f endothelial cell movement by
pericytes and smooth muscle cells: activation o f a latent transforming growth
factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol 109:309.

245.

Antonelli-Orlidge, A., K. B. Saunders, S. R. Smith, and P. A. D'Amore. 1989. An
activated form o f transforming growth factor beta is produced by cocultures o f
endothelial cells and pericytes. Proc Natl Acad Sci U S A 86:4544.

246.

Li, M. O., Y. Y. Wan, S. Sanjabi, A. K. Robertson, and R. A. Flavell. 2006.
Transforming growth factor-beta regulation o f immune responses. Annu Rev
Immunol 24:99.

163

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

247.

Gurney, A. L., S. A. Marsters, R. M. Huang, R. M. Pitti, D. T. Mark, D. T.
Baldwin, A. M. Gray, A. D. Dowd, A. D. Brush, A. D. Heldens, A. D. Schow, A.
D. Goddard, W. I. Wood, K. P. Baker, P. J. Godowski, and A. Ashkenazi. 1999.
Identification o f a new member o f the tumor necrosis factor family and its
receptor, a human ortholog o f mouse GITR. Curr Biol 9:215.

248.

Stephens, G. L., R. S. McHugh, M. J. Whitters, D. A. Young, D. Luxenberg, B.
M. Carreno, M. Collins, and E. M. Shevach. 2004. Engagement o f glucocorticoidinduced TNFR family-related receptor on effector T cells by its ligand mediates
resistance to suppression by CD4+CD25+ T cells. J Immunol 173:5008.

249.

Shimizu, J., S. Yamazaki, T. Takahashi, Y. Ishida, and S. Sakaguchi. 2002.
Stimulation o f CD25(+)CD4(+) regulatory T cells through GITR breaks
immunological self-tolerance. Nat Immunol 3:135.

250.

Kubo, T., R. D. Hatton, J. Oliver, X. Liu, C. O. Elson, and C. T. Weaver. 2004.
Regulatory T cell suppression and anergy are differentially regulated by
proinflammatory cytokines produced by TLR-activated dendritic cells. J Immunol
173:7249.

251.

Pasare, C., and R. Medzhitov. 2003. Toll pathway-dependent blockade of
CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299:1033.

252.

Smith, K. M., J. M. Brewer, P. Webb, A. J. Coyle, C. Gutierrez-Ramos, and P.
Garside. 2003. Inducible costimulatory molecule-B7-related protein 1 interactions
are important for the clonal expansion and B cell helper functions o f naive, T hl,
and Th2 T cells. J Immunol 170:2310.

253.

Hutloff, A., A. M. Dittrich, K. C. Beier, B. Eljaschewitsch, R. Kraft, I.
Anagnostopoulos, and R. A. Kroczek. 1999. ICOS is an inducible T-cell co
stimulator structurally and functionally related to CD28. Nature 397:263.

254.

Biedermann, B. C., and J. S. Pober. 1999. Human vascular endothelial cells favor
clonal expansion of unusual alloreactive CTL. J Immunol 162:7022.

255.

Silber, A., W. Newman, K. A. Reimann, E. Hendricks, D. Walsh, and D. J.
Ringler. 1994. Kinetic expression o f endothelial adhesion molecules and
relationship to leukocyte recruitment in two cutaneous models o f inflammation.
Lab Invest 70:163.

256.

Jutte, N. H., C. J. Knoop, P. Heijse, A. H. Balk, B. Mochtar, F. H. Claas, and W.
Weimar. 1997. Cytotoxicity o f graft-derived lymphocytes: specific for donor
heart endothelial cells? J Heart Lung Transplant 16:209.

164

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

257.

Deckers, J. G., M. R. Daha, S. W. Van der Kooij, and F. J. Van der Woude. 1998.
Epithelial- and endothelial-cell specificity o f renal graft infiltrating T cells. Clin
Transplant 12:285.

258.

Jutte, N. FL, C. J. Rnoop, P. Fleijse, A. H. Balk, B. Mochtar, F. H. Claas, and W.
Weimar. 1996. Human heart endothelial-cell-restricted allorecognition.
Transplantation 62:403.

259.

Brewer, Y., A. Palmer, D. Taube, K. Welsh, M. Bewick, C. Bindon, G. Hale, H.
Waldmann, F. Dische, V. Parsons, and et al. 1989. Effect o f graft perfusion with
two CD45 monoclonal antibodies on incidence o f kidney allograft rejection.
Lancet 2:935.

260.

Lechler, R. I., and J. R. Batchelor. 1982. Restoration o f immunogenicity to
passenger cell-depleted kidney allografts by the addition o f donor strain dendritic
cells. J Exp M ed 155:31.

261.

McKenzie, J. L., M. E. Beard, and D. N. Hart. 1984. Depletion o f donor kidney
dendritic cells prolongs graft survival. Transplant Proc 16:948.

262.

Kreisel, D., A. S. Krupnick, A. E. Gelman, F. H. Engels, S. H. Popma, A. M.
Krasinskas, K. R. Balsara, W. Y. Szeto, L. A. Turka, and B. R. Rosengard. 2002.
Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute
rejection: an alternative mechanism o f allorecognition. Nat M ed 8:233.

263.

Valujskikh, A., O. Lantz, S. Celli, P. Matzinger, and P. S. Heeger. 2002. Cross
primed CD8(+) T cells mediate graft rejection via a distinct effector pathway. Nat
Immunol 3:844.

264.

Kapessidou, Y., C. Habran, S. Buonocore, V. Flamand, L. Barvais, M. Goldman,
and M. Y. Braun. 2006. The replacement o f graft endothelium by recipient-type
cells conditions allograft rejection mediated by indirect pathway CD4(+) T cells.
Transplantation 81:726.

265.

Savinov, A. Y., F. S. Wong, A. C. Stonebraker, and A. V. Chervonsky. 2003.
Presentation o f antigen by endothelial cells and chemoattraction are required for
homing o f insulin-specific CD8+ T cells. J Exp M ed 197:643.

266.

Ibrahim, S., D. V. Dawson, P. Van Trigt, and F. Sanfilippo. 1993. Differential
infiltration by CD45RO and CD45RA subsets o f T cells associated with human
heart allograft rejection. Am J Pathol 142:1794.

267.

Ibrahim, S., D. V. Dawson, and F. Sanfilippo. 1995. Predominant infiltration of
rejecting human renal allografts with T cells expressing CD8 and CD45RO.
Transplantation 59:724.

165

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

268.

Dollinger, M. M., S. E. Howie, J. N. Plevris, A. M. Graham, P. C. Hayes, and D.
J. Harrison. 1998. Intrahepatic proliferation of'naive' and 'memory' T cells during
liver allograft rejection: primary immune response within the allograft. Faseb J
12:939.

269.

Azzawi, M., P. S. Hasleton, P. J. Geraghty, N. Yonan, P. Krysiak, A. El-Gammal,
A. K. Deiraniya, and I. V. Hutchinson. 1998. RANTES chemokine expression is
related to acute cardiac cellular rejection and infiltration by CD45RO Tlymphocytes and macrophages. J Heart Lung Transplant 17:881.

270.

Augustine, J. J., D. S. Siu, M. J. Clemente, J. A. Schulak, P. S. Heeger, and D. E.
Hricik. 2005. Pre-transplant IFN-gamma ELISPOTs are associated with post
transplant renal function in African American renal transplant recipients. Am J
Transplant 5:1971.

271.

Heeger, P. S., N. S. Greenspan, S. Kuhlenschmidt, C. Dejelo, D. E. Hricik, J. A.
Schulak, and M. Tary-Lehmann. 1999. Pretransplant frequency o f donor-specific,
IFN-gamma-producing lymphocytes is a manifestation o f immunologic memory
and correlates with the risk o f posttransplant rejection episodes. J Immunol
163:2267.

272.

Nickel, P., F. Presber, G. Bold, D. Biti, C. Schonemann, S. G. Tullius, H. D.
Volk, and P. Reinke. 2004. Enzyme-linked immunosorbent spot assay for donorreactive interferon-gamma-producing cells identifies T-cell presensitization and
correlates with graft function at 6 and 12 months in renal-transplant recipients.
Transplantation 78:1640.

273.

Reinke, P., E. Fietze, W. D. Docke, F. Kern, R. Ewert, and H. D. Volk. 1994. Late
acute rejection in long-term renal allograft recipients. Diagnostic and predictive
value o f circulating activated T cells. Transplantation 58:35.

274.

Najafian, N., A. D. Salama, E. V. Fedoseyeva, G. Benichou, and M. H. Sayegh.
2002. Enzyme-linked immunosorbent spot assay analysis o f peripheral blood
lymphocyte reactivity to donor HLA-DR peptides: potential novel assay for
prediction o f outcomes for renal transplant recipients. J Am Soc Nephrol 13:252.

275.

Adams, A. B., M. A. Williams, T. R. Jones, N. Shirasugi, M. M. Durham, S. M.
Kaech, E. J. Wherry, T. Onami, J. G. Lanier, K. E. Kokko, T. C. Pearson, R.
Ahmed, and C. P. Larsen. 2003. Heterologous immunity provides a potent barrier
to transplantation tolerance. J Clin Invest 111:1887.

276.

Pantenburg, B., F. Heinzel, L. Das, P. S. Heeger, and A. Valujskikh. 2002. T cells
primed by Leishmania major infection cross-react with alloantigens and alter the
course o f allograft rejection. J Immunol 169:3686.

166

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

277.

Burrows, S. R., R. Khanna, J. M. Burrows, and D. J. Moss. 1994. An alloresponse
in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a
single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease.
J Exp M ed 179:1155.

278.

Gamadia, L. E., E. B. Remmerswaal, S. Surachno, N. M. Lardy, P. M. Wertheimvan Dillen, R. A. van Lier, and I. J. ten Berge. 2004. Cross-reactivity o f
cytomegalovirus-specific CD8+ T cells to allo-major histocompatibility complex
class I molecules. Transplantation 77:1879.

279.

Maruya, E., S. Takemoto, and P. I. Terasaki. 1993. HLA matching: identification
of permissible HLA mismatches. Clin Transpl:511.

280.

Goldrath, A. W., and M. J. Bevan. 1999. Low-affinity ligands for the TCR drive
proliferation o f mature CD8+ T cells in lymphopenic hosts. Immunity 11:183.

281.

Wu, Z., S. J. Bensinger, J. Zhang, C. Chen, X. Yuan, X. Huang, J. F. Markmann,
A. Kassaee, B. R. Rosengard, W. W. Hancock, M. H. Sayegh, and L. A. Turka.
2004. Homeostatic proliferation is a barrier to transplantation tolerance. Nat M ed
10:87.

282.

Kieper, W. C., J. T. Tan, B. Bondi-Boyd, L. Gapin, J. Sprent, R. Ceredig, and C.
D. Surh. 2002. Overexpression o f interleukin (IL)-7 leads to IL -15-independent
generation o f memory phenotype CD8+ T cells. J Exp M ed 195:1533.

283.

Schuler, T., G. J. Hammerling, and B. Arnold. 2004. Cutting edge: IL-7dependent homeostatic proliferation o f CD8+ T cells in neonatal mice allows the
generation o f long-lived natural memory T cells. J Immunol 172:15.

284.

Lewis, D. E., B. E. Gilbert, and V. Knight. 1986. Influenza virus infection induces
functional alterations in peripheral blood lymphocytes. J Immunol 137:3777.

285.

Aspinall, R., and D. Andrew. 2000. Thymic involution in aging. J Clin Immunol
20:250.

286.

Pearl, J. P., J. Parris, D. A. Hale, S. C. Hoffmann, W. B. Bernstein, K. L. McCoy,
S. J. Swanson, R. B. Mannon, M. Roederer, and A. D. Kirk. 2005.
Immunocompetent T-cells with a memory-like phenotype are the dominant cell
type following antibody-mediated T-cell depletion. Am J Transplant 5:465.

287.

Parker, D. C., D. L. Greiner, N. E. Phillips, M. C. Appel, A. W. Steele, F. H.
Durie, R. J. Noelle, J. P. Mordes, and A. A. Rossini. 1995. Survival o f mouse
pancreatic islet allografts in recipients treated with allogeneic small lymphocytes
and antibody to CD40 ligand. Proc Natl Acad Sci U S A 92:9560.

167

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

288.

Larsen, C. P., E. T. Elwood, D. Z. Alexander, S. C. Ritchie, R. Hendrix, C.
Tucker-Burden, H. R. Cho, A. Aruffo, D. Hollenbaugh, P. S. Linsley, K. J. Winn,
and T. C. Pearson. 1996. Long-term acceptance o f skin and cardiac allografts after
blocking CD40 and CD28 pathways. Nature 381:434.

289.

Kirk, A. D., D. M. Harlan, N. N. Armstrong, T. A. Davis, Y. Dong, G. S. Gray, X.
Hong, D. Thomas, J. H. Fechner, Jr., and S. J. Knechtle. 1997. CTLA4-Ig and
anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci
U S A 94:8789.

290.

Sachs, D. H. 2003. Tolerance: o f mice and men. J Clin Invest 111:1819.

291.

Valujskikh, A., B. Pantenburg, and P. S. Heeger. 2002. Primed allospecific T cells
prevent the effects o f costimulatory blockade on prolonged cardiac allograft
survival in mice. Am J Transplant 2:501.

292.

Zhai, Y., L. Meng, F. Gao, R. W. Busuttil, and J. W. Kupiec-Weglinski. 2002.
Allograft rejection by primed/memory CD8+ T cells is CD 154 blockade resistant:
therapeutic implications for sensitized transplant recipients. J Immunol 169:4667.

293.

Chen, Y., P. S. Heeger, and A. Valujskikh. 2004. In vivo helper functions of
alloreactive memory CD4+ T cells remain intact despite donor-specific
transfusion and anti-CD40 ligand therapy. J Immunol 172:5456.

294.

Berner, V., I. Motta, R. Perret, and P. Truffa-Bachi. 1995. Interleukin-2 downmodulates memory T helper lymphocyte development during antigenic
stimulation in vitro. Eur J Immunol 25:3394.

295.

Gupta, M., E. Satyaraj, J. M. Durdik, S. Rath, and V. Bal. 1997. Differential
regulation o f T cell activation for primary versus secondary proliferative
responses. J Immunol 158:4113.

296.

Kreuwel, H. T., S. Aung, C. Silao, and L. A. Sherman. 2002. Memory CD8(+) T
cells undergo peripheral tolerance. Immunity 17:73.

291.

Mirshahidi, S., C. T. Huang, and S. Sadegh-Nasseri. 2001. Anergy in peripheral
memory CD4(+) T cells induced by low avidity engagement o f T cell receptor. J
Exp M ed 194:719.

298.

Kursar, M., K. Bonhagen, J. Fensterle, A. Kohler, R. Hurwitz, T. Kamradt, S. H.
Kaufmann, and H. W. Mittrucker. 2002. Regulatory CD4+CD25+ T cells restrict
memory CD8+ T cell responses. J Exp M ed 196:1585.

299.

Dai, Z., Q. Li, Y. Wang, G. Gao, L. S. Diggs, G. Tellides, and F. G. Lakkis. 2004.
CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory
CD8+ T cells via a CD30-dependent mechanism. J Clin Invest 113:310.

168

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

300.

Iwakoshi, N. N., J. P. Mordes, T. G. Markees, N. E. Phillips, A. A. Rossini, and
D. L. Greiner. 2000. Treatment o f allograft recipients with donor-specific
transfusion and anti-CD 154 antibody leads to deletion o f alloreactive CD8+ T
cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol
164:512.

301.

Clarkson, M. R., and M. H. Sayegh. 2005. T-cell costimulatory pathways in
allograft rejection and tolerance. Transplantation 80:555.

302.

Salama, A. D., X. Yuan, A. Nayer, A. Chandraker, M. Inobe, T. Uede, and M. H.
Sayegh. 2003. Interaction between ICOS-B7RP1 and B7-CD28 costimulatory
pathways in alloimmune responses in vivo. Am J Transplant 3:390.

303.

Ozkaynak, E., W. Gao, N. Shemmeri, C. Wang, J. C. Gutierrez-Ramos, J. Amaral,
S. Qin, J. B. Rottman, A. J. Coyle, and W. W. Hancock. 2001. Importance of
ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol
2:591.

304.

Wang, J., Z. Guo, Y. Dong, O. Kim, J. Hart, A. Adams, C. P. Larsen, R. S.
Mittler, and K. A. Newell. 2003. Role o f 4 -IBB in allograft rejection mediated by
CD8+ T cells. Am J Transplant 3:543.

305.

Cho, H. R., B. Kwon, H. Yagita, S. La, E. A. Lee, J. E. Kim, H. Akiba, J. Kim, J.
H. Suh, D. S. Vinay, S. A. Ju, B. S. Kim, R. S. Mittler, K. Okumura, and B. S.
Kwon. 2004. Blockade o f 4-1BB (CD137)/4-lBB ligand interactions increases
allograft survival. Transpl Int 17:351.

306.

Vu, M. D., M. R. Clarkson, H. Yagita, L. A. Turka, M. H. Sayegh, and X. C. Li.
2006. Critical, but conditional, role o f 0X 40 in memory T cell-mediated
rejection. J Immunol 176:1394.

307.

Yuan, X., A. D. Salama, V. Dong, I. Schmitt, N. Najafian, A. Chandraker, H.
Akiba, H. Yagita, and M. H. Sayegh. 2003. The role o f the CD134-CD134 ligand
costimulatory pathway in alloimmune responses in vivo. J Immunol 170:2949.

308.

Yamada, A., A. D. Salama, M. Sho, N. Najafian, T. Ito, J. P. Forman, R.
Kewalramani, S. Sandner, H. Harada, M. R. Clarkson, D. A. Mandelbrot, A. H.
Sharpe, H. Oshima, H. Yagita, G. Chalasani, F. G. Lakkis, H. Auchincloss, Jr.,
and M. H. Sayegh. 2005. CD70 signaling is critical for CD28-independent CD8+
T cell-mediated alloimmune responses in vivo. J Immunol 174:1357.

309.

Gordon, R. D., B. J. Mathieson, L. E. Samelson, E. A. Boyse, and E. Simpson.
1976. The effect o f allogeneic presensitization on H-Y graft survival and in vitro
cell-mediated responses to H-y antigen. J Exp M ed 144:810.

169

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

310.

Mosier, D. E., R. J. Gulizia, S. M. Baird, and D. B. Wilson. 1988. Transfer o f a
functional human immune system to mice with severe combined
immunodeficiency. Nature 335:256.

311.

Kunstfeld, R., S. Lechleitner, K. Wolff, and P. Petzelbauer. 1998. MCP-1 and
MIP-1 alpha are most efficient in recruiting T cells into the skin in vivo. J Invest
Dermatol 111:1040.

312.

Petzelbauer, P., M. Groger, R. Kunstfeld, E. Petzelbauer, and K. Wolff. 1996.
Human delayed-type hypersensitivity reaction in a SCID mouse engrafted with
human T cells and autologous skin. J Invest Dermatol 107:576.

313.

Spritz, R. A. 1998. Genetic defects in Chediak-Higashi syndrome and the beige
mouse. J Clin Immunol 18:97.

314.

Pober, J. S., A. L. Bothwell, M. I. Lorber, J. M. McNiff, J. S. Schechner, and G.
Tellides. 2003. Immunopathology o f human T cell responses to skin, artery and
endothelial cell grafts in the human peripheral blood lymphocyte/severe combined
immunodeficient mouse. Springer Semin Immunopathol 25:167.

315.

Murray, A. G., J. S. Schechner, D. E. Epperson, P. Sultan, J. M. McNiff, C. C.
Hughes, M. I. Lorber, P. W. Askenase, and J. S. Pober. 1998. Dermal
microvascular injury in the human peripheral blood lymphocyte reconstitutedsevere combined immunodeficient (HuPBL-SCID) mouse/skin allograft model is
T cell mediated and inhibited by a combination o f cyclosporine and rapamycin.
Am J Pathol 153:627.

316.

Lorber, M. I., J. H. Wilson, M. E. Robert, J. S. Schechner, N. Kirkiles, H. Y.
Qian, P. W. Askenase, G. Tellides, and J. S. Pober. 1999. Human allogeneic
vascular rejection after arterial transplantation and peripheral lymphoid
reconstitution in severe combined immunodeficient mice. Transplantation
67:897.

317.

Tellides, G., D. A. Tereb, N. C. Kirkiles-Smith, R. W. Kim, J. H. Wilson, J. S.
Schechner, M. I. Lorber, and J. S. Pober. 2000. Interferon-gamma elicits
arteriosclerosis in the absence o f leukocytes. Nature 403:207.

318.

Lakkis, F. G., and M. H. Sayegh. 2003. Memory T cells: a hurdle to immunologic
tolerance. J Am Soc Nephrol 14:2402.

319.

Lanier, L. L., S. O'Fallon, C. Somoza, J. H. Phillips, P. S. Linsley, K. Okumura,
D. Ito, and M. Azuma. 1995. CD80 (B7) and CD86 (B70) provide similar
costimulatory signals for T cell proliferation, cytokine production, and generation
o f CTL. J Immunol 154:97.

170

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

320.

Kirkiles-Smith, N. C., K. Mahboubi, J. Plescia, J. M. McNiff, J. Karras, J. S.
Schechner, D. C. Altieri, and J. S. Pober. 2004. IL-11 protects human
micro vascular endothelium from alloinjury in vivo by induction o f survivin
expression. J Immunol 172:1391.

321.

Gimbrone, M. A., Jr. 1976. Culture o f vascular endothelium. Prog Hemost
Thromb 3:1.

322.

Zheng, L., T. J. Dengler, M. S. Kluger, L. A. Madge, J. S. Schechner, S. E.
Maher, J. S. Pober, and A. L. Bothwell. 2000. Cytoprotection o f human umbilical
vein endothelial cells against apoptosis and CTL-mediated lysis provided by
caspase-resistant Bcl-2 without alterations in growth or activation responses. J
Immunol 164:4665.

323.

Kluger, M. S., D. R. Johnson, and J. S. Pober. 1997. Mechanism o f sustained Eselectin expression in cultured human dermal microvascular endothelial cells. J
Immunol 158:887.

324.

Hemandez-Fuentes, M. P., S. Stevenson, O. Barroso-Herrera, and R. I. Lechler.
2002. Establishing the optimal method to estimate the frequencies o f alloreactive
CD4+ T cells. Transplant Proc 34:2855.

325.

Sallusto, F., J. Geginat, and A. Lanzavecchia. 2004. Central memory and effector
memory T cell subsets: function, generation, and maintenance. Annu Rev
Immunol 22:745.

326.

Sana, T. R., M. J. Janatpour, M. Sathe, L. M. McEvoy, and T. K. McClanahan.
2005. Microarray analysis o f primary endothelial cells challenged with different
inflammatory and immune cytokines. Cytokine 29:256.

221.

Marelli-Berg, F. M., R. E. Hargreaves, P. Carmichael, A. Dorling, G. Lombardi,
and R. I. Lechler. 1996. Major histocompatibility complex class II-expressing
endothelial cells induce allospecific nonresponsiveness in naive T cells. J Exp
M ed 183:1603.

328.

Lemstrom, K., P. Koskinen, and P. Hayry. 1995. Induction o f adhesion molecules
on the endothelia o f rejecting cardiac allografts. J Heart Lung Transplant 14:205.

329.

Rose, M. L., M. I. Coles, R. J. Griffin, A. Pomerance, and M. H. Yacoub. 1986.
Expression o f class I and class II major histocompatibility antigens in normal and
transplanted human heart. Transplantation 41:776.

330.

Pardi, R., and J. R. Bender. 1991. Signal requirements for the generation o f CD4+
and CD8+ T-cell responses to human allogeneic microvascular endothelium. Circ
Res 69:1269.

171

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

331.

Salom, R. N., J. A. Maguire, D. Esmore, and W. W. Hancock. 1994. Analysis of
proliferating cell nuclear antigen expression aids histological diagnosis and is
predictive o f progression o f human cardiac allograft rejection. Am J Pathol
145:876.

332.

Seder, R. A., R. N. Germain, P. S. Linsley, and W. E. Paul. 1994. CD28-mediated
costimulation o f interleukin 2 (IL-2) production plays a critical role in T cell
priming for IL-4 and interferon gamma production. J Exp M ed 179:299.

333.

Boise, L. H., A. J. Minn, P. J. Noel, C. H. June, M. A. Accavitti, T. Lindsten, and
C. B. Thompson. 1995. CD28 costimulation can promote T cell survival by
enhancing the expression o f Bcl-XL. Immunity 3:87.

334.

Yu, X. Z., M. H. Albert, P. J. Martin, and C. Anasetti. 2004. CD28 ligation
induces transplantation tolerance by IFN-gamma-dependent depletion o f T cells
that recognize alloantigens. J Clin Invest 113:1624.

335.

Linsley, P. S., P. M. Wallace, J. Johnson, M. G. Gibson, J. L. Greene, J. A.
Ledbetter, C. Singh, and M. A. Tepper. 1992. Immunosuppression in vivo by a
soluble form o f the CTLA-4 T cell activation molecule. Science 257:792.

336.

Salomon, B., and J. A. Bluestone. 2001. Complexities o f CD28/B7: CTLA-4
costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol
19:225.

337.

Vanhove, B., G. Laflamme, F. Coulon, M. Mougin, P. Vusio, F. Haspot, J.
Tiollier, and J. P. Soulillou. 2003. Selective blockade of CD28 and not CTLA-4
with a single-chain Fv-alphal-antitrypsin fusion antibody. Blood 102:564.

338.

Haspot, F., C. Seveno, A. S. Dugast, F. Coulon, K. Renaudin, C. Usal, M. Hill, I.
Anegon, M. Heslan, R. Josien, S. Brouard, J. P. Soulillou, and B. Vanhove. 2005.
Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan
degradation and TCR class II B7 regulatory cells. Am J Transplant 5:2339.

339.

Wolk, K., W. D. Docke, V. von Baehr, H. D. Volk, and R. Sabat. 2000. Impaired
antigen presentation by human monocytes during endotoxin tolerance. Blood
96:218.

340.

Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation o f soluble antigen
by cultured human dendritic cells is maintained by granulocyte/macrophage
colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis
factor alpha. J Exp M ed 179:1109.

341.

Lin, H., S. F. Bolling, P. S. Linsley, R. Q. Wei, D. Gordon, C. B. Thompson, and
L. A. Turka. 1993. Long-term acceptance o f major histocompatibility complex

172

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

mismatched cardiac allografts induced by
transfusion. J Exp M ed 178:1801.

CTLA4Ig plus

donor-specific

342.

Fallarino, F., P. E. Fields, and T. F. Gajewski. 1998. B7-1 engagement o f
cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of
CD28. J E x p M ed 188:205.

343.

Kingsley, C. I., M. Karim, A. R. Bushell, and K. J. Wood. 2002. CD25+CD4+
regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent
immunoregulation o f alloresponses. J Immunol 168:1080.

344.

Perrin, P. J., C. H. June, J. H. Maldonado, R. B. Ratts, and M. K. Racke. 1999.
Blockade o f CD28 during in vitro activation o f encephalitogenic T cells or after
disease onset ameliorates experimental autoimmune encephalomyelitis. J
Immunol 163:1704.

345.

Silver, P. B., K. S. Hathcock, C. C. Chan, B. Wiggert, and R. R. Caspi. 2000.
Blockade o f costimulation through B7/CD28 inhibits experimental autoimmune
uveoretinitis, but does not induce long-term tolerance. J Immunol 165:5041.

346.

Beyersdorf, N., S. Gaupp, K. Balbach, J. Schmidt, K. V. Toyka, C. H. Lin, T.
Hanke, T. Hunig, T. Kerkau, and R. Gold. 2005. Selective targeting o f regulatory
T cells with CD28 superagonists allows effective therapy o f experimental
autoimmune encephalomyelitis. J Exp M ed 202:445.

347.

Suresh, M., J. K. Whitmire, L. E. Flarrington, C. P. Larsen, T. C. Pearson, J. D.
Altman, and R. Ahmed. 2001. Role o f CD28-B7 interactions in generation and
maintenance o f CD8 T cell memory . J Immunol 167:5565.

348.

Wood, A. J., and J. Darbyshire. 2006. Injury to research volunteers—the clinicalresearch nightmare. N Engl J M ed 354:1869.

349.

Hopkin, M. 2006. Drug to blame for clinical-trial disaster? news@nature.com.

350.

Davis, S. J., and P. A. van der Merwe. 1996. The structure and ligand interactions
o f CD2: implications for T-cell function. Immunol Today 17:177.

351.

Cooper, D., P. Bansal-Pakala, and M. Croft. 2002. 4-1BB (CD137) controls the
clonal expansion and survival o f CD8 T cells in vivo but does not contribute to
the development of cytotoxicity. Eur J Immunol 32:521.

352.

Yoshinaga, S. K., J. S. Whoriskey, S. D. Khare, U. Sarmiento, J. Guo, T. Horan,
G. Shih, M. Zhang, M. A. Coccia, T. Kohno, A. Tafuri-Bladt, D. Brankow, P.
Campbell, D. Chang, L. Chiu, T. Dai, G. Duncan, G. S. Elliott, A. Hui, S. M.
McCabe, S. Scully, A. Shahinian, C. L. Shaklee, G. Van, T. W. Mak, and et al.
1999. T-cell co-stimulation through B7RP-1 and ICOS. Nature 402:827.

173

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

353.

Koh, K. P., Y. Wang, T. Yi, S. L. Shiao, M. I. Lorber, W. C. Sessa, G. Tellides,
and J. S. Pober. 2004. T cell-mediated vascular dysfunction o f human allografts
results from IFN-gamma dysregulation o f NO synthase. J Clin Invest 114:846.

354.

Strehlau, J., M. Pavlakis, M. Lipman, M. Shapiro, L. Vasconcellos, W. Harmon,
and T. B. Strom. 1997. Quantitative detection o f immune activation transcripts as
a diagnostic tool in kidney transplantation. Proc Natl Acad Sci U S A 94:695.

355.

Pascoe, M. D., S. E. Marshall, K. I. Welsh, L. M. Fulton, and D. A. Hughes.
2000. Increased accuracy o f renal allograft rejection diagnosis using combined
perforin, granzyme B, and Fas ligand fme-needle aspiration immunocytology.
Transplantation 69:2547.

356.

Alderson, M. R., C. A. Smith, T. W. Tough, T. Davis-Smith, R. J. Armitage, B.
Falk, E. Roux, E. Baker, G. R. Sutherland, and W. S. Din. 1994. Molecular and
biological characterization o f human 4 -IBB and its ligand. Eur J Immunol
24:2219.

357.

Ling, V., P. W. Wu, H. F. Finnerty, K. M. Bean, V. Spaulding, L. A. Fouser, J. P.
Leonard, S. E. Hunter, R. Zollner, J. L. Thomas, J. S. Miyashiro, K. A. Jacobs,
and M. Collins. 2000. Cutting edge: identification of GL50, a novel B7-like
protein that functionally binds to ICOS receptor. J Immunol 164:1653.

358.

Ohshima, Y., Y. Tanaka, H. Tozawa, Y. Takahashi, C. Maliszewski, and G.
Delespesse. 1997. Expression and function o f 0X 40 ligand on human dendritic
cells. J Immunol 159:3838.

359.

Beier, K. C., A. Hutloff, A. M. Dittrich, C. Heuck, A. Rauch, K. Buchner, B.
Ludewig, H. D. Ochs, H. W. Mages, and R. A. Kroczek. 2000. Induction, binding
specificity and function o f human ICOS. Eur J Immunol 30:3707.

360.

Godfrey, W. R., F. F. Fagnoni, M. A. Harara, D. Buck, and E. G. Engleman.
1994. Identification o f a human OX-40 ligand, a costimulator of CD4+ T cells
with homology to tumor necrosis factor. J Exp M ed 180:757.

361.

Greenwald, R. J., G. J. Freeman, and A. H. Sharpe. 2005. The B7 Family
Revisited. Annu Rev Immunol 23:515.

362.

Watts, T. H. 2005. Tnf/Tnfr family members in costimulation o f T cell responses.
Annu Rev Immunol 23:23.

363.

Blazar, B. R., B. S. Kwon, A. Panoskaltsis-Mortari, K. B. Kwak, J. J. Peschon,
and P. A. Taylor. 2001. Ligation o f 4-1BB (CD wl37) regulates graft-versus-host
disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow
transplant recipients. J Immunol 166:3174.

174

with permission of the copyright owner. Further reproduction prohibited without permission.

364.

DeBenedette, M. A., T. Wen, M. F. Bachmann, P. S. Ohashi, B. H. Barber, K. L.
Stocking, J. J. Peschon, and T. H. Watts. 1999. Analysis o f 4-1BB ligand (4lBBL)-deficient mice and o f mice lacking both 4-1BBL and CD28 reveals a role
for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to
influenza virus. J Immunol 163:4833.

365.

Harada, H., A. D. Salama, M. Sho, A. Izawa, S. E. Sandner, T. Ito, H. Akiba, H.
Yagita, A. H. Sharpe, G. J. Freeman, and M. H. Sayegh. 2003. The role o f the
ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin
Invest 112:234.

366.

Demirci, G., F. Amanullah, R. Kewalaramani, H. Yagita, T. B. Strom, M. H.
Sayegh, and X. C. Li. 2004. Critical role o f 0X 40 in CD28 and CD 154independent rejection. J Immunol 172:1691.

367.

Akalin, E., S. Dikrnan, B. Murphy, J. S. Bromberg, and W. W. Hancock. 2003.
Glomerular infiltration by CXCR3+ ICOS+ activated T cells in chronic allograft
nephropathy with transplant glomerulopathy. Am J Transplant 3:1116.

368.

Streeter, P. R., X. Zhang, T. V. Tittle, C. N. Schon, A. D. Weinberg, and R. T.
Maziarz. 2004. CD25 expression distinguishes functionally distinct alloreactive
CD4 CD 134 (0X 40) T-cell subsets in acute graft-versus-host disease. Biol Blood
Marrow Transplant 10:298.

369.

Witsch, E. J., M. Peiser, A. Hutloff, K. Buchner, B. G. Domer, H. Jonuleit, H. W.
Mages, and R. A. Kroczek. 2002. ICOS and CD28 reversely regulate IL-10 on re
activation o f human effector T cells with mature dendritic cells. Eur J Immunol
32:2680.

370.

Nurieva, R. I., X. M. Mai, K. Forbush, M. J. Bevan, and C. Dong. 2003. B7h is
required for T cell activation, differentiation, and effector function. Proc Natl
A cadSci U S A 100:14163.

371.

Tafuri, A., A. Shahinian, F. Bladt, S. K. Yoshinaga, M. Jordana, A. Wakeham, L.
M. Boucher, D. Bouchard, V. S. Chan, G. Duncan, B. Odermatt, A. Ho, A. Itie, T.
Horan, J. S. Whoriskey, T. Pawson, J. M. Penninger, P. S. Ohashi, and T. W.
Mak. 2001. ICOS is essential for effective T-helper-cell responses. Nature
409:105.

372.

Valzasina, B., C. Guiducci, H. Dislich, N. Killeen, A. D. Weinberg, and M. P.
Colombo. 2005. Triggering of 0X 40 (CD134) on CD4(+)CD25+ T cells blocks
their inhibitory activity: a novel regulatory role for 0X 40 and its comparison with
GITR. Blood 105:2845.

175

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

373.

Takeda, I., S. Ine, N. Killeen, L. C. Ndhlovu, K. Murata, S. Satomi, K. Sugamura,
and N. Ishii. 2004. Distinct roles for the 0X 40-0X 40 ligand interaction in
regulatory and nonregulatory T cells. J Immunol 172:3580.

374.

Campbell, J. J., K. E. Murphy, E. J. Kunkel, C. E. Brightling, D. Soler, Z. Shen, J.
Boisvert, H. B. Greenberg, M. A. Vierra, S. B. Goodman, M. C. Genovese, A. J.
Wardlaw, E. C. Butcher, and L. Wu. 2001. CCR7 expression and memory T cell
diversity in humans. J Immunol 166:877.

375.

Hendriks, J., L. A. Gravestein, K. Tesselaar, R. A. van Lier, T. N. Schumacher,
and J. Borst. 2000. CD27 is required for generation and long-term maintenance o f
T cell immunity. Nat Immunol 1:433.

376.

Tang, A. L., A. W. Bingaman, E. A. Kadavil, D. B. Leeser, and D. L. Farber.
2006. Generation and functional capacity o f polyclonal alloantigen-specific
memory CD4 T cells. Am J Transplant 6:1275.

377.

Arlettaz, L., C. Barbey, F. Dumont-Girard, C. Helg, B. Chapuis, E. Roux, and E.
Roosnek. 1999. CD45 isoform phenotypes o f human T cells: CD4(+)CD45RA()RO(+) memory T cells re-acquire CD45RA without losing CD45RO. Eur J
Immunol 29:3987.

378.

Debes, G. F., U. E. Hopken, and A. Hamann. 2002. In vivo differentiated
cytokine-producing CD4(+) T cells express functional CCR7. J Immunol
168:5441.

379.

Kim, C. H., L. Rott, E. J. Kunkel, M. C. Genovese, D. P. Andrew, L. Wu, and E.
C. Butcher. 2001. Rules o f chemokine receptor association with T cell
polarization in vivo. J Clin Invest 108:1331.

380.

Unsoeld, H., S. Krautwald, D. Voehringer, U. Kunzendorf, and H. Pircher. 2002.
Cutting edge: CCR7+ and CCR7- memory T cells do not differ in immediate
effector cell function. J Immunol 169:638.

381.

Lovett-Racke, A. E., J. L. Trotter, J. Lauber, P. J. Perrin, C. H. June, and M. K.
Racke. 1998. Decreased dependence o f myelin basic protein-reactive T cells on
CD28-mediated costimulation in multiple sclerosis patients. A marker of
activated/memory T cells. J Clin Invest 101:725.

382.

Amyes, E., C. Hatton, D. Montamat-Sicotte, N. Gudgeon, A. B. Rickinson, A. J.
McMichael, and M. F. Callan. 2003. Characterization of the CD4+ T cell
response to Epstein-Barr virus during primary and persistent infection. J Exp M ed
198:903.

383.

Rivino, L., M. Messi, D. Jarrossay, A. Lanzavecchia, F. Sallusto, and J. Geginat.
2004. Chemokine receptor expression identifies Pre-T helper (Th)l, Pre-Th2, and

176

with permission o f the copyright owner. Further reproduction prohibited without permission.

nonpolarized cells among human CD4+ central memory T cells. J Exp M ed
200:725.
384.

Kassiotis, G., and B. Stockinger. 2004. Anatomical heterogeneity o f memory
CD4+ T cells due to reversible adaptation to the microenvironment. J Immunol
173:7292.

385.

Lodge, P. A., and C. E. Haisch. 1993. T cell subset responses to allogeneic
endothelium. Proliferation o f CD8+ but not CD4+ lymphocytes. Transplantation
56:656.

386.

Marelli-Berg, F. M., D. Scott, I. Bartok, E. Peek, J. Dyson, and R. I. Lechler.
2000. Activated murine endothelial cells have reduced immunogenicity for CD8+
T cells: a mechanism o f immunoregulation? J Immunol 165:4182.

387.

Yano, K., D. Gale, S. Massberg, P. K. Cheruvu, R. Monahan-Earley, E. S.
Morgan, D. Haig, U. H. von Andrian, A. M. Dvorak, and W. C. Aird. 2006.
Phenotypic heterogeneity is an evolutionarily conserved feature o f the
endothelium. Blood.

388.

Kreisel, D., A. S. Krupnick, W. Y. Szeto, S. H. Popma, D. Sankaran, A. M.
Krasinskas, K. M. Amin, and B. R. Rosengard. 2001. A simple method for
culturing mouse vascular endothelium. J Immunol Methods 254:31.

389.

Page, C. S., N. Holloway, H. Smith, M. Yacoub, and M. L. Rose. 1994.
Alloproliferative responses o f purified CD4+ and CD8+ T cells to endothelial
cells in the absence o f contaminating accessory cells. Transplantation 57:1628.

390.

McDouall, R. M., C. S. Page, S. Hafizi, M. H. Yacoub, and M. L. Rose. 1996.
Alloproliferation o f purified CD4+ T cells to adult human heart endothelial cells,
and study o f second-signal requirements. Immunology 89:220.

391.

Perez, V. L., L. Henault, and A. H. Lichtman. 1998. Endothelial antigen
presentation: stimulation o f previously activated but not naive TCR-transgenic
mouse T cells. Cell Immunol 189:31.

392.

Chen, Y., Y. Demir, A. Valujskikh, and P. S. Heeger. 2003. The male minor
transplantation antigen preferentially activates recipient CD4+ T cells through the
indirect presentation pathway in vivo. J Immunol 171:6510.

393.

Sheldon, S., and K. Poulton. 2006. HLA typing and its influence on organ
transplantation. Methods M ol Biol 333:157.

394.

Kieper, W. C., and S. C. Jameson. 1999. Homeostatic expansion and phenotypic
conversion o f naive T cells in response to self peptide/MHC ligands. Proc Natl
A ca d S ci U S A 96:13306.

Ill

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

395.

Goldrath, A. W., C. J. Luckey, R. Park, C. Benoist, and D. Mathis. 2004. The
molecular program induced in T cells undergoing homeostatic proliferation. Proc
Natl Acad Sci U S A 101:16885.

396.

Gudmundsdottir, H., and L. A. Turka. 2001. A closer look at homeostatic
proliferation o f CD4+ T cells: costimulatory requirements and role in memory
formation. J Immunol 167:3699.

397.

Page, C., C. Thompson, M. Yacoub, and M. Rose. 1994. Human endothelial
stimulation o f allogeneic T cells via a CTLA-4 independent pathway. Transpl
Immunol 2:342.

398.

Read, S., R. Greenwald, A. Izcue, N. Robinson, D. Mandelbrot, L. Francisco, A.
H. Sharpe, and F. Powrie. 2006. Blockade o f CTLA-4 on CD4+CD25+ regulatory
T cells abrogates their function in vivo. J Immunol 177:4376.

399.

Kosuge, H., J. Suzuki, R. Gotoh, N. Koga, H. Ito, M. Isobe, M. Inobe, and T.
Uede. 2003. Induction o f immunologic tolerance to cardiac allograft by
simultaneous blockade o f inducible co-stimulator and cytotoxic T-lymphocyte
antigen 4 pathway. Transplantation 75:1374.

400.

Bukczynski, J., T. Wen, K. Ellefsen, J. Gauldie, and T. H. Watts. 2004.
Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human
antiviral cytotoxic T cell responses. Proc Natl Acad Sci U S A 101:1291.

401.

Huang, B. J., H. Yin, Y. F. Huang, J. F. Xu, P. Xiong, W. Feng, F. Zheng, Y. Xu,
M. Fang, and F. L. Gong. 2006. Gene therapy using adenoviral vector encoding 4lBBIg gene significantly prolonged murine cardiac allograft survival. Transpl
Immunol 16:88.

402.

Lee, J., E. N. Lee, E. Y. Kim, H. J. Lee, H. J. Park, C. L. Sun, S. K. Lee, J. W.
Joh, K. W. Lee, G. Y. Kwon, and S. J. Kim. 2005. 4-1BB promotes long-term
survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal
antibodies. Transplant Proc 37:123.

403.

Bansal-Pakala, P., B. S. Halteman, M. H. Cheng, and M. Croft. 2004.
Costimulation o f CD8 T cell responses by 0X 40. J Immunol 172:4821.

404.

Evans, D. E., R. A. Prell, C. J. Thalhofer, A. A. Hurwitz, and A. D. Weinberg.
2001. Engagement o f 0X 40 enhances antigen-specific CD4(+) T cell
mobilization/memory development and humoral immunity: comparison o f
alphaOX-40 with alphaCTLA-4. J Immunol 167:6804.

405.

Murata, K., N. Ishii, H. Takano, S. Miura, L. C. Ndhlovu, M. Nose, T. Noda, and
K. Sugamura. 2000. Impairment o f antigen-presenting cell function in mice
lacking expression o f 0X 40 ligand. J Exp M ed 191:365.

178

Reproduced with permission o f the copyright owner. Further reproduction prohibited without permission.

406.

Blazar, B. R., A. H. Sharpe, A. I. Chen, A. Panoskaltsis-Mortari, C. Lees, H.
Akiba, H. Yagita, N. Killeen, and P. A. Taylor. 2003. Ligation o f 0X 40 (CD134)
regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone
marrow transplant recipients. Blood 101:3741.

407.

Tsukada, N., H. Akiba, T. Kobata, Y. Aizawa, H. Yagita, and K. Okumura. 2000.
Blockade o f CD 134 (OX40)-CD134L interaction ameliorates lethal acute graftversus-host disease in a murine model o f allogeneic bone marrow transplantation.
Blood 95:2434.

408.

Munn, D. H., M. D. Sharma, and A. L. Mellor. 2004. Ligation o f B7-1/B7-2 by
human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic
cells. J Immunol 172:4100.

409.

Grohmann, U., C. Orabona, F. Fallarino, C. Vacca, F. Calcinaro, A. Falomi, P.
Candeloro, M. L. Belladonna, R. Bianchi, M. C. Fioretti, and P. Puccetti. 2002.
CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 3:1097.

410.

Podojil, J. R., and V. M. Sanders. 2003. Selective regulation o f mature IgG l
transcription by CD86 and beta 2-adrenergic receptor stimulation. J Immunol
170:5143.

411.

Quezada, S. A., L. Z. Jarvinen, E. F. Lind, and R. J. Noelle. 2004. CD40/CD154
interactions at the interface o f tolerance and immunity. Annu Rev Immunol
22:307.

412.

Obermeier, F., FI. Schwarz, N. Dunger, U. G. Strauch, N. Grunwald, J.
Scholmerich, and W. Falk. 2003. OX40/OX40L interaction induces the
expression o f CXCR5 and contributes to chronic colitis induced by dextran
sulfate sodium in mice. Eur J Immunol 33:3265.

413.

Kotani, A., T. Hori, Y. Matsumura, and T. Uchiyama. 2002. Signaling o f gp34
(0X 40 ligand) induces vascular endothelial cells to produce a CC chemokine
RANTES/CCL5. Immunol Lett 84:1.

414.

Pitcher, C. J., S. I. Hagen, J. M. Walker, R. Lum, B. L. Mitchell, V. C. Maino, M.
K. Axthelm, and L. J. Picker. 2002. Development and homeostasis o f T cell
memory in rhesus macaque. J Immunol 168:29.

415.

Fontenot, A. P., L. Gharavi, S. R. Bennett, S. J. Canavera, L. S. Newman, and B.
L. Kotzin. 2003. CD28 costimulation independence o f target organ versus
circulating memory antigen-specific CD4+ T cells. J Clin Invest 112:776.

416.

Obhrai, J. S., M. H. Oberbarnscheidt, T. W. Hand, L. Diggs, G. Chalasani, and F.
G. Lakkis. 2006. Effector T cell differentiation and memory T cell maintenance
outside secondary lymphoid organs. J Immunol 176:4051.

179

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

417.

Manes, T. D., J. S. Pober, and M. S. Kluger. 2006. Endothelial cell-T lymphocyte
interactions: iP-10 stimulates rapid transendothelial migration o f human effector
but not central memory CD4+ T cells. Requirements for shear stress and adhesion
molecules. Transplantation 82:S9.

180

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

